64th ASH Annual Meeting and Exposition: Author Index B

B. Inacio, M. C.

2564 - Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Arising from Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Ba Aqeel, S.

58 - Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia
2262 - The Age, Comorbidities and Albumin (ACA) Index Is Independently Associated with Overall Survival in Patients with Mantle Cell Lymphoma (MCL)
2267 - Disparities in Outcomes of Diffuse Large B Cell Lymphoma in Adolescent and Young Adults: A SEER Database Analysis
2496 - Impact of Race on the Mortality of Thrombotic Thrombocytopenic Purpura in the United States: A Population Study
2925 - Clinical Impact of the Intensity of Induction Regimens Prior to Consolidation in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma (PTCL)
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders

Baas, K. P.

676 - The Effect of Hematopoietic Stem Cell Transplantation on Cerebral Perfusion and Oxygen Metabolism in Patients with Sickle Cell Disease
1057 - Effect of Voxelotor on Cerebral Perfusion and Cerebral Oxygen Metabolism in Adult Patients with Sickle Cell Disease; Preliminary Results of the Coverage Study

Baatz, F.

1220 - Bcl11b-Edited Lymphoid Progenitors for the Generation of CAR-Engineered Natural Killer-like Cells with Potent Anti-Leukemic Activity

Baba, A. A.

2352 - Differentially Expressed Proteins in Transfusion-Dependent Thalassemia (TDT) and Their Role in Tdt Disease Severity

Babady, N. E.

2092 - Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Babak, M.

3963 - The Role of Integrin Beta-1 in the Chemoresistance of Acute Myeloid Leukemia

Babatunde, A.

512 - GATA1-Dependent Ceramide Homeostasis Controls Cytokine Signaling and Erythroid Cell Function

Babbs, K.

4387 - Rker-050, a Novel Activin Receptor Type II Ligand Trap, Rescued Anemia and Reduced Bone Loss in a Mouse Model of Myelodysplastic Syndromes

Babcock, R. L.

1221 - STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions

Babcook, M. A.

554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions

Babić, A.

3363 - Use of G-CSF for Bone Marrow Graft Mobilization Increases NK Cell, Treg and iNKT Cell Graft Content, Possibly Lowering the Risk of Severe Acute Gvhd and Chronic Gvhd in HLA-Haploidentical Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PT-CY)

Babic, M.

1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41

Babin, T.

1983 - Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors

Babon, J. J.

454 - Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN

Babu, A. P.

2008 - Interim Results of a Prospective Trial Testing Vaccination Against Pneumococcus before and after CD19 CAR T Cell Therapy to Optimize Humoral Immunity

Babu, M. M.

1965 - Structural Changes in Peptide-Scfv Bispecific Cars Impact T Cell Effector Function Against Acute Myeloid Leukemia

Babu, S.

583 - A Noncoding Germline Variant Creates a Gain-of-Function De Novo Enhancer That up-Regulates IL5 Transcription to Cause Familial Hypereosinophilia, Revealing a Previously Undescribed Mechanism for Human Disease

Babu, S.

602 - ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine
738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Babushok, D. V.

290 - Pediatric-Specific Patterns of Clonal Evolution Arising from Acquired Aplastic Anemia
426 - Real World Effectiveness of “7 + 3” Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia
4862 - Fried’s Frailty Phenotype Predicts Mortality and Survival for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- HLA-restricted Attack and Clonal Evolution in Aplastic Anemia

Baby, S. P.

3828 - New CMC Algorithm for Evaluation of Lupus Anticoagulant

Bacac, M.

1360 - RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Baccaro, A.

3478 - Pre-Clinical Development of a First in Class Half-Life Extended T Cell Engager Targeting ROR-1

Baccelli, I.

435 - The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Bacchus, M.

2515 - The Use of Andexanet Alfa Vs. Four-Factor Prothrombin Complex Concentrates in the Reversal of Life-Threatening Intracranial Hemorrhage

Bach, E.

1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Bachanova, V.

114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
151 - Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
655 - Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
2856 - Finding a Needle in Haystack: Digital-PCR As a Sensitive Tool for MRD Detection in the Circulating-Tumor DNA Samples in Hodgkin Lymphoma
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Bachar Lustig, E.

875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Bachas, C.

838 - Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
4110 - Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements

Bacher, M.

1139 - Modulation of Extravascular Binding of Recombinant Factor IX Impacts Hemostatic Efficacy in Mouse Models

Bachiashvili, K.

461 - ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients

Bachiashvili, K.

4040 - Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53-Mutated Acute Myeloid Leukemia

Bachier, C.

265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4673 - Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Bachier Rodriguez, L.

268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Bachier-Rodriguez, L.

491 - Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant
2070 - Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus
2120 - Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype
3368 - Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center
3404 - Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide
3444 - HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
4763 - TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia
4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis
4944 - Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Bachiller, M.

3287 - Co-Transduced CD19/BCMA Dual-Targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma

Bachireddy, P.

2098 - Expansion of a CD8+ Temra Population and Activating T-Cell Interactions Characterize the Graft Versus Leukemia Response in Relapsed AML

Bachmann, B. O.

2652 - Electron Transport Chain Complex V Inhibition Enhances the Antileukemic Activity of Low-Dose Venetoclax in Acute Myeloid Leukemia

Bachmeier, C. A.

2039 - Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Bachu, M.

2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial

Bachy, E.

Bacigalupo, A.

3119 - Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study
3413 - Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
4717 - Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Backhaus, D.

1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Backhouse, K.

981 - Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Backor, K.

3626 - The Mental Health Burden and Quality of Life Impact of Myelodysplastic Syndromes in Patients and Their Caregivers

Badani, A.

3254 - Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody^®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Badaoui, B.

2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Badar, T.

599 - Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
2754 - Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study
2795 - Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD^highbut Not FLT3-ITD^low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
4022 - Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)
4321 - Differential Impact on Survival in Myeloid Neoplasm Patients with U2AF1 Mutations
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4362 - CPX-351 for Blast-Phase Myeloproliferative Neoplasm (MPN-BP): Mayo Clinic Experience in 10 Consecutive Patients

Badaracco, J.

4865 - Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient and the Value of Addressing the Unmet Need

Badat, M.

2 - An Ancient Transcriptional Hub Couples Developmentally Regulated Gene Expression with Metabolism during Erythropoiesis

Badawi, M. A.

1864 - Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Biomarker-Selected Patients with Relapsed or Refractory Multiple Myeloma: Implication for Dose Selection
4548 - Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Badawi, M.

3365 - Substantial Alteration of Allogeneic Stem Cell Grafts Imposed By COVID-19 Pandemic Related Recommendations

Badawy, S. M.

499 - Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: Prospective Data from the ITP Consortium of North America (ICON) Quality Improvement Initiative
895 - Intravenous Fluid Replacement Therapy and Hospital Outcomes for Vaso-Occlusive Episodes in Patients with Sickle Cell Disease
3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols
3629 - The Influence of Social Vulnerability on the Prognosis of Chronic Myeloid Leukemia in Adults across the United States
4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia
4930 - The Effects of Social Vulnerability on the Prognosis and Outcomes of Hodgkin’s Lymphoma in Adults across the United States

Badbaran, A.

340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
3222 - Impact of High-Risk Disease on Outcome after CAR-T Cell Therapy for Multiple Myeloma: A Meta-Analysis of 759 Patients
3352 - Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies
3415 - Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation
4762 - Allogeneic Stem Cell Transplant for Myelodysplastic Syndrome in the New Molecular Era of IPSS-M

Bade, R.

3635 - Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia

Bader, C.

3408 - Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Bader, G. D.

2633 - A Novel Role for PLK1 in Leukemia Stem Cell Function in Acute Myeloid Leukemia

Bader, P.

370 - Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial
372 - Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study
2122 - Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany
4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Badillo, J.

4548 - Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone

Badillo, M.

1564 - Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma

Badley, A. D.

18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
256 - Targeting a Dominant Negative Splice Variant of TRAIL to Enhance CART Cell Functions

Badolato, R.

1266 - Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)

Badoux, X. C.

92 - Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Badowska, W.

1159 - Real Pandemic World Results of Personalized Prophylaxis of Bleeds in Polish Children and Adolescents with Severe Hemophilia a

Badros, A. Z.

757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial
3246 - Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial
4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Bae, S. H.

3046 - A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit

Baech, J.

4236 - Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Baeder, W.

874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Baek, Sr., D. W.

2935 - Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)

Baek, H. J.

2480 - Epidemiology and Clinical Characteristics of Hemophilia in Korea - Report of the Korean Bleeding Disorder Registry (KBDR)

Baena, R.

2980 - Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Baer, C.

228 - AML and MDS Classification According to Who 2022 and International Consensus Classification: Do We Invent a Babylonian Confusion of Languages?
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
467 - MDS Classification – Do We Still Have to Count Blasts?
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3861 - Molecular Evolution of Ccus Already Follows the Same Rules As MDS Progression
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?

Baer, D. M.

1804 - Risk Factors Predictive of Cardiac Toxicities from Ibrutinib: A Community-Based Retrospective Cohort Study of Patients with NHL in Northern California
1896 - Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib
1907 - Patients with IgM Monoclonal Gammopathy of Undetermined Significance (MGUS) or IgA with an M Band < 1.0 g/DL Have the Same Low Risk of Progression to Lymphoplasmacytic Neoplasm (LPN) As Those with IgG MGUS and an M-Band < 1.5 g/DL

Baer, M. R.

64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
536 - Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
714 - Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
1404 - Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study
2302 - Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
2360 - Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
2778 - Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
3683 - Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance
4067 - Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
4075 - Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)

Baer, S. L.

3427 - Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Baerlocher, G. M.

390 - Therapy in Patients with Chronic Myeloid Leukemia Outside of Clinical Trials: Results of the German CML-Registry (CML-VI)
1279 - Wnt and Notch Pathways Regulate Stemness of Myeloid Leukemia Cells Via IL33/ST2 Signaling

Baertsch, M. A.

309 - Single-Cell Multi-Omic and Spatial Analysis of Nodal B Cell Non-Hodgkin Lymphomas Reveals Plasticity in B Cell Maturation As a Driver of Intratumor Heterogeneity
644 - Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients – Meta-Analysis of 5,808 Trial Patients

Baeten, J. T.

3957 - Targeting ATR in TP53-Mutant AML/MDS

Baeten, K.

93 - Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Baetz, T.

1534 - Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
1620 - Canadian Cancer Trials Group (CCTG) LY.17: A Randomized Phase II Study Evaluating Novel Salvage Therapy Pre-Autologous Stem Cell Transplant (ASCT) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR-DLBCL) - Outcome of Rituximab-Dose-Intensive Cyclophosphamide, Etoposide, Cisplatin (R-DICEP) Versus R-GDP
2835 - Identification of Genetic Subtypes in Follicular Lymphoma

Baez, J.

770 - Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Baez Sosa, V.

- How the Personal Characteristics of Grit and Resilience Relate to Physician Well-Being

Baez Sosa, V.

1893 - A Multi-Centric Descriptive Study of Secondary MGUS in Patients with Cardiac Attr Amyloidosis

Baez Suarez, A.

3817 - Development of a Machine Learning Model Using Electrocardiogram Signals to Determine Acute Pulmonary Embolism

Baeza-Monedero, E.

3619 - Comprehensive Geriatric Assessment Is a Useful Tool for Predicting the Outcome of Elderly Patients with Hematologic Malignancies in Real Life

Bagaev, A.

4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Bagal, B.

469 - Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant
1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
1869 - Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
2976 - Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium
3137 - Targeting Transcriptional Kinase of CDK7 Halts Proliferation of Multiple Myeloma Cells By Modulating the Function of Canonical NF-Kβ Pathway and Cell Cycle Regulatory Proteins
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience
4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Bagg, A.

2901 - Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease
4221 - Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Baggett, C. D.

2287 - Functional Status and Mortality Among Older Adults with Multiple Myeloma

Baggott, C.

2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Bagley, R. G.

63 - The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
376 - Outcomes after Transplant in Relapsed/Refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia Patients Achieving Remissions after Menin Inhibition: SNDX-5613 (revumenib) Ph1 Experience

Baglin, T.

188 - Serpinpc in Persons with Severe Hemophilia (PwH): Updated Results from a Multi-Center, Multi-Part, First-in-Human Study

Bagnato, G.

2904 - Rituximab As an Effective Salvage Therapy in Pretreated Hairy Cell Leukemia Patients: The Bologna Experience

Bagnoli, F.

3438 - Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Bagot, M.

1631 - Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Bagratuni, T.

3167 - Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients

Bagri, A.

1218 - Characterization of Engineered Macrophages and Other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells

Bagri, J.

295 - HOXA9 Nucleates a Repressive Chromatin Complex with Nuclear Matrix-Associated Protein- Safb to Maintain Acute Myeloid Leukemia

Bah, O. M.

4075 - Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Bahadur KC, R.

3469 - Implementing RNAi Therapy Targeting FLT3 in Acute Myeloid Leukemia (AML)

Bahaj, W.

1246 - New Approaches to Chronic Idiopathic Neutropenia in the Era of Clonal Hematopoiesis

Bahaj, W.

507 - Splenectomy for Immune Cytopenias: Treatment Outcomes and Predictors of Response
598 - Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia
791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3062 - Metabolic Dysfunctions Driven By PRPF8 Explain Cases with Ring Sideroblasts without SF3B1 Mutations: Similarity/ Differences of Genotype/ Phenotype Association
3064 - Splicing Analysis Unveils Convergent Transcriptomic Pathways in U2AF1 S34 and Q157 Mutant Myeloid Neoplasia
3087 - Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting

Bahel, P.

3753 - Plasma Proteomic Profiling Illustrates Endothelial and Complement Signature in Patients with Alcohol-Associated Cirrhosis

Bahl, N. E.

3550 - Perspectives of Older Patients with Blood Cancers, Caregivers, and Oncology Clinicians on Benefits and Barriers of Technology for Home Functional Assessment

Bahlis, N. J.

97 - Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC‑1
101 - Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
158 - Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma
159 - Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
245 - Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma
472 - Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
568 - Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial
864 - Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4476 - CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients
4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma
4548 - Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
4793 - Preclinical Study of Enitociclib, a Selective CDK9 Inhibitor, in Combination with Bortezomib, Lenalidomide, Pomalidomide, or Venetoclax in the Treatment of Multiple Myeloma

Bahri, N. S.

1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease

Bai, B.

2853 - Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

Bai, B.

1621 - Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Bai, C.

1319 - ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML

Bai, J.

338 - Development and Validation of a Multiple Factor-Based Prognostic Score System of Thrombosis in Polycythemia Vera (MFPS-PV)
1722 - Comparison of the Efficacy and Safety of Pegylated Interferon Alpha-2b and Common Interferon Alpha in Patients with Myeloproliferative Neoplasms
3050 - Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)
4373 - Mild Fibrosis (MF-1) Increases the Risk of Secondary Cancers in Patients with Myeloproliferative Neoplasms-Clinical Characteristics of 1060 Myeloproliferative Neoplasms Patients with Secondary Cancers

Bai, J.

1626 - Zanubrutinib Plus Rituximab for the Treatment of Elderly Unfit Patients with Previously Untreated Diffuse Large-B Cell Lymphoma
4630 - Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform

Bai, L.

940 - DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Bai, O.

1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
4168 - The Clinical and Translational Exploration of the Role of S1P/SPHK1 Pathway in Non-Hodgkin Lymphoma with Obesity
4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Bai, S.

558 - Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker

Bai, T.

1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease

Bai, X.

1616 - Population Pharmacokinetics (PPK) and Exposure-Response to Support Body Surface Area (BSA)-Based Dosing of Brentuximab Vedotin in Pediatric Patients with Advanced-Stage Newly-Diagnosed Hodgkin Lymphoma (HL)

Bai, X.

1322 - Novel Sirpα-Fc Fusion Protein IMM01 Exhibits Dual Anti-Tumor Activities By Targeting CD47/Sirpα Signal Pathway

Bai, Y.

4271 - Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Bai, Y.

813 - Platelet ERO1α Is Crucial for Ca²⁺ Mobilization and Platelet Activation in Atherothrombosis

Bai, Y.

2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial

Bai, Y.

3519 - Inferior Vena Cava Filter Use at a Large Community Hospital: A Cross-Sectional Analysis

Baidildina, D.

2010 - Allogeneic Donor-Derived Myeloid Antigen Directed CAR-T Cells – for Relapsed/Refractory Acute Myeloid Leukemia in Children after Allogeneic Hematopoietic Stem Cell Transplantation: Report of Three Cases

Baidoun, F.

156 - Outcomes of DLBCL Patients Achieving Complete Remission after R-ICE Chemoimmunotherapy
4235 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Primary Cutaneous CD30+ T-Cell Lymphoma: National Cancer Database Analysis (2004-2018)
4238 - Clinical Characteristics, Survival Outcomes, and Prognostic Factors in Lymphocyte-Depleted Hodgkin’s Lymphoma: National Cancer Database Analysis (2004-2018)

Baik, J.

1551 - High-Resolution Single Cell T-Cell Phenotyping of B-Cell Lineage Lymphomas Reveals Unique Immune Signatures and Potential Targetable Vulnerabilities
2846 - BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas
4128 - Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Baile Gonzales, M.

1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Baile, M.

966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study

Baile, M.

4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Bailén, R.

2093 - Identification of Predictive Models Including Polymorphisms in Cytokines Genes Associated with Post-Transplant Complications after Identical HLA-Allogeneic Stem Cell Transplantation

Bailen, R.

269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era

Bailey, A.

880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Bailey, C.

106 - A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance
4746 - Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma

Bailey, M.

1634 - Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes

Bailey, M.

3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Bailey, M.

1542 - Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)

Bailey, N.

847 - Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
1634 - Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
4438 - Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton’s Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Bailey, S. L.

3837 - Deletion of 12-Lipoxygenase Improves Platelet Function after Storage and Transfusion in Thrombocytopenic Mice

Bailey, S. R.

262 - Patients with Deleterious Germline Variants in STXBP2 Develop Toxicity after CAR-T Cell Therapy with Axicabtagene Ciloleucel

Bailis, J.

3072 - Nonsense-Mediated RNA Decay Disruption Induces Altered Splicing in Spliceosome Mutant Cells

Bailliez, A.

1667 - Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype

Bailly, C.

166 - Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Bailly, S.

956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Baim, A.

1691 - Asciminib As Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)-H. Jean Khoury Cure CML Consortium Study
3011 - Treatment Free Remission after Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed after a Prior Attempt at TKI Discontinuation-H Jean Khoury Cure CML Consortium Study

Baines, A. C.

- Novel Bi-Specific for the Treatment of Patients with Multiple Myeloma - Teclistamab
- Panel Discussion

Bains Chawla, S.

2296 - Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States

Baiocchi, E.

15 - PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Baiocchi, R. A.

15 - PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis
276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia
704 - The FOXO1^TAD-p300-Mediated Lineage Survival Transcription Program Is a Targetable Dependency of Mantle Cell Lymphoma
763 - Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies – Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113
1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
1348 - PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
2839 - Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
3950 - Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics
4658 - New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV⁺ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Bair, S. M.

847 - Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study
958 - Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Baird, J. H.

543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Baird, J. H.

318 - Nivolumab Plus ICE As First Salvage Therapy in High-Risk Relapsed/Refractory Hodgkin Lymphoma

Baird, K.

1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
2926 - Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Real-World Retrospective Study

Baird, S.

1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Bajaj, J.

1235 - Targeting Microenvironmental Signals in Myeloid Malignancies
4384 - Isocitrate Dehydrogenase 2 Mutation Drives Bone Marrow Macrophage Dysfunction without a Complete Block in Hematopoietic Differentiation

Bajel, A.

606 - A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
2732 - Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Bajoghli, B.

1314 - A System-Level Study Reveals That a Defective Thymic Niche Accelerates the T-ALL Initiation

Bajor, M.

1310 - PIM Kinases Regulate Super-Enhancer-Dependent Gene Expression in Diffuse Large B-Cell Lymphoma

Bajpeyi, S.

1278 - Regulation of Oxidative Energy Metabolism By G0S2 in FLT3⁺ AML

Bajrami Saipi, M.

1490 - Overexpression of Oncogenic Inhibitory-ASPP (inhibitor of apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML

Bajwa, A.

847 - Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study

Bajwa, A.

2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Bajwa, R.

1379 - Outcomes of Elderly Patients with Acute Lymphoblastic Leukemia: Trends of Survival in the Last Two Decades
1900 - Cause Specific Analysis of Very Early and Early Mortality in Patients with Multiple Myeloma: Continued Improvements and Changes over Last 25 Years

Bajwa, R. J.

3703 - Predictors and Clinical Complications Associated with Antiphospholipid Antibodies in Sickle Cell Disease

Bakare, O.

900 - Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis
4884 - Pain Attitudes in Adults with Sickle Cell Disease: A Mixed Methods Study

Bakayoko, A.

3959 - Targeting the Mevalonate Pathway in the Mitochondria-Dependent Chemotherapy Resistance of TP53 Mutant Acute Myeloid Leukemia

Bakchoul, T.

2060 - Hypofibrinolysis in Pediatric Patients with Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation
3749 - Platelet Phosphatidylserine Is the Critical Mediator of Increased Thrombus Formation in Heparin-Induced Thrombocytopenia
3839 - Modulating Cold-Induced Platelet Apoptosis to Improve Cell Functionality and Platelet Half-Life

Baker, C.

2831 - Biologic Relevance of Variable Immunoglobulin Gene Diversity in B-Lymphoblastic Leukemia

Baker, D.

2303 - Experiences and Views of Leukemia Patients: A Global Survey
3615 - From Survey to Resource Hub: Chronic Lymphocytic Leukemia (CLL) Global Support Provision

Baker, F.

1339 - Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

Baker, F. G.

4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Baker, J.

2246 - Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

Baker, K. S.

3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Baker, K. S.

375 - Association between Patient-Reported Social Determinant of Health Outcomes and a Social Genomics Profile in Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
3535 - Return to School Challenges Affecting Adolescent Recipients of Allogeneic Hematopoietic Cell Transplantation: A Qualitative Interview Study of Caregivers

Baker, K.

3707 - Natural History of Albuminuria in Pediatric Sickle Cell Anemia

Baker, R.

1586 - Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Baker, R.

753 - Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: Ikema Subgroup Analysis

Baker, R.

1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Baker, S.

1451 - A Novel Inhibitor of FLT3 and Its Drug-Resistant Mutants with Superior Activity to Gilteritinib in Molm-13 Preclinical Acute Myeloid Leukemia Xenograft Model
2769 - Targeting the WT1^mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia
2778 - Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)
4798 - Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Bakhlakh, S.

1059 - Natural History and Rate of Progression of Retinopathy in Patients with Sickle Cell Disease: An 11-Year Retrospective Follow-up Analysis

Bakhtiari, M.

1534 - Crebbp Mutations Are Associated with Shorter Time to Progression in Limited-Stage Follicular Lymphoma Treated with Radiation
2835 - Identification of Genetic Subtypes in Follicular Lymphoma

Bakhtiarigheshlaghbakhtiar, M.

1296 - Single-Cell Profiling of Acute Myeloid Leukemia Identified ARMH1, a Novel Protein Associated with Proliferation, Migration, and Drug Resistance

Bakiri Papaioannou, M.

4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Bakirov, B.

964 - Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Bakkar, M.

3383 - Effect of ABO Mismatch and RBC Alloimmunization on the Outcomes of Patients with Sickle Cell Disease Undergoing Hematopoietic Stem Cell Transplantation

Bakker, M.

1459 - ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine /Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Baksh, M.

3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Bakshi, N.

7 - Impact of Arginine Therapy on Clinical Outcomes, Mitochondrial Function and Oxidative Stress in Children with Sickle Cell Disease Hospitalized with Vasoocclusive Pain Episodes: A Randomized Controlled Trial
3715 - Expansion of Content in the Phenx Toolkit for Sickle Cell Disease Pain

Bakuli, A.

2937 - L-Mind: A Safety and Efficacy Analysis of Tafasitamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Receiving Treatment for at Least 2 Years

Bal, S.

1930 - Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥70y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the Master Trial
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Bal, S.

364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
2299 - Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant
3237 - Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial
3593 - Induction Quadruplet Therapy and Minimal/Measurable Residual Disease (MRD)-Informed Treatment Adaptation in Newly Diagnosed Multiple Myeloma (NDMM): Results from an Academic-Community Pathway
4527 - Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
4528 - Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)
4530 - Drug Class Refractoriness, Not Number of Prior Lines of Therapy (LOT), Properly Classify Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Contemporary Regimens

Bala, N.

805 - Hormonal Contraceptive Use and Association with Thromboembolism in Women with Sickle Cell Disease

Bala, S. C.

2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Balabanian, K.

3110 - Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia

Balagadde, J. K.

4031 - Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute

Balaguer, M.

1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Balagurunathan, Y.

4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Balaian, E.

1753 - Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271⁺ Mesenchymal Stromal Cells

Balaian, L.

1277 - Modeling Premalignant Transformation of Hematopoietic Stem Cells in a Nanobioreactor in Microgravity
1452 - Decreased Embryonic Splicing Repressor Expression Enhances Splicing Modulator Sensitivity in Pediatric Acute Myeloid Leukemia Stem Cells
1453 - Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Balakrishnan, M.

2756 - Bmf-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML

Balakrishnan, V.

2171 - Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)

Balakumaran, A.

2019 - Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Balamurugan, M. A.

2518 - RBC Transfusion to Severe Anemic Murine Neonates Leads to Systemic Inflammation

Balana, A.

3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Balanda, N.

1245 - Novel Disease-Causing Mutations in UBA1 Reveal Disease Mechanisms in Bone Marrow Failure and Inflammation

Balas, A.

1997 - A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)
4704 - Naïve T Cell-Depleted Hematopoietic Graft Combined with Solid Organ Transplantation As Strategy to Induce Tolerance By Transient Mixed Chimerism

Balas, N.

492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
2304 - Processing Speed Improvement in Hematologic Cancer Survivors Treated with Allogeneic Blood or Marrow Transplantation– a Randomized Online Cognitive Training Intervention

Balasa, V. V.

3740 - Characterization of Inborn Errors of Immunity in Recurrent Autoimmune Cytopenias in Children: A Report from Central California Cohort

Balasch Carulla, M.

4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Balashov, D.

872 - Tcrαβ+/CD19+-Depletion in Hematopoietic Stem Cells Transplantation from Matched Unrelated and Haploidentical Donors in Pediatric Acute Lymphoblastic Leukemia Patients in Complete Remission

Balasis, M. E.

457 - Efficacy and Safety of Ruxolitinib for Treatment of Symptomatic Chronic Myelomonocytic Leukemia (CMML): Results of a Multicenter Phase II Clinical Trial
824 - The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms

Balasubramaniam, N.

4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Balasubramanian, P.

1407 - Real-World Outcomes for Acute Promyelocytic Leukemia: Need to Address Induction Mortality
2069 - A Model-Informed Precision Busulfan Dosing in Pediatric Patients Undergoing Hematopoietic Cell Transplantation- Real-World Data
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
4020 - Intracranial Bleeding in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide-Based Regimens: Impact on Relapse and Survival
4317 - Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells
4698 - Population Pharmacokinetics of Mycophenolic Acid in Haploidentical Transplant Recipients Receiving Post-Transplant Cyclophosphamide Based GvHD Prophylaxis

Balasubramanian, S.

4288 - Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data

Balasubramanian, S.

1806 - Patient Characteristics, Treatment Patterns, and Outcomes Following Covalent Btki Discontinuation in a Contemporary Cohort of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients

Balasubramanian, S. K.

598 - Comprehensive Age-Stratified Impact of NPM1 Mutation in Acute Myeloid Leukemia
857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
1246 - New Approaches to Chronic Idiopathic Neutropenia in the Era of Clonal Hematopoiesis
1877 - Early Transcriptional Activity of Vtr-297 – Results from an Ongoing Phase I Clinical Trial
2567 - Intense Immunosuppressive Therapy (anti-thymocyte globulin, alemtuzumab) As Salvage Therapy in Refractory T-Cell Large Granular Lymphocytic Leukemia and Pure Red Cell Aplasia
2752 - Real-World Outcomes and Cardiac Implications of FLT3 Inhibitors in Acute Myeloid Leukemia
2755 - Real-World Outcomes of IDH Mutant AML Patients Treated with or without IDH Inhibitors
2930 - Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3087 - Validation of the Molecular International Prognostic Scoring System in Patients with Myelodysplastic Syndrome
3501 - Picasso: An Open-Source Machine Learning Schema for Annotating Images in Hematology
3969 - Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML

Balay-Dustrude, E.

382 - Race, Ethnicity and Experienced Racism Are Associated with Adverse Physical and Mental Health Outcomes Among Cancer Survivors

Balayo, T.

700 - Haemogenic Gastruloids Recapitulate Developmental Haematopoiesis and Provide an Ontogeny-Relevant Context to Dissect the Origins of Infant Leukemia

Balazs, A.

3848 - De Novo Hematopoiesis from the Fetal LUNG

Balbas, M.

961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Balbin-Cuesta, G.

694 - Identification of Critical Proteins Required for Efficient Von Willebrand Factor Secretion Using CRISPR Knockout Screening
3642 - Identification of Novel Regulators of Erythropoiesis Using Whole-Genome CRISPR-Cas9 Screening
3650 - Identifying Novel Regulators of Erythroid Maturation and Proliferation Using a Genome-Scale CRISPR Activation Screen

Balbo Mussetto, A.

4197 - A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Balciuniene, J.

1010 - Next Generation Sequencing for the Diagnosis of Hereditary Hemolytic Anemias Including Pyruvate Kinase Deficiency: Report from a No-Cost Diagnostic Program

Baldacini, M.

4189 - Differential Phosphoproteomics Deciphers Physiopathology of High-Risk Mantle Cell Lymphoma

Baldauf, H.

4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Balderman, S. R.

279 - Risk of Therapy-Related Acute Myeloid Leukemia (t-AML) in Cancer Patients Treated with Chemotherapy with or without Radiotherapy: A National Population-Based Cohort Study Using SEER Registry
1746 - ANKRD26 Coding Variants in Myeloid Neoplasia

Baldi, A. J.

1026 - Iron Supplementation May Selectively Reprofile the Gut Microbiome in Iron-Deficient Bangladeshi Infants

Baldini, L.

1580 - Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study
3213 - Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3438 - Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Baldomero, H.

3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Balduini, A.

4313 - Haploinsufficiency of Calreticulin Causes Dysregulation of Hematopoiesis and Results in a Myeloproliferative Phenotype in an in-Vivo Mouse Model

Balduini, A.

1005 - Silk Bone Marrow-like Niches for Red Cell Production Ex Vivo

Baldus, C. D.

53 - Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
4665 - Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Balduzzi, A.

370 - Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial
372 - Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study
1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
2122 - Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8⁺ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Baldwin, W. H.

1140 - Marginal Zone B Cells Facilitate CD4 T Cell Proliferation in Response to Factor VIII in Mice with Hemophilia Α

Bales, A.

1112 - The Potential Role of ANKRD36 in Immune Thrombotic Thrombocytopenic Purpura
2457 - Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo

Balev, M.

60 - Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification

Balhuizen, A.

1743 - Therapeutic Potential of an Immune-Modulatory Vaccination Targeting Myeloid-Derived Suppressor Cells in Myelodysplastic Syndrome

Baliakas, P.

745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21^R110

Balicer, R.

3231 - Can We Identify Individuals at Risk to Develop Multiple Myeloma? a Machine Learning Based Predictive Model

Balitsky, A. K.

3587 - Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas

Baljevic, M.

4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Baljevic, M.

4923 - The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Balke-Want, H.

1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Ball, B. J.

Ball, E. D.

1453 - Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling
1932 - Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Ball, G.

4861 - Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

Ball, S.

463 - A Product of “Clash of Titans” or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome
465 - Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
604 - Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351
1484 - Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
1491 - The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
1755 - Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
2794 - Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
4410 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes

Ball, S.

1757 - Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients
3073 - Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
3099 - Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal

Balla, A.

2171 - Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)

Ballan, M.

1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Ballantine, J.

2247 - Prediction of High Acute Care Utilization in Children with Sickle Cell Disease

Ballard, E. W.

3194 - A Retrospective Comparison of the Side Effect Prevalence and Severity of Multiple Myeloma Triplet Vs Quadruplet Induction Therapy

Ballard, S. A.

3535 - Return to School Challenges Affecting Adolescent Recipients of Allogeneic Hematopoietic Cell Transplantation: A Qualitative Interview Study of Caregivers

Balleisen, S.

742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Ballen, K. K.

278 - Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?
4907 - The Impact of Social Vulnerability Index on Survival Following ASCT for Multiple Myeloma

Ballerini, F.

2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study

Ballestero, H.

2006 - In Vivo Generation of Memory-like NK Cells for the Treatment of AML and Myelodysplastic Syndrome; Early Clinical Applications of INKmune^TM

Ballili, M.

3383 - Effect of ABO Mismatch and RBC Alloimmunization on the Outcomes of Patients with Sickle Cell Disease Undergoing Hematopoietic Stem Cell Transplantation

Ballinger, S. W.

2046 - Mitochondrial Transfer to Host Cells from Ex Vivo Expanded Donor Hematopoietic Stem Cells

Balliu, M.

1720 - Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis
4313 - Haploinsufficiency of Calreticulin Causes Dysregulation of Hematopoiesis and Results in a Myeloproliferative Phenotype in an in-Vivo Mouse Model

Balmas-Bourloud, K.

395 - Proteomic and Lipidomic Investigation of an Ex-Vivo Human Model of Sickle Cell Disease Erythropoiesis and Patient Erythrocytes Reveals the Abnormal Localization and Dysfunction of the Proteasome, Disrupted Antioxidant Defenses and Altered Lipid Profiles

Balogh, M.

2183 - Molecular Landscape of Chronic Lymphocytic Leukemia Using Targeted Gene Panel Sequencing

Balounova, J.

1678 - Expression of Jak2 R1063H Leads to Altered Epor/Tpor Signaling, Changes in HSC Fitness and Represents Increased Risk of Thrombosis

Balsat, M.

50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
2724 - Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study

Baltasar, P.

4448 - Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Baltcheva, I.

2571 - Dose–Exposure–Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Baluch, A.

4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Balusu, R.

4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients

Balyan, R.

3338 - Updated Results and Correlative Analysis: Autologous CD30.CAR-T-Cell Therapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (CHARIOT Trial)

Balzarini, M.

1096 - Empagliflozin Modifies Neutrophils’ Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils

Balzarotti, M.

733 - PET-Driven Radiotherapy (RT) in Patients with Low Risk Diffuse Large B-Cell Lymphoma (DLBCL): 5-Year Results of the DLCL10 Multicenter Phase 2 Trial By Fondazione Italiana Linfomi (FIL)
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Bam, N.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Bambace, N.

3453 - The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Bambace, N. M.

661 - Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation
665 - Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

Bamigbola, O. A.

3537 - Patient Reported Experience with Fatigue, a Cross Sectional Study Examining Indolent and Aggressive Lymphomas

Ban, L.

1088 - Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors
2404 - Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England

Banaszak, L. G.

2717 - Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy – a Single Institution Experience from an Academic Center
3635 - Neighborhood Disadvantage, Insurance Status, and Molecular Profiling of Patients with Acute Myeloid Leukemia
4863 - A Quality Improvement Initiative to Improve Implementation of Guideline-Concordant Hereditary Myeloid Malignancy Syndrome Evaluation

Banavali, S.

4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Banchi, M.

1649 - Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

Banda, O.

2147 - Direct Delivery of mRNA-Loaded Lipid Nanoparticles to the Hematopoietic Stem Cell Niche

Bandara, M.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Banderudrappagari, R.

3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Bandini, L.

4071 - A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure

Bandyo, R.

2487 - Derivation and External Validation of Clinical Risk Assessment Model for Cancer Associated Thrombosis in Two Unique U.S. Healthcare Systems

Bandyopadhyay, S.

531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
3261 - Graft-Versus-Host Disease Induces Immune Dysregulation through Irreversible Damage to Specialized Immune-Interacting Fibroblastic Stromal Cells in Secondary Lymphoid Organs

Banerjee, A.

97 - Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC‑1
1911 - Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
3228 - Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Banerjee, K.

3313 - Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma

Banerjee, L.

951 - A Phase Ib/II Study of Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients with Relapsed/Refractory Follicular Lymphoma: Final Analysis and Progression-Free Survival Update

Banerjee, M.

1145 - Unfolded Von Willebrand Factor Interacts with Protein S and Limits Its Anticoagulant Activity

Banerjee, P. P.

168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Banerjee, R.

250 - Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Banerjee, S.

248 - No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Banerji, V.

890 - The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab

Banet, A.

4718 - Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Bang, S. M.

1192 - Treatment Patterns Among Venous Thromboembolism Patients Treated with Anticoagulants By the Presence of Active Cancer in South Korea
2506 - Preliminary Result of a Pilot Study of Apixaban in the Treatment of Splanchnic Vein Thrombosis
2935 - Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)
3046 - A Single-Arm, Open-Label, Multicenter Study to Assess Molecular Response of P1101 Therapy in Patients with Polycythemia Vera and Elevated Hematocrit

Bang, S. Y.

425 - the Prognostic Value of Physical Function in Older Adults with Acute Myeloid Leukemia Treated with Low Intensity Treatment
1392 - Venetoclax with Decitabine Versus Decitabine Monotherapy in Elderly Acute Myeloid Leukemia: A Propensity Score Matched Analysis
2108 - Impact of Different Donor Types on Post-Transplant Disease Control in Patients with MDS Receiving Anti-Thymocyte Globulin (ATG)-Containing Conditioning
4696 - Reduced Toxicity FluBu3 Regimen Showed a Comparable Post-Transplant Outcomes to a Myeloablative BuCy Conditioing in Acute Myeloid Leukemia Patients Receiving First Allogeneic Hematopoietic Stem Cell Transplantation in MRD Negative CR1

Bangalore, S.

4372 - Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Bangi, A.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Bangolo, A.

4511 - Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Bangudi, S.

3562 - Primary Care Provider Use and Depression Screening Among Transitioning Adolescents and Young Adults with Sickle Cell Disease
- Primary Care Provider Use and Depression Screening Among Transitioning Adolescents and Young Adults with Sickle Cell Disease

Banholzer, N.

1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM

Baniewicz, D.

983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Banik, A.

2015 - Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India

Banjanin, B.

1677 - Metaphyseal Stromal Progenitor Cells Are Skewed Via Wnt-Activation Towards Osteogenesis in Progressed Myelofibrosis

Bankar, A.

1371 - Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers
1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up
1380 - Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience
2691 - Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol
4037 - Clinical Outcomes in De Novo Versus Secondary NPM1-Mutated AML
4324 - Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy
4370 - Comparison of Clinical Outcomes between Transplant and Non-Transplant Therapies in Myelofibrosis Following Failure of First-Line JAK-Inhibitor

Banks, C. E.

4193 - Gli3 Is Required for M2 Macrophage Polarization and M2-Mediated Waldenström Macroglobulinemia Growth and Survival

Banks, G.

213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
831 - Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia
1410 - Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia—6-Year Follow-up Results
1689 - A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML)
2729 - A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

Banner, L.

1362 - Targeting Immunosuppressive Macrophages in the Cutaneous T-Cell Lymphoma Microenvironment

Bannerji, R.

2890 - Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)

Bannister, M.

89 - Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition

Bannoura, S.

3969 - Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML

Banos, A.

956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
3117 - A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Bansal, H.

3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Bansal, R.

554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
2032 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes
3343 - The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Bansal, R.

362 - Final Clinical Outcomes from a Phase 2 Trial of Posoleucel, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Clinically Significant Viral Infections Post-HCT
4703 - Lessons Learned from COVID-19 Pandemic: Outcomes after Sars-Cov-2 Infection in Hematopoietic Cell Transplant and Cell Therapy Recipients

Bansil, S.

4598 - Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells

Banti, A.

3813 - Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment

Bantilan, K. S.

1579 - Long-Term Outcome of Patients with Follicular Lymphoma Is Not Fundamentally Affected By KMT2D, EZH2, and Crebbp Mutational Status

Banz, Y.

2531 - Ribonuclease Inhibitor 1 (RNH1) Regulates Myeloid Lineage Choice through Cyclin-Dependent Kinase 1
4791 - Generation Natural Killer Cell-Mimic Nanoparticles for Active Targeting of Acute Myeloid Leukemia

Bao, A.

3230 - T-Cell Senescence and Exhaustion Are Associated with Interval Progression of Multiple Myeloma before Autologous Hematopoietic Cell Transplant

Bao, G.

3470 - Characterization of Hemoglobin Variants Due to in-Frame Deletions in the β-Globin Gene from CRISPR/Cas9 Gene Correction for Sickle Cell Disease
4081 - Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism

Bao, H.

336 - Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Bao, H.

4228 - A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Bao, K.

1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Bao, K.

229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study

Bao, L.

4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Bao, L.

2255 - Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study
4565 - Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Bao, X.

601 - Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Bao, Y.

4243 - Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis

Bao, Y.

3880 - NLRP6 in the Bone Marrow Microenvironment Regulates HSPC Quiescence Via MGP/RUNX2

Baptista, J. P. R.

4940 - Hematology Referral, Stroke Recurrence and Mortality Among Patients with First Ischemic Stroke and Polycythemia or Thrombocytosis

Baptista, M. J.

4175 - Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications

Baptista, P. M.

3741 - A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation

Baptiste, A.

4893 - Clinical Course and Outcomes in Older Patients with Sickle Cell Disease at a Community Hospital

Bar, N.

162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
4671 - Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Bar-Natan, M.

60 - Prognostic Impact of Day 14 Bone Marrow (D14 BM Bx) in Acute Myeloid Leukemia (AML) in the Setting of European Leukemianet (ELN) Risk Classification
1735 - Molecularly Targeted Combination Therapy for Advanced Phase Myeloproliferative Neoplasm: MPN-RC 119

Bar-On, Y.

1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Bar-Shai, A.

4736 - Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes – a Single Center Longitudinal Cohort Analysis

Barabe, F.

48 - High Fatality CBFA2T3-GLIS2 Pediatric Acute Megakaryoblastic Leukemia Is Sensitive to BCL-X_L Inhibition
1433 - Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study

Barabino, L.

1803 - Infection Risk Evaluation Based on a Novel Scoring System in Chronic Lymphocytic Leukemia (CLL) Patients at Diagnosis

Baragetti, A.

1096 - Empagliflozin Modifies Neutrophils’ Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils

Barajas, J. M.

2587 - Human Models of NUP98-Rearranged Leukemia Reveal Fusion-Specific Molecular Mechanisms
3282 - Establishing Immunocompetent Leukemia Models to Investigate the Impact of CAR T Cells on the Immune Microenvironment and Bone Marrow Niche
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion

Barajas, S. O.

2540 - Chronic Inflammation Drives p53 Mutant Clonal Hematopoiesis Via Activating the NLRP1 Inflammasome

Barakat, E.

101 - Role of TNFRSF17 and GPRC5D Structural and Point Mutations in Resistance to Targeted Immunotherapies in Multiple Myeloma (MM)
864 - Dysfunctional Hyper-Expanded Clonotypes and Lack of TCR Clonal Replacement Predict Resistance to T Cell Engagers in Multiple Myeloma
4476 - CRBN Structural Changes, Copy Number Changes and COP9 Signalosome Subunits Gene Expression Mediate Sensitivity to New Celmod Compound CC-92480 in Multiple Myeloma Patients

Barakat, L. P.

898 - Barriers to Transition from Pediatric to Adult Care in Adolescents and Young Adults with Sickle Cell Disease: A Mixed-Method Study on the Impact of Systems of Inequity

Barakat, R.

821 - A Link between Blood Flow and the Inflammatory Networks That Govern Hematopoietic Stem Cell Specification

Barakat, S.

890 - The Economic Impact of Treatment Sequencing in the Management of Chronic Lymphocytic Leukemia in Canada Using Venetoclax Plus Obinutuzumab

Baral, A.

2202 - Identification and Outcomes of Low-Risk PE Admissions: A Community Experience

Baran, A. M.

1558 - Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment
1794 - Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment
1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions
4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Baran, B.

3789 - Personalization of Clotting Factor VIII Replacement Therapy Based on Population Pharmacokinetics in Adult Patients with Severe Hemophilia a Who Frequently Switch Factor VIII Concentrates

Baran, N.

1335 - Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia
2610 - Mdm2 Loss of Heterozygosity Cooperates with Mutant p53 in the Development of Acute Myeloid Leukemia
2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
3956 - Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia
3958 - ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Altering Drp1-Dependent Mitochondrial Fission and Metabolism
3979 - Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes

Baran-Marszak, F.

3110 - Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia

Barankiewicz, J.

1822 - Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
4615 - CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Baranwal, A.

1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
2806 - Characteristics and Outcomes of Radiation Therapy-Related Myeloid Neoplasms
3094 - Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
3095 - Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53therapy-Related Myeloid Neoplasm Patients with Poor Outcome
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Barasa, N.

511 - De Novo Germline DHX38 Variant Associated with Alternative Splicing of Multiple Transcripts in Iron-Related Pathways in a Patient with Atypical Congenital Dyserythropoietic Anemia with Ring Sideroblasts

Barash, Y.

1416 - Non-Canonical Exon Usage in Pediatric Leukemia: Implications for Chemoresistance

Baratam, P.

1423 - Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups

Baratè, C.

2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

Baratto, L.

2885 - FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort

Barba, C.

2425 - Actin Bundling Protein L-Plastin Regulates Megakaryocyte Membrane Rigidity and Platelet Spreading

Barba, P.

264 - The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
4663 - CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Barba, P.

155 - Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
439 - YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma
4631 - Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry

Barbagallo, J.

1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

Barbanti, M. C.

653 - Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia

Barbany, G.

4141 - The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia

Barbaric, D.

49 - Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Barbarich, L. C.

2438 - Pregnancy Induces a Thrombogenic Platelet Transcriptome in Mice

Barbaro, P.

2397 - Benchmarking Paediatric Sickle Cell Care in Australia

Barbato, A.

3159 - Arginine Deprivation in Microenvironment Makes Multiple Myeloma Resistant to Proteasome Inhibitors Via Increased Lactate Release and Metabolic Rewiring

Barber, A.

243 - Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway

Barber, I.

684 - NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells

Barberio, C.

4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Barberio, J.

1858 - Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs

Barbie, D.

3734 - Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Barbieri, D. A.

2591 - Corticotropin Releasing Hormone Binding Protein (CRHBP) Regulates Hematopoietic Function and Acts As a Novel AML Tumor Suppressor through a Crh-Independent Mechanism

Barbosa, Jr., A.

2151 - Clinical Validation of Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of B Neoplasia

Barbosa, I.

3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations

Barbosa-Morais, N. L.

363 - Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Barbour, A.

4649 - JAK1 Inhibition during CAR T-Cell Treatment Does Not Affect CAR T-Cell Proliferation, Persistence, or Function

Barbu, E. A.

4088 - A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

Barbui, A. M.

4638 - Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab

Barbui, T.

2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Barbui, T.

744 - Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Barbullushi, K.

3438 - Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients
4761 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Barbus, M.

227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Barcella, L.

1114 - Role of Hemostatic Biomarkers for the Identification of Patients with LONG-COVID19 Syndrome: Results from the ‘Accordi’ Study
1118 - Inflammatory and Coagulation Biomarkers in Patients with Sars-COV2 Infection Receiving COVID-19 Convalescent Plasma: The Bergamo Registry

Barcella, M.

817 - Unveiling the Biological Role of Peripheral Blood Human Circulating Hematopoietic Stem and Progenitor Cells
1999 - Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Barcellini, W.

31 - Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
506 - Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
1012 - Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
1017 - Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study
1021 - Mitapivat Improves Iron Overload in Patients with Pyruvate Kinase Deficiency
1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)
1208 - Concomitant Use of Sutimlimab and COVID-19 Vaccines in Patients with Cold Agglutinin Disease from the Phase 3 Cardinal and Cadenza Studies
1747 - Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-of-Concept Study
2325 - Hemolytic Markers, Mortality, and Thromboembolic Events in Cold Agglutinin Disease (CAD): A Retrospective Analysis of the Optum Electronic Health Record Database in the United States
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
3079 - Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study
3883 - Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study
LBA-2 - Oral Monotherapy with Iptacopan, a Proximal Complement Inhibitor of Factor B, Has Superior Efficacy to Intravenous Terminal Complement Inhibition with Standard of Care Eculizumab or Ravulizumab and Favorable Safety in Patients with Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia: Results from the Randomized, Active-Comparator-Controlled, Open-Label, Multicenter, Phase III APPLY-PNH Study

Barcellos, A.

1802 - Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
3183 - Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Barcenas-Lopez, D. A.

2832 - Whole Transcriptome Analysis in Mexican Children with High-Risk Acute Lymphoblastic Leukemia: A Preliminary Report from the Migiccl

Barcic, A.

1860 - Advanced Risk Stratification in Multiple Myeloma Beyond Traditional FISH: The First Prospective Real-World Evidence for SKY92 Gene Expression Profiling

Barclay, D. N.

3798 - Joint Status and Bleeding Phenotype Characterization in Severe and Non-Severe Hemophilia a and B

Barco, S.

140 - Social Determinants of Health and Pulmonary Embolism Treatment and Mortality: The Nationwide Inpatient Sample

Bardahl, J. G.

2206 - Fever and Neutropenia Management and Infectious Prevention Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study
4842 - Infectious Disease Antimicrobial Prophylaxis Strategies in Children with Severe or Very Severe Aplastic Anemia: A North American Pediatric Aplastic Anemia Consortium (NAPAAC) Study

Bardelli, G.

3035 - A Phase 1 Dose-Escalation Study of the Oral Epichaperome Inhibitor, Zelavespib (ZEL) in Combination with Ruxolitinib (RUX), in Patients with Relapsed Myelofibrosis: Results of the Dose Escalation Stage

Bardet, V.

2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network

Bardhan, O.

2416 - Trib1 Inhibition Promotes the Klr Effector State and Augments Checkpoint Blockade to Enhance T Cell Function during T Cell Exhaustion

Bardini, M.

4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Bardini, M.

1343 - Targeting Hyperactivated Lck in PAX5 Rearranged Pediatric B-Cell Precursors Acute Lymphoblastic Leukemia
2833 - Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia
3977 - The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance

Bardy, P. G.

2133 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

Bareau, B.

1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Barella, S.

3728 - Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

Barera, G.

817 - Unveiling the Biological Role of Peripheral Blood Human Circulating Hematopoietic Stem and Progenitor Cells

Baretton, G.

1499 - Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia

Barg, A. A.

2512 - Pediatric Splanchnic Vein Thrombosis: Systematic Review and Meta-Analysis
2513 - Venous Thromboembolism in Children, Adolescents and Young Adults: Findings from the Riete Registry

Bargay, J.

118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Bargay, J.

866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial

Bargay, J.

867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Bargou, R. C.

3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Bari, S.

325 - A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia

Bariana, M.

2682 - Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Barina, L.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Barion, B. G.

3751 - Extracellular Vesicles As Markers of Inflammation and Hypercoagulability during the First Month of Sars-COV-2 Infection in Outpatients and Hospitalized Patients

Barisic, D.

703 - Smarca4 (Brg1) Controls Germinal Center B-Cell Development and Is a Haploinsufficient Tumor Suppressor in Lymphoma

Bark, D.

- Microsystems Based Technologies to Measure and Model Hemostasis

Bark, K.

455 - Transcriptional and Metabolic Profiling Reveals Alpha-Ketoglutarate As a Novel Mediator of Aberrant Platelet Activity and Inflammation in Myeloproliferative Neoplasms

Barker, F.

4802 - A Rapid Genotyping Assay for CSF Accelerates Diagnosis and Treatment Initiation for CNS Malignancies

Barker, J. N.

127 - Analysis of 372 Adult Allograft Recipients Reveals Associations between Non-European Ancestry, Low Socioeconomic Status, and Receipt of HLA-Disparate Grafts
881 - Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia
2077 - Tracking Immune Reconstitution in the Bone Marrow Following Allogeneic Hematopoietic Transplantation in Humans Reveals Early Dominance of Innate Lymphoid Populations
2092 - Outcomes and Management of Sars-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation (HCT) and CAR-T Therapy

Bärmann, B. N.

3554 - The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation

Barnard, J.

791 - Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia

Barnard, L.

762 - Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) – Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Barner, J.

Barnes, J. A.

937 - KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Barnes, Y.

3632 - Fatalities from Tumor Lysis Syndrome (TLS) after Anti-Hyperuricemic Monotherapy – Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Barnett, A.

141 - Bleeding Risk in Atrial Fibrillation and Thrombocytopenia: A Propensity Matched Cohort Study

Barnett, K.

4876 - Characteristics and Prevalence of Posttraumatic Stress Disorder and Posttraumatic Stress Symptoms Among Adults with Hemophilia a and B

Barnett, K.

1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea

Barnett, K. R.

1301 - Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment
2625 - Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia

Barney, M. E.

3760 - Effect of Rosuvastatin on Inflammatory Cytokines during Murine DVT Resolution

Barnfield, C.

2566 - Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Barnidge, D.

3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

Barnum, J. L.

3429 - Distinct Patterns in the Reconstitutions of Treg and T-Helper Subsets after Autologous Hematopoietic Stem Cell Transplantation in Juvenile-Onset Systemic Sclerosis Patients
3432 - Autologous Stem Cell Transplantation (ASCT) for Refractory Juvenile-Onset Systemic Sclerosis (jSSc) Is Safe and Well Tolerated and Improves Clinical and Patient-Reported Outcomes

Baro, E.

4284 - Minority Patients in the US Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy: A SEER-Based Simulation on Representation and Impact of Proximity to Authorized Treatment Center (ATC)

Barochia, A.

3711 - Pulmonary Function before and after Hematopoietic Cell Transplant in People Living with Sickle Cell Disease

Baron, F.

302 - Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
535 - 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG
3450 - Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation

Baron, F.

363 - Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Baron, J.

58 - Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia
4061 - MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Baron, J. A.

4897 - Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas

Baron, M.

312 - EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients

Barone, A.

1035 - Association between Myocardial Iron Overload and Diffuse Myocardial Fibrosis in Thalassemia Major
3728 - Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

Barone, M.

1469 - Extracellular Vesicle-Based Liquid Biopsy Shows Clinical Relevance and Reveals Links with Single-Cell Metabolic Signature in Acute Myeloid Leukemia
4127 - Parallel Detection of Single-Cells and Extracellular Vesicles from Bone Marrow and Peripheral Blood Reveals Asymmetric Immunometabolic Profile in Acute Myeloid Leukemia

Barone, M.

2167 - Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling

Barr, H.

102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

Barr, P. M.

730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
1794 - Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment
1802 - Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
1809 - Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years
1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions
2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Barraco, D.

3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Barraco, D.

621 - Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Barraco, F.

235 - Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
1777 - Correlation of Clonal Hematopoiesis in Vexas Syndrome with Immunophenotype Alterations in CD34+ HSPCs (Hematopoietic Stem Progenitors Cells): Multiparametric Flow Cytometry Heterogeneity in CD34+CD38- Stem Cells Fraction and Upregulation of CD90 Thy-1 By Unsupervised Strategy Using PCA, Tsnee and Flowsom
3045 - Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Barragán, E.

1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Barrans, S.

735 - Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
2959 - Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)
4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Barranta, M. E.

2582 - Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag

Barredo, J. C.

3949 - AMPK Downregulates Histone Gene Expression Via Dissociation of a Chromatin-Associated Transcription Complex in Response to Metabolic Stress in Acute Lymphoblastic Leukemia

Barrell, A.

4570 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Barrena, S.

2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Barrera, L.

4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease

Barreras Ruiz, N.

2264 - Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy

Barreto, E. F.

4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Barreto, J. N.

4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Barreto Rodriguez, C. V.

3940 - MYCN Is Required in Immature T-ALL and Bears Epigenetic Marks Associated with Cell Identity

Barrett, E.

2757 - Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Barrett, M.

737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Barrett, T. J.

2392 - Acupuncture Alleviates Pain and Improves Quality of Life in Patients with Sickle Cell Disease

Barretta, E.

495 - Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

Barretta, E.

2827 - Diagnostic Utility of Whole Genome Sequencing in Adults with B-Other Acute Lymphoblastic Leukaemia

Barreyro, L.

2585 - UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies

Barrie, M.

3356 - Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network

Barrientos, A.

3483 - The Marine Product Elatol Is a Novel Inhibitor of Mitochondrial Translation Triggering the Integrated Stress Response and Apoptosis in Leukemia and Lymphoma Cells

Barrientos, J. C.

4431 - Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

Barrientos, J. C.

92 - Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study
1796 - Integrin Signaling Pathway Is Crucial for the Recently Divided Fraction of CLL Cells and Facilitates Cell Migration in a Disease Progressive Manner
1809 - Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years
2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
3112 - CD8+ T Cells from Patients with CLL Show Evidence of Granzyme B and Perforin Cytotoxic Capacity, Which Is Enhanced upon Exposure to Exogenous IL2 and/or IL21
3132 - Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
4429 - Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Barrientos Risso, C.

750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders

Barrington, S. F.

315 - Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy
319 - External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Barrio, S.

1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy
1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients
1882 - Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket

Barriocanal, C.

2264 - Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy

Barrios, M.

1026 - Iron Supplementation May Selectively Reprofile the Gut Microbiome in Iron-Deficient Bangladeshi Infants

Barrios-García, M.

2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study

Barry, J. M.

- The Great Influenza: The Epic Story of the Deadliest Plague in History

Barsan, V.

4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Barta, S. K.

154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
662 - Clinical Development of Senza5^TMCART5: a Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas
763 - Observational Cohort Study of People Living with HIV (PWH) Treated with CD19-Directed CAR T Cell Therapy for B-Cell Lymphoid Malignancies – Interim Results of AIDS Malignancy Consortium (AMC) Study AMC-113
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1512 - Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
2016 - Interleukin-18 Secreting Autologous Anti-CD19 CAR T-Cells (huCART19-IL18) in Patients with Non-Hodgkin Lymphomas Relapsed or Refractory to Prior CAR T-Cell Therapy
2265 - Real-World Treatment Patterns and Clinical Outcomes with Brentuximab Vedotin or Other Standard Therapies in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): A Retrospective Chart Review Study in the United States
2911 - A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma
2961 - Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Newly-Diagnosed Germinal Center Aggressive B Cell Lymphoma
2982 - Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with First Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Curative-Intent Immunochemotherapy
2988 - Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder
3280 - Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel
4281 - Clinical Laboratory Mutation Analysis Performed on Tumor Biopsies from Patients with Relapsed/Refractory Aggressive B Cell Lymphoma Treated with Palliative-Intent Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Bartalucci, N.

342 - Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis
4313 - Haploinsufficiency of Calreticulin Causes Dysregulation of Hematopoiesis and Results in a Myeloproliferative Phenotype in an in-Vivo Mouse Model

Bartash, R.

4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Bartels, M.

9 - Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat

Bartelt-Hofer, J.

3565 - Fitusiran Reaches People’s with Hemophilia and Their Caregivers’ Treatment Expectations: Qualitative Semi-Structured Interviews of Participants of ATLAS-OLE Trial (Interim analysis)
3566 - Patients with Hemophilia and Their Caregivers Prefer Treatment Attributes That Enable a More Active Lifestyle with Lower Risk of Inhibitor Development

Barth, D.

519 - Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors

Barth, P.

4570 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Barthe, A.

939 - Choline Kinase a Is Required for Alkylating Agent Resistance in T-Cell Acute Lymphoblastic Leukemia

Bartholdy, B.

1292 - Mechanisms of Cistromic Repositioning of the Transcription Factor PU.1

Barthuber, C.

4399 - Validation of a Novel Algorithm with a High Specificity in Ruling out MDS

Bartlett, C.

1959 - Non-Genotoxic Conditioning Approach for Autologous Hematopoietic Stem Cell Therapies through Transient mRNA Engineering Using Vector-Free Microfluidic Cell Squeeze® Technology

Bartlett, J. B.

2030 - Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Bartlett, N. L.

74 - Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma
77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
170 - Impact of Monoclonal Protein at Diagnosis on Outcomes in Patients with Marginal Zone Lymphoma: A Multicenter Cohort Study
441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
793 - Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
795 - Early Relapse within 24 Months after Frontline Systemic Therapy (POD24) Is Associated with Worse Survival in Patients with Marginal Zone Lymphoma: A US Multisite Study
1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2883 - Baseline PET Metabolic Tumor Volume Predicts Outcome in Advanced Follicular Lymphoma Patients Who Received First-Line Immunochemotherapy but Not Those Treated with Lenalidomide-Rituximab in the Phase III Relevance Study
2906 - Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
3319 - ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
4667 - Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Bartlett, N. L.

610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
4230 - Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Bartok, E.

1352 - NLRP3-Independent Inflammasome Activation By Proteasome Inhibitors

Bartoletti, D.

3761 - Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study

Bartolucci, P.

1060 - Is There an Acute Cardiac or Hepatic Involvement in Hospitalized Sickle Cell Disease Patients with a Vaso-Occlusive Crisis ?
3484 - Impact of Carotid Geometry on Sickle Cell Diseases-Related Cerebral Vasculopthy Development
3685 - Neutron Spin Echo Spectroscopy Allows an Extremely Precise Evaluation of Hemoglobin S Structure and Dynamics, and Provides Insights on HbF Therapeutic Target
3689 - Fetal Hemoglobin Induced Improvement in Relative Age of Sickle Red Blood Cells Determined through Glycated Hemoglobin Assessment By Flow Cytometry
3718 - Cervical Artery Lesions in Adults with Sickle Cell Disease : Are They Disease-Related ?
3719 - Impact of Transfusion Program during Pregnancy on the Obstetrical Outcomes in Sickle Cell Disease Women

Barton, D. F.

4915 - The Top Concerns at and Since Diagnosis: Standard v. High Risk Myeloma Patients

Barton, D.

3325 - Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Barton, J. C.

2461 - Regulation of VWF Cleavage Is Mediated By Coupling ADAMTS13 D- and C- Domain Binding Sites

Barton, K. S.

3535 - Return to School Challenges Affecting Adolescent Recipients of Allogeneic Hematopoietic Cell Transplantation: A Qualitative Interview Study of Caregivers

Barton, M.

181 - Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)
2252 - Efficacy of Interventions to Build Transition Readiness for Youth with Sickle Cell Disease: A 13-Year Evaluation of a Healthcare Transition Program

Barton-Baxter, M.

1145 - Unfolded Von Willebrand Factor Interacts with Protein S and Limits Its Anticoagulant Activity

Bartram, J.

4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Bartram, J.

819 - Hematopoietic Flt3+ Multipotent Progenitors Are Organized in Discrete Functionally and Hierarchically Distinct Populations

Bartsch, K.

2524 - Mirages – REDS Explorer: An Online Portal for Longitudinal Metabolomics Data from the REDS-III RBC Omics Study

Bartsch, L.

438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Bartyzel-Palinska, S.

3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Bartzeliotou, A.

3690 - The Clinical Significance of the Glomerular Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) in Renal Function of Caucasian Patients with Compound Heterozygosity for Hb S and β-Thalassemia

Barua, A.

1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms

Baruchel, A.

905 - Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors
1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Barué, V.

1880 - Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study

Baruwa Etti, A.

3710 - Real-World Outcomes in Adult Sickle Cell Disease Patients Treated with Crizanlizumab, Voxelotor or Both

Barve, A.

3874 - Sickle Cell Disease Compromises the Hematopoietic Stem Cells Bone Marrow Niche with Age

Barve, M. A.

229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Barwe, S. P.

2648 - Preclinical Validation of EZH2 and HDAC I Dual Inhibition As a Potent Therapy for Refractory Myeloid Leukemia Associated with Down Syndrome
2654 - Azacitidine and Panobinostat Overcome Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A-rearranged Pediatric AML
3966 - A Bone Marrow Mimetic 3D Co-Culture Model for Ex Vivo drug Testing of Down Syndrome-Myeloid Leukemia Cells
3972 - Selinexor Prolongs Survival in Patient-Derived Xenograft Models of Down Syndrome Myeloid Leukemia

Barzilai, M.

4331 - Chronic Myeloid Leukemia Reduces Survival in Elderly Patients (Age ≥ 75 Years Old): An Israeli Multicenter Retrospective Study

Barzilai-Birenboim, S.

520 - Thrombin Generation Is Differentially Affected By Anticoagulants in Patients with Acute Lymphoblastic Leukemia – an Ex-Vivo Study
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia

Basak, G. W.

2034 - Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
3648 - Hypoxia Regulates the Immunoregulatory Properties of CD71⁺ Erythroid Cells
4672 - Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Basanthakumar, A.

207 - Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas

Basar, R.

168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma

Basara, N.

832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

Basheer, F.

4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme

Basher, F.

479 - The DNA-Sensor AIM2 Promotes BCR-Activated B Cells in Chronic Graft-Versus-Host-Disease

Bashey, A.

491 - Phase II Study of PD-1 Blockade Following Fludarabine/Melphalan-Based Autologous Transplantation for Acute Myeloid Leukemia Patients Ineligible for Allogeneic Transplant
2070 - Differences in Patterns of Infections Among Allogeneic Hematopoietic Cell Transplant Patients Receiving Letermovir Prophylaxis for Cytomegalovirus
2120 - Selecting the Best Transplant Donor (HLA-Matched vs. Haploidentical) for Patients with Lymphoid Malignancy Based on Recipient HLA-B-Leader Genotype
3368 - Frequency and Clinical Significance of Mixed T-Cell Chimerism Following Myeloablative Busulfan and Cyclophosphamide Conditioning in HLA -Matched Donor Transplants for Myeloid Malignancies: An Analysis of 179 Patients Transplanted at a Single Center
3404 - Effect of CMV Reactivation and Letermovir Use on Chronic Gvhd Incidence Following Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers
3444 - HLA Evolutionary Divergence (HED) Informs the Effect of HLA-B-Loci Mismatch on Relapse and Disease Free Survival after Haploidentical Hematopoietic Cell Transplantation (Haplo) with Post-Transplant Cyclophosphamide (PTCY)
4763 - TBI-Based Myeloablative Conditioning Prior to Haploidentical Versus Matched Donor Transplantation for Acute Lymphoblastic Leukemia
4944 - Transition from Initial Therapy to Hematopoietic Cell Transplantation for Non-Favorable Risk Acute Leukemia and MDS Patients in the Era of Haploidentical Donor Availability: Assessment of Efficacy, Barriers and Racial Disparities in 269 Consecutive Patients Treated in an Integrated Leukemia/HCT Program

Bashir, Q.

115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
1929 - Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis
2128 - HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT
3405 - Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
3426 - Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond
4725 - Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis
4738 - Phase II Trial of Venetoclax (Ven) in Combination with Azacitidine (AZA) As Maintenance Therapy for High-Risk Acute Leukemia Following Allogeneic Stem Cell Transplantation (SCT)
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience
4764 - Transplant Outcomes for TP53 AML and MDS in a Contemporary Era

Bashir, S.

205 - Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

Bashirians, G.

4785 - Global Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy

Basile, M.

1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study

Basilico, C.

4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Basilico, S.

4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Basit, J.

4277 - R-CHOP Versus R-EPOCH in Primary Mediastinal Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
4925 - Second Primary Malignancy in Waldenström Macroglobulinemia: Insights from a Population-Based Analysis

Basit, M. A.

3766 - Efficacy and Safety of Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Immune Thrombocytopenia

Baskar, J.

1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Baskar, R.

4628 - Long-Term Follow-up of CD19/22 CAR Therapy in Children and Young Adults with B-ALL Reveals Efficacy, Tolerability and High Survival Rates When Coupled with Hematopoietic Stem Cell Transplantation

Baskar, S.

4488 - Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma

Basker, N.

2280 - Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort

Baskin-Doerfler, R.

1212 - ETV6 Represses TNF during Stress Hematopoiesis and Regulates HSC Self Renewal

Basma, N.

3951 - Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Basnet, B.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Basom, R.

3504 - Utilization of Natural Language Processing in Venous Thromboembolism Identification

Basood, M.

1344 - Inhibition of MAPK-ERK Signaling Pathway Overcomes Microrna-Mediated Ibrutinib Resistance in Mantle Cell Lymphoma

Bass, F.

2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
4042 - Clinical Characteristics of Chilean Adult Patients with Acute Myeloid Leukemia (AML): Analysis within the Framework of the Epidemiological Registry of AML of the Pethema Group

Bassanelli, G.

2507 - Acute Pulmonary Embolism and Cancer: Clinical Features, Management and Short-Term Course. Findings from the COPE Study

Bassermann, F.

116 - Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
1241 - Single Cell Transcriptomic Analysis of the Bone Marrow Microenvironment Uncovers a Role for Antigen Presentation Processes in MDS/AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
3919 - Targeting Extracellular Vesicle Secretion in Combination with Venetoclax Synergistically Induces Apoptosis in FLT3-ITD+ AML

Basset, A.

4486 - The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Basset, M.

3191 - Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Bassett, D.

698 - Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Bassett, R.

168 - Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Bassik, M.

209 - Genetic and Pharmacological Inhibition of BTK Increases Dasatinib Sensitivity in Vitro and In Vivo Including CNS-Infiltrating E2A-PBX1⁺/Pre-BCR⁺ ALL Cells
3998 - Niclosamide Inhibits Proliferation of Leukemia Cells and Synergizes with Chemotherapy

Bassiri, H.

2411 - Quantification of Neutrophil Extracellular Traps (NETs) in Pediatric Patients with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) through Plasma and Peripheral Smear Analysis
3733 - Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Basso, A.

2158 - Combined Inhibition of MCL1 By AZD5991 and BCL2/Bclxl By AZD4320 As Promising Strategies to Overcome Acute Leukemia Tumor Burden and Niche Chemoresistance
3476 - HCK Inhibition Displays Antineoplastic Activity on Acute Leukemia and Promotes Immune Regulation of the Bone Marrow Tumor Microenvironment

Basso, J.

2734 - Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

Basso-Ricci, L.

817 - Unveiling the Biological Role of Peripheral Blood Human Circulating Hematopoietic Stem and Progenitor Cells

Bastacky, M.

2754 - Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Bastian, L.

438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Bastida, J. M.

1136 - Identification By Longread Nanopore Sequencing of a Complex Structural Variant in ITGB3 with a Founder Effect Causing Glanzmann's Thrombasthenia in Two Unrelated Patients

Bastidas-Mora, G.

4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Bastos-Oreiro, M.

155 - Salvage Treatment with Novel Agents Is Preferable to Standard Chemotherapy in Patients with Large B-Cell Lymphoma Progressing after Chimeric Antigen Receptor T-Cell Therapy
269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
764 - Impact of Scholar-1 Refractoriness Criteria on the Efficacy of CAR-T Therapy in Aggressive B Cell Lymphoma, Compared with Non-Refractory Patients: A Real World Geltamo/Geth Study
1571 - Rituximab Maintenance after R-Bendamustine or R‐CHOP in First‐Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
4175 - Lymphomagenic Roles of MYC, E2F and Mir-150-5p in Plasmablastic Lymphoma: Therapeutic and Prognostic Implications
4208 - Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo
4210 - Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group
4275 - Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group

Basu, C.

158 - Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Basu, M.

4797 - High Throughput Pre-Clinical Models to Determine a Synergistic Molar Ratio of 5-Azacitidine to Venetoclax and Uncover Resistance Mechanisms to 5-Azacitidine and Venetoclax Combination Therapy in Acute Myeloid Leukemia

Basu, S.

3000 - A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA

Basu, S.

2280 - Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort
3245 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
4553 - Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
4559 - Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Basudhar, D.

361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Basyal, M.

946 - Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax
1335 - Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Bat, T.

857 - A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia
2441 - COVID-19 Associated 60-Day Acute VTE Events in Hospitalized Patients Can be Predicted By D-Dimer and Prior VTE but Not By Reticulated Platelets
3060 - Molecular Patterns Identify Distinct Subclasses of Myeloid Neoplasia
3818 - Clinico-Molecular Risk Factors and Management of Thrombosis in a Large Real-Life Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria in the New Era of Anti-Complement Inhibitors and Doacs

Bataller, A.

1695 - Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia
3090 - Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)
4401 - Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome

Bataller Torralba, À.

3284 - CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia

Batchala, P.

4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Batchelor, T.

1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group
4802 - A Rapid Genotyping Assay for CSF Accelerates Diagnosis and Treatment Initiation for CNS Malignancies

Bateman, C.

715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Bates, B.

200 - LPA81: Discovery of an Exceptionally Potent Protac Degrading Native and Mutant BCR-ABL1 Oncoprotein in CML

Bates, C. D.

3537 - Patient Reported Experience with Fatigue, a Cross Sectional Study Examining Indolent and Aggressive Lymphomas

Bates, D.

4894 - Patient-Reported Outcomes Among Adults with Hemophilia A on Prophylactic Treatment

Bates, L.

172 - "...Paying to be a Patient in the Hospital and the Parking Lot": Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers
380 - "If You Don’t Trust Your Doctor That Much...You’d Feel Less Confident Doing a Research Study": Factors Influencing Black Patient Participation in Hematology Trials
383 - "You Have Your Knowledge, but I Have My Knowledge of My Body": The Hematologist-Patient Relationship and Enrollment of Black Participants in Clinical Trials

Bates, V.

3823 - Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status

Bathala, T. K.

1378 - Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia

Bathini, S.

4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Batinić, D.

3363 - Use of G-CSF for Bone Marrow Graft Mobilization Increases NK Cell, Treg and iNKT Cell Graft Content, Possibly Lowering the Risk of Severe Acute Gvhd and Chronic Gvhd in HLA-Haploidentical Bone Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PT-CY)

Batlevi, C. L.

263 - Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy
323 - Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
730 - Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
954 - Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
2036 - Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy
2844 - LymphGen Classification of Diffuse Large B-Cell Lymphoma in a Cohort of Adolescent and Young Adult (AYA) Patients
2862 - Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies
4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
4169 - Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing
4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma
4222 - Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation
4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Batra, A.

281 - Effects of Autoimmune Disease on Non-High Risk MDS Outcomes: A Population Analysis

Batsuli, G.

2241 - Assessment of Menstrual Health and Bleeding Symptoms in Adolescent Girls and Young Women with Sickle Cell Disease

Batt, T. J.

1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

Batta, K.

87 - Integrative Analysis of Blast Phase Chronic Myelomonocytic Leukemia Reveals Distinct Transformation Phenotypes Predictive of Drug Response
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
2561 - The Functional and Molecular Alterations in Human Bone Marrow Mesenchymal Stem Cells in Chronic Myelomonocytic Leukemia

Battaglia, T.

4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Battault, S.

88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Batten, L. M.

218 - FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Batten, T.

1810 - First-in-Human Phase I Trial of a ROR1 Targeting Bispecific T Cell Engager (NVG-111) in Combination with Ibrutinib or As Monotherapy in Subjects with Relapsed Refractory Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL)

Battilà, I.

3824 - Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases

Battinelli, E. M.

- Platelets and Cancer Immune Escape

Battipaglia, G.

2124 - Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Battista, M.

2895 - Impact of COVID-19 Pandemic Waves on Outcomes of Patients with Previously Untreated Advanced Follicular Lymphoma Enrolled in the Urban Ambispective Study in Italy

Battistella, M.

1631 - Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Battistini, R.

1649 - Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

Battram, A. M.

976 - Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells
4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Battula, V. L.

1315 - Activin-like Kinase 2 (ALK2/ACVR1) Is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia

Bauer, D. E.

1259 - Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model
4786 - Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness

Bauer, K.

3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma

Bäuerle, T.

3348 - Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Bauersachs, R.

3819 - Early Time Courses of Recurrent Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

Baues, C.

317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Baughman, T.

1328 - Pharmacodynamic Effects of Nirogacestat, a Gamma Secretase Inhibitor, on B-Cell Maturation Antigen in Healthy Participants

Baughn, L. B.

1830 - Variation in the Immune Tumor Microenvironment in Relation to Self-Reported Race in Individuals with Multiple Myeloma
1850 - Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
4177 - Characterization of Genetic Findings Underlying Aggressive B-Cell Lymphomas with Atypical Results on MYC Break-Apart Fluorescence in Situ Hybridization (FISH) Analysis
4544 - Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Baugier de Materre, A.

616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)

Baul, S. N.

2353 - Differential Erythrocyte Phosphatidylserine Exposure Is Associated with Variations in Clinical and Haemostatic Parameters: A Study Involving E-β and β Thalassemia Compared to Normal Population

Baumann, A.

2252 - Efficacy of Interventions to Build Transition Readiness for Youth with Sickle Cell Disease: A 13-Year Evaluation of a Healthcare Transition Program
2378 - Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes

Baumann, A.

860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma

Baumann, I.

564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia

Baumann Kreuziger, L.

1185 - Validation of Natural Language Processing for the Identification of Venous Thromboembolism in Radiologic Reports
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations

Baumann, M.

345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Baumann, S.

3348 - Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Baumann, T.

1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Baumeister, S. H.

2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
4662 - Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Baumgartner, F.

- Comparing Malignant Monocytoses across Classification Systems

Baumlin, P.

441 - Relapse Is Uncommon in Patients with Large B-Cell Lymphoma Who Are in Complete Remission at the End of Fixed-Course Glofitamab Treatment
737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Baur, R.

2863 - Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Bautista, F.

66 - Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Bautista Sirvent, F. J.

3987 - Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results from the ITCC-059 Phase IA and Phase II Trial
4047 - Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results from the ITCC-059 Phase 1B Trial

Bautista Sirvent, F. J.

1459 - ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine /Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia

Bauvais, M.

4404 - Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Bauzon, M.

402 - Selective Modulation of Activated Protein C Activities By an Exosite-Specific Nanobody Library
2458 - CT-001, a Rapid Clearing Factor VIIa, Provides Pro-Hemostatic Activity to Reduce Blood Loss in Coagulopathic Conditions Induced By Activated Protein C

Bavaro, D.

4927 - Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Bavli, N.

1135 - Bortezomib in Relapsed/Refractory Autoimmune-Mediated Thrombotic Thrombocytopenic Purpura: A Single-Center Case Series and Systematic Review

Baxter, J. E.

739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Baxter, N. N.

1597 - Treatment Patterns and Outcomes in Adolescent and Young Adults with Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Impact Cohort Population-Based Study
2263 - Prevalence, Severity, Trajectory, and Predictors of Symptom Burdens Among Adolescents and Young Adults with Hodgkin Lymphoma: A Population-Based Cohort Study

Bay, J. O.

985 - Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS
1652 - Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry
2130 - Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma

Bayés-Genís, A.

2180 - In silico Evaluation of BTK Inhibitors Mechanisms That Could Induce Atrial Fibrillation and Hypertension in the Treatment of Chronic Lymphocytic Leukemia

Bayewitz, A.

2398 - A Rare Case of Lenalidomide Providing Control of Severe Sickle Cell Anemia in a Patient with Coexisting Multiple Myeloma

Bayley, A.

663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b

Bayliss, T. J.

4570 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Baz, R. C.

1306 - Multiple Myeloma Evolution Is Characterized By Dynamic Epigenetic Landscapes
1848 - A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2118 - Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
2268 - Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
3232 - An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
3251 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study
3252 - A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma
3257 - Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma
3355 - Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Bazarbachi, A. H.

268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma

Bazarbachi, A.

302 - Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party
2095 - Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT
2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2126 - Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis
2130 - Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma
2136 - Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
- Global Hematology

Bazargan, A.

316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment

Bazeos, A.

4288 - Characterizing Diffuse Large B Cell Lymphoma (DLBCL) Disease Biology Features and Survival Outcomes By Patient Racial Groups Using Real World Data

Bazin, J. L.

3437 - Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

Bazinet, A.

944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
2125 - Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years
4059 - A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up

Bazou, D.

1886 - Targeted Metabolomics Approach Identifies Alterations in the Plasma Metabolome of Multiple Myeloma Patients with and without Extramedullary Spread
4519 - Proteomic Characterisation of the Plasma Proteome in Extramedullary Multiple Myeloma Identifies Potential Prognostic Biomarkers

Bazzi, T.

2421 - A Prospective Study Evaluating the Serological Profile of the Novel Coronavirus (COVID-19) Vaccines in Cancer Patients

Bazzo Catto, L. F.

2564 - Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Arising from Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Bdeir, K.

1110 - Modulation of Ultralarge Immune Complexes in Heparin-Induced Thrombocytopenia

Be Harvel, M.

1584 - Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting

Beà, S.

634 - Generation of Richter Transformation Models throughout Chronic Lymphocytic Leukemia Patient-Derived Xenografts: A Clonal Evolution Model
725 - Whole-Genome Analysis of Histone Modifications Reveals New Insights into the Biology and Clinical Behavior of Mantle Cell Lymphoma Subtypes

Beach, K. F.

1903 - Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination

Beach, M. C.

900 - Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis

Beagrie, R.

2 - An Ancient Transcriptional Hub Couples Developmentally Regulated Gene Expression with Metabolism during Erythropoiesis

Bear, J.

1889 - Antibody Response to COVID-19 mRNA Vaccine in Patients with Multiple Myeloma and Waldenstrom’s Macroglobulinemia after Primary Immunization and Booster: Reactivity to the Sars-Cov-2 WT Virus, Delta and Omicron Variants

Beas, F.

1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma

Beasley, L.

3850 - Extracellular DEK Activates NRF2 Antioxidant Targets and Drives Expansion of Functional and ROS-Low Human Hematopoietic Stem Cells

Beaton, N.

3483 - The Marine Product Elatol Is a Novel Inhibitor of Mitochondrial Translation Triggering the Integrated Stress Response and Apoptosis in Leukemia and Lymphoma Cells

Beatty, N.

486 - A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia

Beaty, M. W.

3673 - Novel Sheep Model of Sickle Cell Disease Reproduces Human Clinical and Laboratory Parameters

Beaubrun, A.

807 - Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations

Beauchamp, E.

4098 - SLFN11 Is a Potential Biomarker and Modulator of Treatment Response in AML

Beauchamp, E.

1332 - Targeting N-Myristoylation for Adult Acute Myeloid Leukemia Therapy

Beauchesne, P.

663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b
1974 - Functional T Cell Assays Are Predictive of Pre-Clinical Potency to Generate Allogeneic, Hypoimmune CD19 CAR T Cells

Beauchesne, P.

485 - Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

Beaumont, K.

327 - Dual Targeting of HDM2 and PPM1D As a Novel Therapeutic Approach for Myelofibrosis

Beaumont, T.

3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Beaumont, T.

808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Beaupain, B.

3723 - Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients

Beauvais, D.

112 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
1652 - Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

Beauverd, Y.

4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Beaven, A. W.

2946 - A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas
4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Beaver, L.

276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia
1326 - The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)

Beavers, A.

2186 - Novel Electronic Consultation for Sickle Cell Disease Inpatient Management

Beazley, D.

925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
2545 - Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point

Becares, J.

2264 - Real-World Evidence of Collecting Quality of Life (QoL) and Symptoms Perception Using the HM-PRO© Tool As a Patient-Reported Outcome Measure (PROM) in Patients with Lymphoma While Receiving Intravenous Chemotherapy
4936 - Feasibility of Electronic Patient-Reported Outcome (ePRO) Measurement Using PRO-CTCAE® Questionnaire to Improve Quality of Life Assessment and Healthcare Resources Management in Patients with Lymphoma Receiving Intravenous Chemotherapy

Becattini, C.

522 - Rivaroxaban Versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism: A Head-to-Head Analysis of the United States Cohort of the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban: (H2H-OSCAR-US)
2507 - Acute Pulmonary Embolism and Cancer: Clinical Features, Management and Short-Term Course. Findings from the COPE Study
3819 - Early Time Courses of Recurrent Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer

Becerra-Dominguez, L.

167 - CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Becher, B.

943 - Single-Cell Map of Childhood Acute Myeloid Leukaemia Using Variational Auto-Encoders
3342 - CAR T Cells and Their Immune Environment Synergize to Shape Distinct Immune Profiles in Response Versus Toxicity in B Cell Lymphoma Patients

Becherini, P.

3140 - Clonal Hematopoiesis: Exploiting Molecular Landscape of Multiple Myeloma Patients for Choosing the Most Appropriate Therapeutic Strategy
4458 - The Multi-Kinases Inhibitor ARQ531 Enhanches Anti-MM Activity of Imids By Dual Deregulation of MAP- and Cyclin-Dependent Kinases Activities

Becht, R.

1388 - A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL – a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Becilli, M.

775 - Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD

Beck, A.

3971 - The Novel Bispecific Innate Cell Engager (ICE^®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

Beck, D. B.

1182 - Thrombotic Manifestations in Patients with Vexas Syndrome
1245 - Novel Disease-Causing Mutations in UBA1 Reveal Disease Mechanisms in Bone Marrow Failure and Inflammation
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
- UBA1 Mutations and the Role of Ubiquitylation in Bone Marrow Failure
- Q&A

Beck, D. B.

2541 - Clonal Hematopoiesis in Vexas Syndrome

Beck, D.

1211 - Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions

Beck, J.

51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Beck, J. T.

82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
1598 - Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Beck, N.

246 - Pathological RANK Signaling in Combination with TCL1 Drives a Multiple Myeloma-like Disease in Mice

Becker, A. L.

3903 - Loss of Cell Fate Determinant LLGL1 Impairs Leukemia Development in Acute Myeloid Leukemia

Becker, H. J. J.

922 - Activated CMPs Act in Concert with the Spleen and Accelerate Hematopoietic Inflation after Transplantation

Becker, H.

239 - Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Becker, K.

1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Becker, M. W.

1235 - Targeting Microenvironmental Signals in Myeloid Malignancies
1761 - Therapeutic Modulation of the Marrow Microenvironment in MDS: A Phase I Trial of Abaloparatide and Bevacizumab
2046 - Mitochondrial Transfer to Host Cells from Ex Vivo Expanded Donor Hematopoietic Stem Cells
2555 - Human NGFR+/VCAM-1+/Mcam+ Bone Marrow-Derived Stromal Cells (NVML) Provide Enhanced Support for Normal Hematopoiesis and Are Disrupted in Myelodysplastic Syndrome
4384 - Isocitrate Dehydrogenase 2 Mutation Drives Bone Marrow Macrophage Dysfunction without a Complete Block in Hematopoietic Differentiation

Becker, M.

1284 - CBFB-MYH11 Is Required for the Maintenance of Inv(16) AML

Becker, N.

1855 - The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway
4479 - Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

Becker, P. S.

2683 - Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study
4073 - Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy
4687 - Sinusoidal Obstruction Syndrome in Adult Patients with B-Cell Acute Lymphoblastic Leukemia Treated with Inotuzumab Prior to Hematopoietic Stem Cell Transplantation

Becker, P. S.

496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Becker, S.

2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study

Beckert, V.

1576 - Population Pharmacokinetics and Exposure–Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma

Beckius, A.

2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Beckman, A.

1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series

Beckman, J. D.

1040 - Histone Deacetylase 6 Inhibition Prevents Vaso-Occlusion and Pain in Sickle Cell Mice
- How RBC and Endothelial Cell Interactions Influence Thrombosis in MPNs

Beckmann, E.

3377 - Treosulfan-Based Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Patients with Myelodysplastic Syndrome (MDS): Promising Survival Outcome Including Patients with High-Risk Disease

Beckwith, J. B.

1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

Becnel, M. R.

960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
1929 - Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Beder, T.

438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Bedi Singh, S.

4316 - PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary or Secondary Myelofibrosis and Severe Thrombocytopenia

Bednarski, J. J.

1214 - BCLAF1 Regulates Expression of AP-1 Genes and Fetal Hematopoietic Stem Cell Repopulation Activity
2419 - DNA Damage Signals Repress SYK in Early B Cells to Limit Leukemic Transformation

Beechinor, R. J.

4024 - Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens

Beedle, E.

2955 - A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)

Beedupalli, K.

2196 - ADAMTS13 Overtesting in Hospitalized Patients with Suspected TTP: A Retrospective Study

Beeker, A.

950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
1533 - Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma
1800 - Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Beenakumary, A. A.

3609 - Bortezomib Maintenance Appears Feasible, Safe and Effective in Newly Diagnosed Multiple Myeloma in a Resource Limited Setting - a Retrospective Analysis from South India

Beer, P.

2680 - STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma
3152 - CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Beerman, I.

1215 - Functional and Molecular Heterogeneity of Aging Hematopoietic Stem Cells

Begemann, M.

1263 - Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance

Beghin, A.

3055 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: Role of Disease Status and Chimerism on Long-Term Outcomes

Beghini, A.

4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Begic, X.

1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
4727 - Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Begley, S.

2313 - Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Begna, K.

421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
537 - Outcome of Patients with Acute Myeloid Leukemia Following Failure of Front-Line Venetoclax Plus Hypomethylating Agent Therapy
1402 - Molecular Predictors of Response and Survival in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy
1403 - Characteristics and Outcomes of Patients with BCOR Mutated Myeloid Neoplasms
3056 - Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome
3074 - Clinical and Molecular Characteristics of ETV6 Mutated Myeloid Malignancies
3086 - Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival
4064 - Venetoclax Plus Hypomethylating Agent (HMA) Based Induction for Treatment-Naive Older/Unfit Patients with FLT3-Mutated Acute Myeloid Leukemia (AML)

Begna, K. H.

62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
1715 - Determinants of Survival and Retrospective Comparisons in 183 Clinical Trial Patients with Myelofibrosis Treated with Ruxolitinib, Fedratinib, Momelotinib, or BMS-911543 JAK2 Inhibitor between 2007 and 2013
2541 - Clonal Hematopoiesis in Vexas Syndrome
4350 - Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm
4375 - Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Bégué, R.

3590 - High Incidence and Mortality of Invasive Fungal Disease in Children and Young Adults with Hematologic Malignancies in Hawaii and Pacific Islands

Béguelin, W.

708 - DTX1 Controls Germinal Center B-Cell Development and Lymphomagenesis

Beguin, Y.

1835 - Integrative Analysis of Proteomics and Transcriptomics Reveals the Etrb As Novel Single Target and New Combinatorial Targets for Multiple Myeloma
3376 - Early Hepatotoxicity in Patients with Myelofibrosis after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
4637 - Initial Clinical Results of Atalanta-1, a Phase I/II Trial of Point-of-Care Manufactured GLPG5101 (19CP02) in RR NHL

Beham-Schmid, C.

842 - Loss of Nr4a1 Causes an Elevated Expression of Co-Inhibitory Receptor:Ligand Axes and Results in a Diminished T Cell-Mediated Lymphoma Cell Killing in Aggressive Lymphoma
2159 - The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax

Behan, S.

732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Behare, S.

1832 - Evaluation of Repotrectinib’s Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo

Behdad, A.

849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
1520 - Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
1546 - Nodular Lymphocyte Predominant Hodgkin Lymphoma with Splenic Involvement Is Characterized By Inflamed Tumor Microenvironment, High Expression of Checkpoint Molecule Gene-Signature and Adverse Outcome
2838 - Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site

Behdenna, A.

3155 - Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Behera, T. R.

4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Behjati, S.

3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

Behlendorf, T.

1130 - Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag – Results of the 5^th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Behnan, T. T.

1435 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Behnert, A.

2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7

Behr, G.

3349 - Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein–Barr Virus-Positive (EBV⁺) Leiomyosarcomas (LMS)

Behrens, E. M.

2411 - Quantification of Neutrophil Extracellular Traps (NETs) in Pediatric Patients with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) through Plasma and Peripheral Smear Analysis
3733 - Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions

Behrens, Y. L.

2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Behrooz, A.

3497 - A Sensitive Machine Learning-Based Approach to Assess Multiple Myeloma t(11;14) Genetic Subtype from Histopathology Images

Beider, K.

2657 - CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Beidler, D.

1071 - Progress: Responsiveness Validation of an Electronic Patient Reported Outcome (ePRO) in Adults with Sickle Cell Disease (NCT05407805)

Beier, F.

1263 - Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance
4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Beier, R.

3902 - Transient Monosomy 7 Is a Rare Event in Young Children with SAMD9L Syndrome

Beilhack, A.

477 - Endothelial Cells Activate Alloreactive CD4⁺ T Cells to Initiate Acute Graft-Versus-Host Disease
1085 - Exogenous M-CSF Protects from Lethal a. Fumigatus pulmonary Infection By Tissue-Resident Alveolar Macrophages Early after Hematopoietic Cell Transplantation
1945 - Harnessing the Expression of TNFR2 on Tregs to Prevent Agvhd

Beiske, K.

734 - Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study
2853 - Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma
2864 - Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma

Beitinjaneh, A.

4658 - New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV⁺ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Bejan, C.

1223 - Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis

Bejanyan, N.

365 - Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
538 - Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience
779 - Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations
2131 - Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS
3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia
4633 - Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
4706 - Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Bejar, R.

2758 - A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2767 - A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2893 - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies
4390 - DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS
4414 - Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Bejjani, A.

2432 - Monogenic and Polygenic Contributions to Venous Thromboembolism (VTE) and Splanchnic Thrombosis in Patients (pts) with Pancreatic Cancer (PC)

Bekadja, M. A.

2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation
3212 - Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Bekendam, R. H.

- Platelet Dysfunction and Thrombosis in Myelofibrosis

Bekkers, M.

1342 - Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Bekoz, H.

2983 - Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Beksac, M.

247 - Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
1905 - Single Center Real World Data That Compares Autologous Stem Cell Transplant in the Era of Anti-CD38 Monoclonal Antibody Based Treatments for AL Amyloidosis
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Beksac, M.

3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3242 - MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
4680 - Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021

Belada, D.

609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R²) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Belada, D.

953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1619 - First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Belada, D.

1639 - How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?
1665 - Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Belcher, J. D.

180 - Cold Exposure Induces Vaso-Occlusion and Hyperalgesia in Mice with Sickle Cell Disease That Is Dependent on Complement Activation
1040 - Histone Deacetylase 6 Inhibition Prevents Vaso-Occlusion and Pain in Sickle Cell Mice
3675 - Extracellular Vesicles from Sickle Red Blood Cells Activate Endothelial Cells and Trigger Von Willebrand Factor-Mediated Sickle Red Cell Adhesion

Beldinanzi, M.

2824 - Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Belén Vidriales, M.

945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Belfon, A.

3412 - Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Belhabri, A.

211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
2737 - Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
2750 - Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Belhadj, K.

449 - Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa
761 - Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Belhadj Merzoug, K.

1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Belhassen, M.

4443 - Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the Snds Database (OSIRIS)

Belhocine, R.

4718 - Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Belickova, M.

1742 - Upregulation of ZEB1-Derived Circular RNAs Is Associated with SF3B1-Mutated Myelodysplastic Neoplasms
1749 - Aging-Related Gene Expression Signatures Define Likelihood of Disease Progression in Patients with Lower-Risk Myelodysplastic Syndromes
1783 - Risk Assessment in Patients with Myelodysplastic Neoplasms Using the Molecular International Prognostic Scoring System: A Single-Center Study from the Czech Republic
3975 - Targeting of SFK and G6PD Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations
4112 - Changes of Transcriptomic Landscape in Blasts of Responding and Refractory Acute Myeloid Leukemia Patients after Chemotherapy
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Beligaswatte, A.

1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Beligaswatte, A. M.

2133 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

Beliveau, F.

2816 - IL1R1 Expression Predicts the Benefit from Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics

Belizaire, R.

1271 - UBR5 Is a Hect E3 Ubiquitin Ligase That Regulates Chromatin Bound Nuclear Hormone Receptor Stability
3063 - Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML

Belkeziz, N.

3484 - Impact of Carotid Geometry on Sickle Cell Diseases-Related Cerebral Vasculopthy Development
3718 - Cervical Artery Lesions in Adults with Sickle Cell Disease : Are They Disease-Related ?

Belkina, A. C.

2405 - A Specialized Population of Monocyte-Derived Tracheal Macrophages Promote Airway Epithelial Regeneration
3848 - De Novo Hematopoiesis from the Fetal LUNG

Bell, A.

3325 - Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Bell, C.

283 - KLF1 Acts As a Pioneer Transcription Factor Via SMARCA4 to Open Chromatin and Facilitate Redeployment of an Enhancer Complex Containing GATA1 and SCL

Bell, H. L.

4137 - Dual Targeting of MDM2 and BCL2/Bclxl Demonstrates Potent Synergistic Activity in High-Risk Adult Acute Lymphoblastic Leukemia

Bell, J. A.

996 - Ethical Prioritization of Patients to CAR T-Cell Therapies: Tool Development and Process

Bell, J.

3846 - Characterization of Dynamic Niche Signaling Modules during Embryonic Hematopoietic Development Using Spatial Transcriptomics

Bell, S.

1058 - Trials in Progress: Two Randomized, Double-Blind, Multicenter, Placebo-Controlled Trials Investigating the Efficacy of Voxelotor on Cerebral Blood Flow and Neurocognitive Function in Patients with Sickle Cell Disease

Bellanger, C.

845 - CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients
1826 - TP53 CRISPR/Cas9 Reveals Strict BAX Dependence in the Response to BH3 Mimetic Targeting MCL1
2680 - STP938, a Selective CTPS1 Inhibitor, Shows Single Agent Activity and Synergy with BCL2 Inhibition in Preclinical Models of Mantle Cell Lymphoma

Bellanne-Chantelot, C.

3723 - Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients

Bellarosa, D.

1310 - PIM Kinases Regulate Super-Enhancer-Dependent Gene Expression in Diffuse Large B-Cell Lymphoma
1333 - PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia
1822 - Super-Enhancer-Driven PIM Kinase Upregulation in Multiple Myeloma Maintains the Plasma Cell-Specific Oncogenic and Microenvironmental Circuits, and Can be Efficiently Targeted By the Pan-PIM Inhibitor MEN1703
2867 - MEN1703-Mediated PIM Kinases Inhibition Impairs Protumoral and Immunosuppressive Phenotype and Functions of Macrophages in Classical Hodgkin Lymphoma

Belle, I.

2005 - Effective Cell Dose and Functional Attributes of Azercabtagene Zapreleucel (azer-cel; PBCAR0191) Associate with Allogeneic CAR T-Cell Safety and Efficacy in Patients with Relapsed/Refractory B-Cell Lymphoma

Bellesso, M.

3129 - Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL
3549 - Financial Impact of Imatinib Discontinuation in Brazil – a Real World Evidence Pharmacoeconomic Study in Chronic Myeloid Leukemia of a Private Institution

Belli, A. J.

1802 - Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
3183 - Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Belli, F.

1333 - PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

Belli, S.

161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Bellido, M.

348 - Subcutaneous Epcoritamab in Patients with Richter’s Syndrome: Early Results from Phase 1b/2 Trial (EPCORE CLL-1)
1645 - First-Line Treatment and Outcome of T-Cell Prolymphocytic Leukemia in the Netherlands; A Nationwide Population-Based Study
1800 - Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial
4008 - The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Bellini, M.

744 - Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
4765 - Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Bellissimo, D.

590 - Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Bellissimo, D. B.

1166 - Characterization of CNVs in a Large Cohort of VWD Patients Reveals Relationship between Disrupted Regions, Clinical Variables and Disease Type

Bellissimo, T.

4158 - Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Bellman, P.

3605 - Hematological and Non-Hematological Toxicities in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide, and Dexamethasone (DPd)

Bello, C.

2946 - A Pilot Study Evaluating Acalabrutinib for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphomas

Bello-Manga, H.

2396 - Insights into Vaso-Occlusive Crises-Related Readmissions in Patients with SCD across Geographic Regions

Bellofiore, C.

3191 - Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Bellomarino, V.

2824 - Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome

Bellomo, C.

4673 - Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Bellone, M.

- Nutrition Gut Microbiome Connection (Translational Focus)

Bellosillo, B.

339 - Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Bellver, M.

4240 - Prospective Assessment of Motor Neurotoxicity and Sarcopenia in CD30+ Lymphoma Patients Treated with Brentuximab Vedotin. Single Center Multidisciplinary Unit Experience

Belmondo, T.

956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Belot, A.

2282 - Evaluation of Participation and Recruitment Bias in a Prospective Real-Life Multicentric Cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for Newly Diagnosed Lymphoma Patients over One Year in a Hematology Department of Teaching Hospital

Belotti, A.

471 - Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy
3213 - Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
4575 - Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Belotti, D.

1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8⁺ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Belousov, A.

1544 - Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide
2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
4272 - Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application

Belova, E.

4159 - Correlative Biomarkers for CART19 Response in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Belsham, E.

829 - High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Belsky, J.

2914 - Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children’s Oncology Group (COG) AHOD1331 Study

Beltrami, G.

710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Beltrami Moreira, M.

3809 - Sars-Cov-2 Vaccination in Pre-Existing and De Novo ITP: A Single Center Experience with Long-Term Follow-up

Beltran, A. L.

2774 - Promising Safety and Efficacy Results from an Ongoing Phase 1b Study of Pembrolizumab Combined with Decitabine in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
4051 - Interim Results of a Phase 1/2 Study of Pembrolizumab Combined with Blinatumomab in Patients with Relapsed/Refractory (r/r) ALL

Beltran, B. E.

445 - Clinical Features, Treatment Patterns, and Outcomes Among 837 Patients with Adult T-Cell Leukemia-Lymphoma in the Real-World Setting: A Comparison of Endemic Regions
2965 - Progression of Disease within 5 Months of Adult T-Cell Leukemia-Lymphoma (ATL5) As a Clinical Endpoint for High-Risk Mortality Outcomes in the Real-World Setting: A Multinational Cohort Analysis
2980 - Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Real World Experience in Latin America. A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
4244 - Treatment Patterns and Survival of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma in Latin America
4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Beltrán, B. E.

2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Beltrán, C.

3199 - Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup

Bemrich-Stolz, C. J.

504 - Diagnosis and Management of Isolated Neutropenia: A Survey of Pediatric Hematologists Oncologists
2251 - Vaccine Schedule Disparities Exist for Pediatric Patients with Sickle Cell Disease

Ben Shlomo, Y.

3231 - Can We Identify Individuals at Risk to Develop Multiple Myeloma? a Machine Learning Based Predictive Model

Ben Yehuda, D.

4847 - End-of-Life Therapeutic Burden: A Comparative Study of Hematologic and Solid Tumor Malignancies

Ben-Califa, N.

515 - Erythropoietin Administration Delays B Cell Maturation and Promotes B Cell to Erythroid Transdifferentiation in Mice

Ben-Crentsil, N. A.

824 - The Long Non-Coding RNA MALAT1 Is Necessary for Hematopoietic Stem and Progenitor Cell Expansion and Preleukemic Myeloproliferation in TET2 Deficient Myeloid Neoplasms

Ben-David, Y.

3269 - Transcription Factor Fli-1 Regulates T Cell Immunity and Tolerance in Gvh and GVL Responses

Ben-Neriah, S.

71 - Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma
308 - Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma
546 - Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
555 - Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia
844 - TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
4166 - Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Benachour, S.

4101 - Comparison of Risk Stratification Tools (ELN-2022, ELN-2017, Lindsley et al., Papaemmanuil et al. and ALFA classifier) in Predicting Outcomes of Patients with Acute Myeloid Leukemia

Benajiba, L.

326 - JAK Inhibition Mediates Clonal Selection of RAS Pathway Mutations in Myeloproliferative Neoplasms
341 - Distinct Clinico-Molecular Arterial and Venous Thrombotic Scoring Systems for MPN Patients Risk Stratification
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Benakli, M.

2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Benard, F.

4248 - Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Benatti, S. V.

1114 - Role of Hemostatic Biomarkers for the Identification of Patients with LONG-COVID19 Syndrome: Results from the ‘Accordi’ Study

Benavente, C.

4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Benavente Cuesta, C.

3536 - COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies
4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Benayed, R.

2862 - Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

Benbarche, S.

456 - RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

Benboubker, L.

1880 - Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France: The Remix Study
1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Benbrahim, O.

1726 - Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study
3115 - Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Bence-Bruckler, I.

1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Bencini, S.

4394 - Characteristics and Distribution of Erythroid Progenitors and Precursors Correlate with Erythropoiesis Stimulating Agents (ESAs) Response in Lower Risk Myelodysplastic Syndromes

Bencomo, A. E.

1278 - Regulation of Oxidative Energy Metabolism By G0S2 in FLT3⁺ AML
1465 - 19S Proteasome Subunits As Oncogenes and Prognostic Biomarkers in FLT3-Mutated Acute Myeloid Leukemia (AML)

Bencrentsil, N.

45 - XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Bendapudi, P. K.

401 - Coagulation Factor XII Is Activated Via Noncanonical Binding to Platelet Integrin αIIbβ3
1178 - Use of Plasmic Scores to Aid Diagnosis of aHUS: A Real-World Analysis of Hospitalized Patients from the Premier Healthcare Database
4803 - A Machine-Learning Derived Red Blood Cell Morphology Tool Enables Differential Diagnosis and Novel Single-Cell Analyses

Bendek, G.

2228 - Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Bender, B.

3145 - Non-Coding RNAs Regulate Novel Signaling Pathways in AL Amyloidosis That Are Targetable By BCL2, PI3K and MEK Inhibitors

Bendia, E.

3824 - Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases

Bendig, S.

438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Bene, M. C.

50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
1257 - Efficacy of Anti-Sars-Cov-2 mRNA Vaccines in Adults with Severe Acquired Aplastic Anemia with or without Allograft
2086 - Sars-Cov-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Transplant Recipients
2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
3045 - Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim
3420 - Higher Proportions of Monocytic-Myeloid-Derived Suppressive Cells (mMDSC) before Allotransplant Predict Relapse in Acute Leukemia Patients
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo
4404 - Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Béné, M. C.

873 - Early In Vivo Generation of Vγ9Vδ2 T Cells after Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide: A Monocentric Phase 1 Study
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
3410 - Incidence and Severity of COVID-19 Infections in a Cohort of 211 Allotransplanted Patients after One or Two Boosters during the Omicron Wave in France
4270 - Clinical Research in Western Africa: Efficacy and Safety of a Phase II Study of R-CHOP in First-Line DLBCL in Senegal
4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351
4688 - Addition of ATG to Clofarabine-Based Reduced Intensity Conditioning Regimen with PBSC and Ptcy in Adults with Myeloid Malignancies

Benedetti, F.

2909 - The Addition of Romidepsin to CHOEP and High-Dose Chemotherapy Plus Stem Cell Transplantation Did Not Ameliorate the Outcome of Untreated Angioimmunoblastic T-Cell or Follicular T-Helper Lymphoma: Subgroup Analysis of Phase II FIL-PTCL13 Study
4717 - Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Benedicenti, F.

785 - Adaptive Routes of Hematopoietic Stem Cell Differentiation to Disease Conditions and Age in Gene Therapy Patients
817 - Unveiling the Biological Role of Peripheral Blood Human Circulating Hematopoietic Stem and Progenitor Cells

Benelli, C.

909 - Bone Marrow Tfr2 Deletion Modulates Systemic Metabolism in β-Thalassemic Mice to Sustain Augmented Erythropoiesis

Benes, V.

2544 - Cell Cycle and Differentiation Arrest in Senescent Population of Human Hematopoietic Stem and Progenitor Cell Compartment

Benesova, K.

1639 - How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?
2852 - Sequencing-Based Analysis of Clonal Evolution of 25 Mantle Cell Lymphoma Patients at Diagnosis and after Failure of Standard Immunochemotherapy

Benetton, M.

3878 - Mesenchymal Stromal Cell Secretome in Acute Myeloid Leukemia Bone Marrow Niche

Benevolenskaya, E.

3247 - Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance

Benevolo, G.

744 - Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Bengtzén, S.

2797 - Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing
2802 - Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Benhamida, J. K.

498 - Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms

Beninga, J.

4486 - The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Benini, F.

4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD

Benintende, G.

3119 - Predictive and Prognostic Molecular Biomarkers in Familial Chronic Lymphocytic Leukemia: A Pilot Monocentric Study

Benites, B. D.

1077 - Cognitive Assessment in Brazilian Adults with Sickle Cell Disease (SCD): The Burdens of Sociocultural Background and Correlations with Neuroimaging Findings

Benitez Carabante, M. I.

3451 - Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Benitez Kruidenier, S.

1634 - Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Benitez, O.

3793 - Esplorhem: Evaluation of Spanish Experience of Using Florio^® Haemo Digital Medical Device for Treatment Monitoring in Hemophilia Patients. a Preliminary Report

Benitez, O.

2162 - Assay Development and Small Molecule Screens for Inhibitors of an RNA Binding Protein Implicated in Hematologic Malignancies

Benito, L.

4926 - Impact of the COVID-19 Pandemic on the Incidence Registry of Hematological Neoplasms in the Region of Madrid (Spain). Preliminary Report of 2014-2021

Benito, L.

3536 - COVID-19 Severity and Survival over Time in Vaccinated Patients with Hematologic Malignancies

Benito, R.

1786 - TRAF3 Alterations Identify a Subgroup of Patients with Adverse Clinical Outcome and Induce Metabolic Reprogramming in Chronic Lymphocytic Leukemia
2822 - IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Benjamin, C. L.

369 - Late Graft Failure in MDS and Acute Leukemia Patients Receiving Allogenic Hematopoietic Cell Transplantation with Post Transplant Cyclophosphamide As Gvhd Prophylaxis

Benjamin, E. S.

4317 - Rxra Overexpression Improves the Sensitivity to Imatinib In-Vitro/in-Vivo By Disrupting the Oxidative Capacity of Chronic Myeloid Leukemia Cells

Benjamin, R.

1926 - Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Benjamin, R.

1922 - Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years
2029 - Improvement in Lymphoma CAR-T Outcomes over Time in the UK – CAR-T Learning Curve or Better Bridging?
4540 - Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma
4574 - Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Benjamini, O.

93 - Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study
4444 - Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody AZD7442 (tixagevimab-cilgavimab) Against Sars-Cov-2 Variants in Patients with CLL

Benkali, K.

1247 - Pharmacokinetic Characterization and Exposure-Response Relationship of Crovalimab in the COMPOSER and COMMODORE 3 Trials of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Benkerrou, M.

183 - Hydroxyurea Is Associated with Later Onset of Occurrence of Acute Splenic Sequestration Episodes in Sickle Cell Disease: Lessons from the European Sickle Cell Disease Cohort – Hydroxyurea (ESCORT-HU) Study

Benkova, K.

1413 - Single Cycle of Blinatumomab Followed By High-Dose Chemotherapy in the Induction Therapy for Ph-Negative Acute Lymphoblastic Leukemia in Adults. Primary Endpoint Analysis of the Blina-Cell Trial

Benkwitz-Bedford, S.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Benlloch, L. E.

468 - Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Bennaceur Griscelli, A.

1684 - The Anti-HIV Drug Nelfinavir Exhibits Synergistic Activity with Tyrosine Kinase Inhibitors and Circumvents TKI-Resistance Conferred By T315I-Mutated BCR-ABL

Bennani, N. N. N.

13 - High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group
615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
1591 - Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study
1738 - Mutational Profiling of Rosai-Dorfman Disease and Association with Phenotype: A Multi-Institutional Study
4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4374 - Efficacy of MEK Inhibitors in Erdheim Chester Disease
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Bennedsen, T.

1569 - Impact of Trial Eligibility Criteria on Outcomes of 1,245 Patients with Follicular Lymphoma Treated in the Real-World Setting: A Danish Population-Based Study

Benner, A.

227 - Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications – Results of the Harmony Alliance AML Database
304 - Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML – Results of the European Harmony Alliance
2697 - Long-Term Follow-up of AML Patients Treated Intensively before the Era of Targeted Agents. a Big Data Analysis from the Harmony Collaboration

Benner, A.

832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2075 - Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation

Benner, A.

759 - Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Bennett, A. V.

1458 - Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial

Bennett Caces, D.

93 - Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The Glow Study

Bennett, C.

289 - Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial
499 - Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: Prospective Data from the ITP Consortium of North America (ICON) Quality Improvement Initiative
681 - Pediatric Evans Syndrome Displays Broad Immune Dysregulation Characterized By Extra-Follicular B-Cell Responses and Unique Autoantibody Repertoire
2440 - Quantitative Platelet Adhesion and Platelet Geometry-Sensing Assays for Evaluating Mild Bleeding Disorders

Bennett, C.

3658 - Tmprss6 Depletion-Mediated Iron Deficiency Attenuates the Clinical Course of Plasmodium Berghei Infection in Mice

Bennett, C.

1440 - Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor Accentuates CD47 Blockade Therapy Resulting in Long Term Survival in Acute Myeloid Leukemia
4798 - Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Bennett, E. J.

2529 - Hematopoietic Stem Cells Depend upon Aggrephagy to Maintain Protein Homeostasis and Self-Renewal Activity

Bennett, J.

931 - IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Bennett, K.

1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Bennett, L.

2323 - TNFα and Anti-IFNγ Rescues Chronic Anemia of Inflammation Phenotype in Tnfαko Mice Treated with Heat-Killed Brucella Abortus

Bennett, M.

400 - Sustained Factor VIII Activity Following Single Dose of Non-Viral Integrating Gene Therapy

Bennett, R. L.

2627 - Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma

Bennett, R.

4298 - R-DA-EPOCH Treatment Is Highly Effective Therapy for Primary Mediastinal Large B-Cell Lymphoma: A Real-World Multi-Centre Retrospective Evaluation
4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Bennett, S.

4045 - Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime" Study

Bennett, S.

1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Benni, M.

2355 - Link between Bone Marrow and Cardiac Iron Overload in Thalassemia Major

Bennington, S.

1060 - Is There an Acute Cardiac or Hepatic Involvement in Hospitalized Sickle Cell Disease Patients with a Vaso-Occlusive Crisis ?

Benoun, J. M.

2169 - Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein–Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion

Bensaber, H.

1652 - Anti-CD19 CAR T-Cell Therapy for Patients with Richter Syndrome: A Lysa Study from the Descar-T Registry

Bensi, L.

1064 - Newborn Screening for Sickle Cell Disease in Italy : Report of 7 Years of a Low Cost and Reproducible Program in an Area of Immigration of High Risk Population

Bensinger, W. I.

4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Bensken, W. P.

3599 - Diffuse Large B-Cell Lymphoma (DLBCL) Treatment Patterns and Outcomes in the Oldest-Old (≥85 years): A SEER-Medicare Database Analysis
4932 - Outcomes and Characteristics of Untreated Diffuse Large B-Cell Lymphoma (DLBCL) Patients: A SEER-Medicare Database Analysis

Benson, Jr., D. M.

565 - Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
2266 - Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race
3230 - T-Cell Senescence and Exhaustion Are Associated with Interval Progression of Multiple Myeloma before Autologous Hematopoietic Cell Transplant
4490 - The Co-Occurrence of 1q21+/1q23+ and t(4;14) Abnormalities with Specific Clone Size Is Predictive of Shorter Response to Transplant in Patients with Multiple Myeloma
4798 - Preclinical Development of Hosu-53, a Novel Potent Dihydroorotate Dehydrogenase Inhibitor with Impressive Single Agent Efficacy and Combination Approaches in Hematological Malignancy

Benson, E. L.

2207 - Perception of Marijuana Use, Risk/Benefits in Sickle Cell Disease

Bensoussan, D.

1964 - IFN-γ Primed Wharton’s Jelly Mesenchymal Stromal Cells Inhibit T Cell Proliferation By Synergistic IDO and Mitochondrial Transfer Mechanisms

Bensussan, A.

3142 - Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

Bentivegna, S.

1743 - Therapeutic Potential of an Immune-Modulatory Vaccination Targeting Myeloid-Derived Suppressor Cells in Myelodysplastic Syndrome

Bentley, J. K.

2298 - Understanding the Patient Experience of Those Who Have Undergone or Considered CAR T-Cell Therapy in the United States: CAR T-Cell Therapy Patient Engagement Project (CPEP)

Bento, C.

3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Bento De Miguel, L.

320 - Laboratory Prognostic Index (LaPI) in Diffuse Large B Cell Lymphoma: Validation Study on Behalf of the Spanish Lymphoma Cooperative Group (GEL-TAMO)
4208 - Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Bento, L.

269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
3397 - Haploidentical Donor Vs. Mismatch Unrelated Donor in Reduced Intensity Conditioning Transplant: A Study from the Spanish Group of Hematopoietic Transplant and Cell Therapy (GETH-TC)

Bentur, O. S.

4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Benvenuti, P.

3191 - Predictors of Hematologic Complete Response Achievement and Maintenance in Patients with AL Amyloidosis Treated with Non-Transplant Chemotherapy

Benyamini, N.

1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Benzaquén, A.

269 - Role of Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory Large B-Cell Lymphomas in the CART Era
658 - Recent Bendamustine Treatment before Apheresis Has a Negative Impact on Outcomes in Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
3451 - Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Benzar, T.

4881 - Outcomes in Pregnant HbSS and HbSβ0-Thalassemia Sickle Cell Disease Patients Receiving Scheduled Exchange Transfusions: A Retrospective Study

Benzi, E.

1197 - Continuous Platelet Infusion Is an Effective Alternative to Conventional Transfusion in Reducing Platelet Transfusions in Critically Ill Pediatric Patients with Refractory Thrombocytopenia

Benzohra, A.

878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial

Beppu, L.

1690 - Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring

Bera, E.

2793 - AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network
3886 - Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Berard, E.

1405 - Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Berastegui, N.

2597 - Characterization of Transcriptional Alterations Leading to Aberrant Myeloid Differentiation in Myelodysplastic Syndromes

Beratto, L.

3668 - Alterations of Neuromuscular Environment Are Associated with Chronic Tissue Hypoxia in β-Thalassemia Patients

Berbaum, M.

2305 - A Mixed Methods Study to Examine the Influence of Structural Racism on Treatment in Acute Myeloid Leukemia

Berberich-Siebelt, F.

3146 - Immune Checkpoint CD200/CD200R Decreases T Cell-Mediated Cytotoxicity Via Dok2 and Is Regulated By P53 in Multiple Myeloma

Berbis, J.

905 - Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Berceanu, A.

50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
985 - Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS
2724 - Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Berchanskiy, D.

2168 - A Novel Multi-Analytic Clinical Diagnostic Assay to Detect HLA Loss of Heterozygosity in Post-Hematopoietic Cell Transplant Relapse Patients

Berdeja, J. G.

157 - Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
361 - KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation
364 - Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study
461 - ASTX727-03: Phase 1 Study Evaluating Oral Decitabine/Cedazuridine (ASTX727) Low-Dose (LD) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients
868 - Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in Karmma Achieving Prolonged Survival
1859 - Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study
1933 - A Phase 1/2 Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, PK and Efficacy of ZN-d5, a Novel BCL-2 Inhibitor, for Treatment of Subjects with Relapsed/Refractory AL Amyloidosis
1937 - Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1
2004 - Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)
3314 - KarMMa-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation
4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Berdel, W. E.

212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
280 - Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

Bereczky, T.

2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Berelovich, J.

2743 - Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice – a Prospective Analysis from the Revive Study
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group

Berens, E.

958 - Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Berenson, J. R.

1832 - Evaluation of Repotrectinib’s Anti-MM Effects in Combination with Bortezomib, Carfilzomib, Cyclophosphamide, and Dexamethasone in Vitro and Ex Vivo

Berentsen, S.

2857 - Gene Expression Analysis Reveals Downregulation of Complement Receptor 1 in Cold Agglutinin Disease

Berentsen, S.

1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Beretta, S.

1029 - Intracellular Iron Overload Induces Metabolic Switching in Active Hematopoietic Stem Cells in Beta-Thalassemia

Berezniuk, I.

2609 - Multi-Omic Approaches Reveal Leukemia Stem Cell Gene Regulatory Mechanisms

Bereznyakova, O.

2254 - Cognitive Screening in Adults with Sickle Cell Disease: Prospective Validation of the Rowland Universal Dementia Assessment Scale

Berg, S.

2700 - Measures of Structural Racism Predict ICU Admission Following Intensive Chemotherapy for AML

Berg, T.

4092 - Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Bergamin, R.

4422 - Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity

Bergan, R. C.

421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial

Berge, R.

4154 - Therapeutic Potential and Role of CD38 in Cutaneous T-Cell Lymphoma Pathogenesis

Berger, A.

4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?

Berger, C.

3222 - Impact of High-Risk Disease on Outcome after CAR-T Cell Therapy for Multiple Myeloma: A Meta-Analysis of 759 Patients
3352 - Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies
3415 - Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Bergér, D.

935 - Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Berger, G.

1089 - Deep Multi-Omic Analysis of Familial Hemophagocytic Lymphohistiocytosis Reveals Distinctive Immune Features of the Disease

Berger, K.

2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
4866 - Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website

Berger, M. G.

3016 - Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML

Berger, M. F.

2862 - Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

Bergeron, B. P.

1301 - Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment
2625 - Chromatin Accessibility Landscapes of B-Cell Acute Lymphoblastic Leukemia Identify Extensive Epigenomic Reprogramming and Heterogeneity Among Subtypes
3983 - Genetic and Epigenetic Cis-Regulatory Disruptions Impacting the Canonical Wnt Signaling Repressor TLE1 Gene Promote Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia

Bergeron, J.

2254 - Cognitive Screening in Adults with Sickle Cell Disease: Prospective Validation of the Rowland Universal Dementia Assessment Scale

Bergeron, J.

LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Bergeron, M.

1435 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Bergerson, J.

683 - Abnormal Cytotoxic T-Cell Expansion in the Bone Marrow of Patients with SASH3 Deficiency and Cytopenias
3456 - Highly Efficient & Specific Repair of MAGT1 Mutation in Xmen Patient T Cells and Hematopoietic Stem Cells

Berges, M. E.

184 - Hydroxyurea with Dose Escalation to Reduce Primary Stroke Risk in Children with Sickle Cell Anemia in Dominican Republic: The Sacred Trial

Berghold, A.

488 - A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Bergmann, A. K.

438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
1476 - Treatment Outcomes of Childhood Picalm:MLLT10⁺ Acute Leukemias: An International Retrospective Study
3902 - Transient Monosomy 7 Is a Rare Event in Young Children with SAMD9L Syndrome
4139 - Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia
4148 - Deciphering the Somatic and Germline Structural Variation Landscape in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia By Whole Genome Optical Mapping

Bergmeier, W.

2437 - Decreased Platelet Reactivity and Function in a Mouse Model of Pancreatic Cancer
2442 - Accelerated Platelet Clearance in Mice with Constitutive Store-Operated Calcium Entry Is Independent of Caldag-GEFI/Rap1 Activation
3755 - Identification of Receptors and Signaling Pathways Mediating the Platelet Contribution to Clotting Parameters in Thromboelastography (TEG)

Bergonzini, G.

1064 - Newborn Screening for Sickle Cell Disease in Italy : Report of 7 Years of a Low Cost and Reproducible Program in an Area of Immigration of High Risk Population

Bergsagel, P. L.

566 - Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
637 - Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma
768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
1821 - Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance
3136 - Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model
3149 - Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma
3172 - LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity
3186 - Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
3214 - Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic
3240 - Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC^®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination

Bergstrom, D.

117 - Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma

Bergua Burgués, J. M.

945 - Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Berinstein, N. L.

4223 - Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom’s Macroglobulinemia: The Brawm Study

Berk, G. I.

3990 - B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma
4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Berkahn, L.

315 - Long Follow-up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma (RATHL) Trial (CRUK/07/033) Confirms the Safety of Both De-Escalation and Intensification of Chemotherapy

Berkowitz, B.

2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry

Berlanga, O.

967 - Transient M-Proteins: Epidemiology, Causes, and the Impact of Mass Spectrometry: The Istopmm Study
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Berliner, N.

926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
3726 - The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Berloco, F.

4811 - Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs

Berman, D. M.

2040 - Plasma Microbial Cell-Free DNA to Characterize Infection Vs Cytokine Release Syndrome in Pediatric Patients with B ALL after CAR T Cell Therapy

Berman, E.

881 - Prospective Analysis to Determine Barriers to Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed and Relapsed Acute Leukemia

Berman, J.

47 - Simultaneous Inhibition of SIRT3 and Cholesterol Homeostasis Targets AML Stem Cells By Perturbing Fatty Acid β-Oxidation and Inducing Lipotoxicity

Berman, J. N.

2578 - A Zebrafish Model of Dnajc21 Deficiency Identifies Essential Roles in Granulocyte Differentiation and Metabolic Regulation
2608 - Characterizing the Role of KMT2C Mutations in Rapid-Onset Infant Leukemia
- Loss of Dnajc21 Leads to Neutropenia and Metabolic Alterations in Zebrafish
- Q&A

Bermejo-Peláez, D.

4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates

Bermúdez, A.

104 - Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
2114 - Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT

Bermúdez, A.

3447 - A Second Haploidentical Stem Cell Transplantation (HAPLO-SCT2) after Relapse from First Haplo-SCT Is Feasible and Produces Results That Are Comparable to Data Reported after Second SCT in an HLA-Matched Setting - a Study on Behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Bermudez, M. A.

1881 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort
4712 - Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic Graft vs. Host Disease: A Report of Two Phase I/II Trials

Bermudez, V. P.

163 - A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Bernacki, R.

4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Bernal del Castillo, T.

1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
1772 - ERCC6L2 in Early-Onset Adult Myelodysplastic Syndrome without Pre-Existing Disorder
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Bernal, T.

460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
4377 - Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Bernal-Mizrachi, L.

3250 - Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
4522 - Association of Socioeconomic Status with Adherence, Progression Free and Overall Survival to Oral Agents in Multiple Myeloma Patients

Bernard, E.

826 - Patient-Derived iPSCs Faithfully Represent the Genetic Diversity and Cellular Architecture of Human Acute Myeloid Leukemia
3097 - Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Bernard, J.

1663 - Phase 1b Trial of Subcutaneous Epcoritamab in Pediatric Patients with Relapsed or Refractory (R/R) Aggressive Mature B-Cell Neoplasms (EPCORE Peds-1)

Bernard, L.

661 - Ex Vivo Generation and Infusion of Anti-Minor Histocompatibility Antigen Expanded T Cells for Patients Who Relapse after Allogeneic HLA-Matched Stem Cell Transplantation
665 - Improved Outcomes of UM171-Expanded Cord Blood Transplantation Compared with Other Graft Sources: Real World Evidence

Bernard, L.

3453 - The EBMT Disease Risk Stratification System (DRSS) Allows Prediction of Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Bernard, M.

2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Bernardelli, A.

1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study

Bernardi, M.

464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results
4742 - Patients Reported Outcomes (PROs) Are Still Unsatisfactory Among AML Long-Term Survivors: The Impact of Chronic GvHD in a Prospective Study on 15 Years Transplant Activity

Bernardi, M.

1834 - Glutamate Metabolism Shapes Osteoclast Differentiation: New Potential Therapeutic Target to Block Osteoclastic Bone Resorption in Multiple Myeloma Patients
3005 - Identification of the Proteasome Subunits PSMB4 and PSMD4 As Novel Targets in Multiple Myeloma Patients Carrying 1q21 Amplification

Bernardi, S.

3055 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: Role of Disease Status and Chimerism on Long-Term Outcomes

Bernardo, M. E.

817 - Unveiling the Biological Role of Peripheral Blood Human Circulating Hematopoietic Stem and Progenitor Cells

Bernareggi, D.

3297 - Knock-in of the BCL2 G101V Mutation in Human iPSC-Derived NK Cells Generates Venetoclax Resistance and Improves Activity Against Venetoclax Resistant AML

Bernareggi, D.

666 - A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

Bernasconi, D.

3201 - Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non–Lenalidomide-Based Treatments in the Real-World MM-034 Study
4493 - Safety and Survival Outcomes in the Non-Interventional Post-Authorization Study of Patients Treated with Pomalidomide for Relapsed and Refractory Multiple Myeloma: A Sub-Analysis of Patients with Prior Triple Class Exposure

Bernasconi, L.

863 - RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Bernasconi, P.

3413 - Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia
4717 - Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study

Bernaudin, F.

185 - Impact of Hydroxyurea and Vaso-Occlusive Crisis on Ovarian Follicle Density in Girls and Young Females with Sickle Cell Disease
675 - Impact on Silent Infarct Incidence of Early Screening of the Extracranial Portion of the Internal Carotid in a Longitudinal Cohort-Study of Children with Sickle Cell Anemia

Bernes-Lasserre, P.

552 - Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model
4180 - Immunocompetent 3D Follicular Lymphoma Model: A Preclinical Tool to Design Tailored Immunotherapies

Bernhardt, C.

4359 - Diagnosis and Treatment of MPN in Real Life – Interim-Analysis of an Exploratory Chart Review on 960 ET and MF Patients in Germany

Bernhardt, M. B.

2762 - Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial

Bernhardt, M. B.

904 - Severe Adverse Events Associated with Concentrations of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia Patients

Bernhart, E.

2159 - The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergistic Effect with Venetoclax

Bernier, A.

2282 - Evaluation of Participation and Recruitment Bias in a Prospective Real-Life Multicentric Cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for Newly Diagnosed Lymphoma Patients over One Year in a Hematology Department of Teaching Hospital

Berning, E. M.

1053 - Feasibility of Near-Infrared Spectroscopy for Monitoring Hemodynamic Changes in Patients with Sickle Cell Disease Treated with Mitapivat
2181 - Non-Invasive Optical Characterization of Tissue Hemodynamics in Sickle Cell Patients Undergoing Treatment with Isoquercetin

Berning, P.

957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
4758 - Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Bernstein, B. E.

827 - Clonal Hematopoiesis Evolves into Dendritic Cell Neoplasm through the Acquisition of UV Mutations in the Skin

Bernstein, I. D.

3849 - Clonal Analysis Reveals Functional and Transcriptional Heterogeneity of Self-Renewing Fetal Liver Hematopoietic Stem Cells

Bernstein, Z. S.

4535 - Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia

Bernt, K. M.

44 - The Role of GATA2 in Drug Resistance in AML
531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
1486 - Proteotranscriptomic Strategy to Discover Acute Myeloid Leukemia Immunotherapy Targets
2819 - Single-Cell Transcriptomics Reveals Similarity of Aggressive Infant Acute Lymphoblastic Leukemia Cells to Early Hematopoietic Progenitors
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

Berrera, M.

2798 - CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Berres, M. L.

2995 - Non-Canonical Gli1 Activation Mediates Profibrotic Hematopoiesis-Stroma Crosstalk in MPN

Berret, J.

353 - ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Berrien-Elliott, M. M.

3294 - Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Berrios, D.

3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Berrueco, R.

3793 - Esplorhem: Evaluation of Spanish Experience of Using Florio^® Haemo Digital Medical Device for Treatment Monitoring in Hemophilia Patients. a Preliminary Report

Berry, C.

4086 - Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Berry, J.

4841 - Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique

Berry, K.

1196 - Evaluation of Bivalirudin Weight-Based Dosing in Obese Patients

Berry, T.

459 - Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
1713 - MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Bersanelli, M.

464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
4378 - Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies
4415 - Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Bertaina, A.

4388 - Novel Humanized Loss-of-Function NF1 Mouse Model of Juvenile Myelomonocytic Leukemia

Bertaina, V.

775 - Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD

Bertamini, L.

3216 - Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
4495 - Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
4538 - Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study

Bertelli, S.

995 - Domiciliary Nursing Management for Patients Affected By Multiple Myeloma during Covid-19 Pandemia in the Viterbo Home Care Unit: Data Analysis from March 2020 to March 2022

Bertelsen, K.

874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia
4592 - The Pharmacokinetic and Pharmacodynamic Characterization of Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate for Targeted Conditioning Prior to Transplant, in Nonhuman Primates

Berthiaume, L. G.

1332 - Targeting N-Myristoylation for Adult Acute Myeloid Leukemia Therapy

Berthier, E.

1690 - Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring

Berthon, C.

211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
1398 - Standard Risk-Assessment of AML Doesn’t Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy
2804 - LSC17 Score Is Complementary with Minimal Residual Disease to Stratify NPM1-Mutated Acute Myeloid Leukemia: An ALFA Study

Berthon, C.

2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

Berti, E.

3438 - Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Bertinchamp, R.

1554 - Characteristics of Circulating KSHV-Infected Cells during Active KSHV+ Multicentric Castleman Disease

Berto-Junior, C.

2363 - Antiviral Response and HIV-1 Inhibition in Sickle Cell Disease

Bertola, N.

2581 - Study of Angiogenic Potential and Oxidative Metabolism in Mesenchymal Stromal Cells Derived from Shwachman-Diamond Syndrome Patients

Bertoli, C.

1435 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Bertoli, S.

4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Bertoli, S.

1405 - Optimizing the Supportive Care of Intensive Chemotherapy in AML : Impact of Vitamin C and D Supplementation in Patients with NPM1 Mutation. a Dataml Registry Study
2737 - Long-Term Survival of Acute Myeloid Leukemia Responding Patients Who Stopped Azacytidine and/or Venetoclax Because of Poor Tolerance or Physician Choice: A Retrospective Multicenter Study from the French Innovative Leukemia Organization (FILO)
2738 - Dexaml-02 : A Phase II Study of Dexamethasone Added to Induction and Postremission Therapy in Older Patients with Newly Diagnosed AML. a French Innovative Leukemia Organization (FILO) Study

Bertollini, T.

126 - Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy

Bertomeu, T.

3976 - Targeting PLZF Enhances Glucocorticoid Sensitivity in Acute Myeloid Leukemia

Berton, M.

1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment

Bertoni, C.

1213 - Tetraspanin CD82 Regulates Hematopoietic Stem and Progenitor Cell Quiescence & Regeneration

Bertoni, F.

1523 - Single Cell RNA-Seq of Extranodal Marginal Zone Lymphoma (MZL) Identifies Site-Specific and Shared Features in Both B and T Cell Components
1989 - PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)
2886 - Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Bertovich, D.

401 - Coagulation Factor XII Is Activated Via Noncanonical Binding to Platelet Integrin αIIbβ3

Bertrand, A.

1964 - IFN-γ Primed Wharton’s Jelly Mesenchymal Stromal Cells Inhibit T Cell Proliferation By Synergistic IDO and Mitochondrial Transfer Mechanisms

Bertrand, O.

1007 - Genetic Evidence That Dimerization of Glycophorin a Is Critical for Red Cell Invasion By Plasmodium Falciparum but Not for the Binding of EBA-175

Bertrand, Y.

2569 - Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)
3987 - Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results from the ITCC-059 Phase IA and Phase II Trial

Bertrand, Y.

8 - Effects of Pyruvate Kinase Activators on Red Blood Cell Rheology, Sickling and Senescence in Sickle Cell Disease
905 - Cardiac and Vascular Risks Are the Essential Parameters for Long-Term Surveillance of Lower Risk Childhood Acute Leukemia Survivors

Bertrand, Y.

266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2576 - HLA-Haploidentical Stem Cell Transplantation in Children with Inherited Bone Marrow Failure Syndromes: A Retrospective Analysis on Behalf of EBMT Severe Aplastic Anemia Working Party

Bertrums, E. J.

3926 - Retrospective Lineage Tracing of Pediatric Acute Myeloid Leukemia Using Single-Cell Whole Genome Sequencing

Bertsch, U.

860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma

Bertsias, G.

2410 - Investigation of Neutrophil Extracellular Trap (NET) Induction in Patients with Chronic Idiopathic Neutropenia Bearing Mutations in the Mediterranean Fever (MEFV) Gene

Bertuccio, S. N.

3878 - Mesenchymal Stromal Cell Secretome in Acute Myeloid Leukemia Bone Marrow Niche

Bertz, H.

4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Bescond, C.

4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Besemer, B.

759 - Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome

Beshears, J.

2384 - Cognitive Dysfunction Worsens with Age in Patients with Sickle Cell Disease in the Modern Treatment Era
3694 - Functional Connectivity and Executive Function Abilities Strengthen without Change in Structural Connectivity after Transfusion in Children with Sickle Cell Disease

Beshensky, D.

4735 - RDW Is an Independent Prognostic Biomarker in Patients with Chronic Graft-Versus-Host-Disease

Besisik, S. K.

3253 - Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Besley, C.

997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
2034 - Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party
2124 - Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom
4663 - CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
4672 - Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Besse, A.

1819 - Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

Besse, A.

1840 - The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Besse, L.

1819 - Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

Besse, L.

1840 - The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Besses Raebel, C.

1731 - Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients

Bessette, P.

4608 - Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 or IL-21 Cytokines Results in Enhanced Anti-Tumor Activity

Besson, C.

3127 - Association between Cumulative Airborne Dioxin Exposure and Chronic Lymphocytic Leukemia/Non-Hodgkin's Lymphoma Risk in a Nested Case-Control Study within the French E3N Cohort

Besson, T.

1514 - Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Best, A.

136 - Hemostatic Biomarkers Predict Risk of Thromboembolism (TE), Severe COVID-19 and Mortality: A Report from the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)

Best, C.

2985 - Validating the Prognostic Value of Anemia and Thrombocytopenia in Latin American Patients with Diffuse Large B-Cell Lymphoma: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Best, S.

85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

Bestebroer, J.

1116 - Predicting Platelet Age Using Artificial Intelligence Techniques

Betancur, S.

4086 - Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Betbadal, A.

4828 - The Next Step in Telehealth Education in a Low-Income Setting: Implementing a Project Echo for Sickle Cell Disease

Betech Antar, V.

3190 - ¹¹c-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to ¹⁸f-FDG PET/CT and Prognostic Value Evaluation

Betensky, M.

3739 - Investigating Biomarkers for Primary Immunodeficiency Disorders in Patients with Autoimmune Cytopenia

Bethge, W.

4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
371 - Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
2130 - Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
3373 - Long-Term Outcome of Second Allogeneic Stem Cell Transplantation (HSCT2) for Primary Graft Failure in Patients with Acute Leukemia in Remission: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4665 - Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
4761 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation from Different Donor Types in Primary Refractory Acute Myeloid Leukemia: A Report from the ALWP of the EBMT

Bethke, U.

2002 - Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Bethony, J.

721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features

Betti, S.

744 - Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Bettini, C.

190 - A Computer-Aided Diagnosis Tool for the Detection of Hemarthrosis By Remote Joint Ultrasound in Patients with Hemophilia

Bettini, L. R.

1515 - First Description of a Frameshift PAX5 Germline Variant in Two Siblings with B-Cell Precursor Acute Lymphoblastic Leukemia

Betts, B. C.

114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate

Betz, B.

836 - Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia

Betz, K.

109 - Single-Cell RNA-Seq Reveals an Interferon-Driven Inflammatory CD4 Naïve T Cell Subpopulation at Day 100 in Hematopoietic Stem Cell Transplant Patients That Ultimately Develop Chronic Gvhd

Betz, K.

111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
165 - Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site
3407 - Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

Beuger, B. M.

1065 - Pleiotropic Effects of Hydroxyurea on Red Blood Cell and Neutrophil Phenotype in Patients with Sickle Cell Disease; Data from the Notice Study

Beutel, G.

1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Bevan, Y.

1463 - Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction

Beverloo, B.

215 - Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders
648 - Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification
4047 - Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results from the ITCC-059 Phase 1B Trial
4569 - Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Beverstock, S. L.

1672 - High Grade B Cell NHL Outcomes: Real World Experience from the UK

Beverungen, D.

4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Bewarder, M.

1309 - Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Bewersdorf, J. P.

130 - Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid Leukemia
599 - Predictors of Long-Term Outcome in TP53-Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
1231 - The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
3044 - Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure
4409 - International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents – a Systematic Review and Meta-Analysis

Bewersdorf, J.

530 - U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies

Bewicke-Copley, F.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
1318 - Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia

Bexte, T.

1991 - CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML

Beyar Katz, O.

1658 - Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Beyar-Katz, O.

3301 - G-CSF Mobilized Apheresis As an Alternative Source of CAR T-Cells

Beyer, E. C.

3684 - Plasma Mir Let-7c Is a Marker of Previous Acute Chest Syndrome in Sickle Cell Disease

Beygi, S.

2038 - A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Beygi, S. B.

543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas

Beylergil, V.

1606 - Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis

Beylot-Barry, M.

1631 - Lacutamab in Patients with Advanced Sezary Syndrome: Results from an Interim Analysis of the Tellomak Phase 2 Trial

Beynon, V.

506 - Long-Term Improvements in Patient-Reported Outcomes in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
1021 - Mitapivat Improves Iron Overload in Patients with Pyruvate Kinase Deficiency
1773 - A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes
2328 - Long-Term Hemoglobin Response and Reduction in Transfusion Burden Are Maintained in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat
2330 - ACTIVATE-KidsT: Mitapivat in Children with Pyruvate Kinase Deficiency Who Are Regularly Transfused
2335 - ACTIVATE-Kids: Mitapivat in Children with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
3644 - Mitapivat Improves Markers of Hemolysis and Erythropoiesis in Patients with Pyruvate Kinase Deficiency Irrespective of Hemoglobin Response

Bezavada, L.

3855 - DDB1 and CUL4 Associated Factor 7 (DCAF7) Is Essential for Hematopoiesis

Bezieau, S.

3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Bezombes, C.

552 - Combination of Ibrutinib and Nivolumab Overcomes Ibrutinib Resistance in a Novel Patient-Derived Mantle Cell Lymphoma 3D Model
4180 - Immunocompetent 3D Follicular Lymphoma Model: A Preclinical Tool to Design Tailored Immunotherapies

Bezzerri, V.

587 - Deletion of eif6 Partially Rescues Survival, but Not Neutropenia, of Zebrafish Model of Shwachman-Diamond Syndrome: The Roles of Sbds and Eif6 in Perturbing Lipid Metabolism

Bezzerri, V.

2581 - Study of Angiogenic Potential and Oxidative Metabolism in Mesenchymal Stromal Cells Derived from Shwachman-Diamond Syndrome Patients

Bhad, P. A.

786 - Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo, CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction

Bhadresha, K.

1473 - Molecular Landscaping of Exosomal Protein and miRNA Cargo in Acute Myeloid Leukemia

Bhagnani, T.

906 - Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-Inspired or Non-Pediatric Inspired Regimens: A Real-World Analysis Using Claims Data

Bhagunde, P.

2472 - Development of a Quantitative Systems Pharmacology Model to Explore Hemostatic Equivalency of Antithrombin Lowering
3788 - A Population Pharmacokinetic (PopPK) Model to Characterize Efanesoctocog Alfa (BIVV001) Factor VIII (FVIII) Activity Levels in Patients with Severe Hemophilia A

Bhagwat, N.

210 - PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Anti-Leukemic Activity in Preclinical Primary Models of Human B-ALL, T-ALL, and CLL
1348 - PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds

Bhagwat, N.

1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Bhai, P.

3546 - Clinical Features and Mutational Landscape of Patients Referred for Suspected Essential Thrombocytosis: A Descriptive Study Using a ‘Real-World’ Database

Bhalla, K. N.

204 - Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression
1449 - Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells
2601 - Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
3973 - Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background
4074 - Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study

Bhally, H.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Bhandari, A.

2342 - Rusfertide Analog-PN23114 As a Hepcidin Mimetic Provides Efficacy Benefits in Conjunction with Phlebotomy in Mouse Model for Hereditary Hemochromatosis

Bhandari, S.

4433 - Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome (RS)

Bhanderi, V. K.

4491 - Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Bhandoola, A.

717 - Progenitor Sub-Populations in Treatment Resistant T-ALL

Bhansali, R.

154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Bhansali, R. S.

615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1514 - Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Bharadwaj, S.

2090 - Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Bhardwaj, V.

70 - IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function

Bhasin, M.

948 - A Single Cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow
1296 - Single-Cell Profiling of Acute Myeloid Leukemia Identified ARMH1, a Novel Protein Associated with Proliferation, Migration, and Drug Resistance
1475 - Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia

Bhasin, N.

4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia

Bhasin, S. S.

948 - A Single Cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow
1296 - Single-Cell Profiling of Acute Myeloid Leukemia Identified ARMH1, a Novel Protein Associated with Proliferation, Migration, and Drug Resistance
1475 - Connecting Genetic Heterogeneity with Single-Cell Transcriptome Dysregulations in Pediatric Acute Myeloid Leukemia

Bhaskar, S.

151 - Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Bhaskar, S.

4666 - Efficacy of CD19 Directed Therapies in Large B-Cell Lymphoma (LBCL) Relapsing after Chimeric Antigen Receptor (CAR) T-Cell Therapy

Bhaskaran, R.

2315 - Ruxolitinib for Myelofibrosis in Resource Limited Settings : A Slip between the Cup and the Lip

Bhat, D. K.

3388 - Percent Patient NK and T Cells at Day 28 Predict Graft Outcome after Haploidentical Hematopoietic Cell Transplant for Sickle Cell Disease

Bhat, P.

1229 - Epigenetic Dysregulation Leads to Enhanced IL-1β Signaling and Transcriptional Responses in TET2 Deficient HSPCs
1230 - Primary HSPC-Derived Monocytes with DNMT3A p.R882H Exhibit Activated Myeloid Cell Gene Signatures
1232 - Combined Single-Cell Transcriptomics and Mitochondrial Lineage Tracing Identify IL-6 Signaling Responses in TET2 Clonal Hematopoiesis of Indeterminate Potential

Bhat, R.

895 - Intravenous Fluid Replacement Therapy and Hospital Outcomes for Vaso-Occlusive Episodes in Patients with Sickle Cell Disease

Bhat, S. A.

1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
1812 - Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
2903 - Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
3118 - FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Bhat, S.

3330 - Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)
4646 - Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Bhatia, J.

1773 - A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Bhatia, K.

4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Bhatia, K.

2156 - Development of a Potent DNA Damaging Agent LP-284 for Treatment of Mantle Cell Lymphoma

Bhatia, K. G.

4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Bhatia, M.

12 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease
579 - Gonadal Hormone Production after Hematopoietic Cell Transplant (HCT) in Patients with Sickle Cell Disease (SCD): A Stellar Study

Bhatia, R.

119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
1325 - PRMT5 Inhibition Enhances Elimination of FLT3-ITD AML Stem Cells in Combination with TKI Treatment
1686 - Metabolic Adaptation to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukemia Stem Cells
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
3931 - Activating a Non-Genetic MYC-Regulating Pathway Sensitizes Acute Myeloid Leukemia to Bromodomain Inhibition
4040 - Optimal Induction and Consolidation Strategy for Patients with Complex Karyotype and TP53-Mutated Acute Myeloid Leukemia

Bhatia, S.

150 - Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia
1343 - Targeting Hyperactivated Lck in PAX5 Rearranged Pediatric B-Cell Precursors Acute Lymphoblastic Leukemia
2833 - Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia
3977 - The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance

Bhatia, S.

119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
903 - Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children’s Oncology Group Study (COG-AALL03N1)
1641 - Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
2299 - Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant
2304 - Processing Speed Improvement in Hematologic Cancer Survivors Treated with Allogeneic Blood or Marrow Transplantation– a Randomized Online Cognitive Training Intervention
3584 - COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies
4528 - Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)
4719 - The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease
4933 - A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study
- Germ Line Risk Factors for Second Malignant Neoplasms After Treatment for Pediatric Hematologic Malignancies

Bhatla, T.

1510 - Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331

Bhatlekar, S.

2425 - Actin Bundling Protein L-Plastin Regulates Megakaryocyte Membrane Rigidity and Platelet Spreading
2426 - The Common Racially Diverse Human PAR4 Variant Thr120 Causes Worse Outcomes in a Mouse Stroke Model Via Platelet-Mediated NET Formation: Prevention By P-Selectin Blockade

Bhatnagar, B.

2270 - Patterns of Neuropathy in ALL Patients Treated with Vincristine Based Regimens with and without Tyrosine Kinase Inhibitors
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Bhatnagar, N.

3294 - Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Bhatnagar, V.

3183 - Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Bhatt, A. S.

LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Bhatt, N. S.

3535 - Return to School Challenges Affecting Adolescent Recipients of Allogeneic Hematopoietic Cell Transplantation: A Qualitative Interview Study of Caregivers
4933 - A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study

Bhatt, N. S.

776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
4871 - Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes

Bhatt, S.

1502 - Cellular Plasticity As Mechanisms to Escape from NOTCH1-Inhibition in T-ALL

Bhatt, V.

2079 - Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study
3031 - Characteristics and Clinical Outcomes in Patients (Pts) With Polycythemia Vera (PV) Receiving Ruxolitinib (RUX) After Hydroxyurea (HU): A Longitudinal Analysis From REVEAL
4714 - Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized, Phase 3 REACH3 Study

Bhatt, V. R.

573 - Ruxolitinib for Treatment of Steroid Refractory Sclerotic Chronic Graft-Versus-Host Disease (cGVHD): Results of a Multicenter Phase II Trial
2220 - Understanding the Treatment Preferences of Adults with Cancer
4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?

Bhattacharya, P. K.

3979 - Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease

Bhattacharyya, A.

3419 - Bone Mineral Densitometry Diagnostic Yield Remains High Beyond 10 Years Post Allogeneic Stem Cell Transplant
4728 - Ibrutinib for Steroid Refractory Chronic Graft Vs Host Disease - Real World Experience

Bhattacharyya, J.

1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Bhattacharyya, R.

2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore

Bhattacharyya, S.

3280 - Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Bhattarai, K. R.

1301 - Epigenetic Fine Mapping and Functional Dissection of Inherited Non-Coding Variation Impacting the Pharmacogenomics of Acute Lymphoblastic Leukemia Treatment

Bhatti, S.

4245 - Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers

Bhayadia, R.

1991 - CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML
2769 - Targeting the WT1^mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia

Bhayana, V.

3522 - The Practice and Clinical Utility of Trace Metal Testing for Hematology Patients: A Retrospective Cohort Study

Bhella, S.

1380 - Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience
1642 - Clinical Characteristics and Disease Outcomes in Primary Bone Lymphoma: Retrospective Study
1898 - Chromosome 1q Abnormalities Are Not an Independent Predictor of Survival in Multiple Myeloma
3583 - Frailty in Patients Undergoing Chimeric Antigen Receptor T-Cell (CAR T) Therapy at Princess Margaret Cancer Centre: A Prospective Pilot Study
4512 - Correlation Amongst Scoring of Various Frailty Tools in Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Bhide, A.

1134 - Characterisation of Platelet Sensitivity in Immune Thrombocytopenia Identifies Distinct Subgroups with Either Higher or Lower Platelet Sensitivity

Bhise, S.

3499 - Single-Cell Multiomics of Pre- and Post- Remission Bone Marrow from a Pediatric Patient with JMML Reveal Distinct Progenitors and Inflammatory Monocytes Which Are Eliminated By Chemotherapy
4586 - Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation

Bhoekhan, M.

808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination

Bhoi, S.

745 - A Comprehensive DNA Methylome Analysis of Stereotyped and Non-Stereotyped CLL Reveals an Epigenetic Signature with Strong Clinical Impact Encompassing IGHV Status, Stereotypes and IGLV3-21^R110

Bhojwani, D.

66 - Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
2670 - TBL1 Inhibitor, Tegavivint, Supresses Cell Survival and Promotes Sensitivity to Chemotherapy in ALL and AML
3963 - The Role of Integrin Beta-1 in the Chemoresistance of Acute Myeloid Leukemia

Bhoopalan, S.

776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease

Bhosale, S. P.

4641 - Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Bhuller, K.

732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia

Bhurani, D.

1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
2716 - Real World Data on Unique Challenges and Outcomes of Older Patients with AML from Resource Limited Settings: Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial
3628 - Acute Myeloid Leukemia during the COVID Pandemic: Impact and the Indian Experience

Bhurtel, H.

4128 - Erythroid and Megakaryocytic Differentiation Program in JAK2-Mutated Acute Myeloid Leukemia with or without Antecedent Myeloproliferative Neoplasm

Bhusal, K.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Bhushan, B.

3246 - Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Bhutani, D.

3582 - The Impact of Hispanic Ethnicity on Disease Characteristics in Multiple Myeloma

Bhutani, M.

757 - Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Bhutani, M.

1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
1934 - Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Bhuyan, G. S.

4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

Bi, C.

1565 - Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma

Bi, L.

1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Biagi, A.

2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
4356 - Risk Factors for Thrombosis in Patients Aged > 60 Years with Essential Thrombocythemia without Previous Thrombotic Events

Biagini, S.

775 - Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)

Bianchi, A.

4126 - Acute Myeloid Leukemia (AML) Risk Stratification Using the European Leukemianet 2022 Classification in a Real-Life Cohort of Patients from Sardinia, Italy

Bianchi, E.

4320 - Peripheral Blood Cytotoxic T Cells from Myelofibrosis Patients Show Early Exhausted Features Targetable By CTLA-4 Inhibition

Bianchi, G.

3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
4570 - A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Bianchi, M. P.

1649 - Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

Bianchi, M.

936 - MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells

Bianchi, P.

1017 - Thrombotic and Infectious Complications in Patients with Autoimmune Hemolytic Anemia: A Multicenter Observational Study
1747 - Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-of-Concept Study
3079 - Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Bianchi, P.

2329 - Comorbidities and Complications in Pediatric Patients with Pyruvate Kinase Deficiency Enrolled in the Peak Registry
2332 - Age of Onset of Complications in Patients with Pyruvate Kinase Deficiency: Analysis from the Peak Registry

Bianchini, M.

2228 - Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Bianchini, M.

3015 - The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2^nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
3019 - Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure

Bianco, M.

2228 - Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial

Bianco, T. M.

2787 - High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia

Biancon, G.

530 - U2AF1 Splicing Factor Mutations Affect RNA Subcellular Compartmentalization in Myeloid Malignancies
2170 - Harmonizing the Annotation of Hematopoietic Populations in Single-Cell Atlases with the Cell Marker Accordion
3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy

Biavati, L.

4113 - Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Bibikova, E.

1788 - Establishment and Characterization of Mouse Models with Primary and Acquired BTK Inhibitor Resistance
2675 - CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy

Bicchieri, M.

464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Bicchieri, M.

4378 - Synthetic Data Generation By Artificial Intelligence to Accelerate Translational Research and Precision Medicine in Hematological Malignancies
4415 - Multi-Modal Analysis and Federated Learning Approach for Classification and Personalized Prognostic Assessment in Myeloid Neoplasms

Bick, A. G.

926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
1223 - Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis
1230 - Primary HSPC-Derived Monocytes with DNMT3A p.R882H Exhibit Activated Myeloid Cell Gene Signatures
1232 - Combined Single-Cell Transcriptomics and Mitochondrial Lineage Tracing Identify IL-6 Signaling Responses in TET2 Clonal Hematopoiesis of Indeterminate Potential
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
3867 - Clonal Hematopoiesis and Heart Failure with Preserved Ejection Fraction

Bickers, C.

2004 - Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
4639 - A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC‑Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Bidère, N.

845 - CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Bidet, A.

2735 - Epag 2015 : A Phase II Randomized Placebo-Controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy. a French Innovative Leukemia Organization (FILO) Study

Bidikian, A.

1367 - Predictors of Veno-Occlusive Disease (VOD) of the Liver in Patients Treated with Inotuzumab Ozogamicin (InO) Containing Regimen in B-Cell Acute Lymphoblastic Leukemia
1378 - Baseline Liver Elastography Does Not Predict Risks of Hepato-Toxicity to Reduced Dose Inotuzumab Therapy Combined with Minihcvd in B-Cell Acute Lymphoblastic Leukemia
2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations
3000 - A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA
4330 - Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy
4819 - A Novel NGS Assay to Detect Any KMT2A fusion Transcript at Low Levels

Bidollari, I.

625 - Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study
1710 - An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Biedermann, A.

4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Biedermann, S.

2002 - Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Biehl, M.

863 - RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination

Bieker, J. J.

514 - Mutation in Erythroid-Specific Transcription Factor EKLF/KLF1 Elevates Erythroid Metabolism and Induces Inflammation

Bielohuby, M.

1139 - Modulation of Extravascular Binding of Recombinant Factor IX Impacts Hemostatic Efficacy in Mouse Models

Bielorai, B.

3987 - Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia – Results from the ITCC-059 Phase IA and Phase II Trial
4047 - Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) – Results from the ITCC-059 Phase 1B Trial

Biemond, B. J.

9 - Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat
580 - Quality of Life and Personal Life Goals of Adult Sickle Cell Disease Patients after Curative Allogeneic Stem Cell Transplantation: A Mixed Methods Study
676 - The Effect of Hematopoietic Stem Cell Transplantation on Cerebral Perfusion and Oxygen Metabolism in Patients with Sickle Cell Disease
877 - Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study
1057 - Effect of Voxelotor on Cerebral Perfusion and Cerebral Oxygen Metabolism in Adult Patients with Sickle Cell Disease; Preliminary Results of the Coverage Study
1059 - Natural History and Rate of Progression of Retinopathy in Patients with Sickle Cell Disease: An 11-Year Retrospective Follow-up Analysis
1065 - Pleiotropic Effects of Hydroxyurea on Red Blood Cell and Neutrophil Phenotype in Patients with Sickle Cell Disease; Data from the Notice Study
1068 - Movement Behavior in Adults with Sickle Cell Disease Compared to Healthy Adults: Preliminary Results
1426 - Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study
4008 - The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine
4700 - Improved T-Cell Chimerism and Successful Withdrawal of Immunosuppression after Non-Myeloablative Stem Cell Transplantation for Sickle Cell Disease with Azathioprine/Hydroxyurea Preconditioning Added to Alemtuzumab/TBI Conditioning

Bieniaszewska, M.

2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Bierhoff, H.

298 - Functional Role of Histone Variant macroH2A1 (H2AFY) in Acute Myeloid Leukemia (AML)

Bierings, M.

215 - Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders
266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
372 - Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
4663 - CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Large Real-World Series from Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Bierings, R.

1116 - Predicting Platelet Age Using Artificial Intelligence Techniques

Bierly, A.

4655 - A Phase 1b Dose Expansion Study Evaluating Safety, Preliminary Anti-Tumor Activity, and Accelerated T Cell Reconstitution with NT-I7 (Efineptakin Alfa), a Long-Acting Human IL-7, Administered Following Tisagenlecleucel in Subjects with Relapsed/Refractory Large B-Cell Lymphoma

Bierman, P. J.

728 - Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma

Biernacki, M. A.

4586 - Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation

Biesiadny, S.

3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones

Biezuner, T.

3854 - Unraveling at Diagnosis Chemoresistant Relapse-Initiating Clones in Acute Myeloid Leukemia: Combined Functional and Genomic Analyses Using Single-Cell-Derived Hematopoietic Stem and Progenitor Cell Subpopulations

Biffi, A.

776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
2173 - CD72 Is a Pan-Tumor Antigen Associated with Childhood Acute Leukemia
4602 - Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia

Bigas, A.

3895 - Multiplex CRISPR/Cas9 Gene Editing in Human Stem Cells to Model Clonal Competition in GATA2 Deficiency

Bigenwald, C.

727 - Should Adolescents and Young Adults with Hodgkin Lymphoma be Treated As Children or Adults?

Biggar, R. J.

4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Bigger, B.

782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA

Biggs, B. A.

1026 - Iron Supplementation May Selectively Reprofile the Gut Microbiome in Iron-Deficient Bangladeshi Infants

Bigioni, M.

1333 - PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

Bignotti, A.

1112 - The Potential Role of ANKRD36 in Immune Thrombotic Thrombocytopenic Purpura
2457 - Coagulation Factor VIII Enhances the Cleavage of Von Willebrand Factor By ADAMTS13 In Vivo
2489 - Elevated Plasma Levels of Von Willebrand Factor and Syndecan-1 Predict 60-Day Mortality in Patients with Severe and Critical COVID-19
3807 - Netosis and the Formation of Neutrophil Extracellular Traps (NETs) in Patients with Severe and Critical COVID-19 May Contribute to Disease Progression and Thrombosis

Bigogno, A.

1303 - IFITM3 Acts As a PIP₃ Scaffold in TCR-PI3K Signaling
2660 - CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma
3936 - Repressive β-Catenin-Ikaros Complexes Are Essential to Prevent Clonal Evolution of Human Lymphopoiesis

Biham Rochwerger, K.

1181 - Levels and Activity of Von Willebrand Factor in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Bijou, F.

234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Bila, J.

3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Bila, J.

3242 - MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Bilal Abid, M.

4729 - Younger Matched Unrelated Donors Confer a Decreased Relapse Risk As Compared to Older Sibling Donors for Adult B-Cell ALL Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Bilbao, C.

1485 - Pethema NGS-AML Project. Final Analysis and Clinical Validation of New Genomic Classifications
1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Bilbao, D.

550 - B-Cell Receptor Signaling Modulates Cholesterol Biosynthesis in Diffuse Large B-Cell Lymphoma
1291 - The NLRC4 Inflammasome Drives Myelodysplastic Syndrome By Linking Epigenetic Reprogramming and Innate Immune Signaling
1298 - Tyrosine Phosphorylation of CARM1 Promotes Its Enzymatic Activity and Alters Its Target Specificity in Myeloid Neoplasms with Hyperactivated JAK2

Bilgin, Y. M.

851 - A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
1530 - Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

Bilir, P.

4861 - Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients with Relapsed or Refractory Follicular Lymphoma in the United States

Bill, M.

3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia

Bill, M.

1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation

Billett, H. H.

3702 - Leg Ulcer Prevalence and Outcomes in a Real-World, Multicenter, Retrospective Study of Patients Treated with Voxelotor
4919 - Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis

Bilmon, I.

3419 - Bone Mineral Densitometry Diagnostic Yield Remains High Beyond 10 Years Post Allogeneic Stem Cell Transplant

Bilodeau, M.

48 - High Fatality CBFA2T3-GLIS2 Pediatric Acute Megakaryoblastic Leukemia Is Sensitive to BCL-X_L Inhibition

Biltibo, E.

3390 - Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide
4527 - Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)

Binaschi, M.

1333 - PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

Binatti, A.

2843 - A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

Bindal, P.

2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy
4935 - Clonal Myeloid Disorders Following CAR T-Cell Therapy

Bindels, E.

37 - Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Binder, B.

73 - Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Binder, F.

1375 - Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Binder, M.

1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Binder, M.

768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
970 - Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3196 - Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
3899 - Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis
4483 - Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes

Binder, V.

3870 - Ing4-Deficiency Confers Resistance to Inflammatory Stress through Enhanced Hematopoietic Stem Cell Quiescence

Binelli, L. S.

4105 - Dysregulated Activating and Inhibitory Receptors on Natural Killer Cells Predicts Immune Escape and Poor Outcomes in Acute Myeloid Leukemia

Binenbaum, Y.

788 - Prediction of Initial Risk Group, B/T Subtype, and ETV6-RUNX1 Translocation in Pediatric Acute Lymphoblastic Leukemia By Deep Convolutional Neural Network Analysis of Giemsa-Stained Whole Slide Images

Bingham, N.

3148 - Multiple Myeloma-Derived Circulating Extracellular Vesicles Affect Normal Human Stromal Cell Behaviour and Promote Tumor Progression: A Multi-Omic Approach

Bini, R.

4354 - Real-World Management of Advanced Systemic Mastocytosis Treated with Midostaurin: Analysis of Patients Who Completed 12 Months of Follow-up from an Italian Observational Study (OVIDIO)

Binkley, M. M.

2384 - Cognitive Dysfunction Worsens with Age in Patients with Sickle Cell Disease in the Modern Treatment Era
3694 - Functional Connectivity and Executive Function Abilities Strengthen without Change in Structural Connectivity after Transfusion in Children with Sickle Cell Disease

Binns, L. A.

3470 - Characterization of Hemoglobin Variants Due to in-Frame Deletions in the β-Globin Gene from CRISPR/Cas9 Gene Correction for Sickle Cell Disease

Binotto, G.

1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)

Binz, K.

3634 - The Role of a Multi-Center Tumor Board Discussion in Managing Acute Leukemia in Under-Resourced Settings

Biondi, A.

49 - Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol
3977 - The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance
4597 - Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Biondi, A.

150 - Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia
1096 - Empagliflozin Modifies Neutrophils’ Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils
1266 - Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)
1343 - Targeting Hyperactivated Lck in PAX5 Rearranged Pediatric B-Cell Precursors Acute Lymphoblastic Leukemia
1515 - First Description of a Frameshift PAX5 Germline Variant in Two Siblings with B-Cell Precursor Acute Lymphoblastic Leukemia
1962 - Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia
1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
2057 - Impact of Donor and Patient CMV Serology in Children Receiving First Geno-Identical or Unrelated HSCT for Malignant Hematological Disease: An EBMT Retrospective Registry Study
2581 - Study of Angiogenic Potential and Oxidative Metabolism in Mesenchymal Stromal Cells Derived from Shwachman-Diamond Syndrome Patients
2674 - Activina : A Key Factor Mediating Chemoresistance in B-Cell Type Acute Lymphoblastic Leukemia
2833 - Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia
4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease
4151 - A New in Vitro Model of Cortical Cerebral Organotypic Slices to Study Central Nervous System Microenvironment Modification By Leukemia Cells
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8⁺ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Biondi, M.

1962 - Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia

Biondo, J.

3589 - Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States
4852 - Understanding Patient Preferences for Chronic Lymphocytic Leukemia Treatments

Biondo, M.

3761 - Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
4365 - Neutrophil to Lymphocyte Ratio (NLR) at Diagnosis Is a Predictor of Venous Thrombosis and Poor Outcome in Patients with Prefibrotic Primary Myelofibrosis
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study

Biran, N.

1931 - The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma
4683 - Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Biran, N.

2112 - Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
4511 - Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost

Birbeck, G.

3524 - Implementation of Transcranial Doppler Ultrasound Stroke Risk Screening in Urban and Rural Sickle Cell Disease Clinics in Zambia

Bird, S. A.

243 - Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway

Birdwell, C. E.

204 - Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression
2601 - Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1
2663 - Bruton’s Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors
3967 - Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53
3973 - Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Birger, Y.

1089 - Deep Multi-Omic Analysis of Familial Hemophagocytic Lymphohistiocytosis Reveals Distinctive Immune Features of the Disease

Birhiray, R. E.

3255 - In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Birken, C. S.

3508 - Defining Anaemia across the Lifecycle in Healthy Reference Populations: An Analysis for Guideline Development

Birkett, J.

4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Birnberg, A.

663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b

Birsen, R.

1330 - C/EBPα Confers Dependence to Fatty Acid Biosynthetic Pathways and Vulnerability to Lipid Oxidative Stress in FLT3-Mutant Leukemia

Birtas Atesoglu, E.

2983 - Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Bischof, L.

1481 - Quantitative Impact of Mutated NPM1 MRD in Patients with AML Undergoing Allogeneic Stem Cell Transplantation
2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
2103 - Outcomes of Patients with Acute Myeloid Leukemia Receiving a Second Allogeneic Stem Cell Transplantation
3449 - Prognostic Impact of Measurable Residual Clonal Hematopoiesis after Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
4756 - Prognostic Impact of the 2022 European Leukemia Net Risk Classification in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation

Bisho, I.

1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)

Bishop, M. R.

151 - Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma
554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
657 - Population Pharmacokinetic Model Identifies an Optimal Fludarabine Exposure for Improved Outcomes after CD19-Directed CAR T Cell Therapy for Aggressive B-NHL: Analysis from the Cell Therapy Consortium
849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2936 - Prospective Multi-Center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas
3313 - Phase 1 Study of CART-Ddbcma for the Treatment of Subjects with Relapsed and /or Refractory Multiple Myeloma
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4730 - Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies
4929 - Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Bishop, R. T.

2661 - Acid Ceramidase (ASAH1) Is a Key Mediator of Drug Resistance in Refractory Multiple Myeloma

Bisht, K.

3157 - High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Bishton, M.

1088 - Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors
1544 - Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide
1563 - Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study
2404 - Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England

Bisignano, D.

1333 - PIM Inhibition By SEL24/MEN1703 Combines Synergistically with Gilteritinib in FLT3-ITD Preclinical Models of Acute Myeloid Leukemia

Bisio, V.

1675 - Comprehensive Analysis of Mesenchymal Cells from Myeloproliferative Neoplasm (MPN) Patients Reveals the Role of HOXB7 in Myelofibrosis Induction
3110 - Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia

Biswajit, D.

1397 - Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (pRISM) of the Hematology Cancer Consortium (HCC)
3022 - Low Dose Dasatinib Is Not As Active in a CML CP Cohort Enriched with Intermediate/High-Risk CML Chronic Phase: A Phase IIb Multi-Center Trial

Biswas, M.

2150 - Key Role of Kupffer Cells in IL-1 Dependent Activation of CD8⁺ T Cell Responses to AAV Transgene Product in Liver
3281 - Augmenting the Persistence and Efficacy of Engineered Regulatory T Cells to Suppress Anti-Drug Antibody Formation

Biswas, M.

126 - Combination Therapy to Enable AAV Re-Dosing and Mitigate Transgene Immunity in Liver-Targeted Gene Therapy

Bitetti, J.

4549 - Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Bito, X. R.

2040 - Plasma Microbial Cell-Free DNA to Characterize Infection Vs Cytokine Release Syndrome in Pediatric Patients with B ALL after CAR T Cell Therapy

Bitsani, A.

3813 - Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura: Real-World Multicenter Data on Re-Administration and Plasma Exchange Free Treatment

Bittar, G.

2723 - Specific Nucleotide Substitutions and Stressors Erode Highly Conserved Genomic Regions in Acute Myelogenous Leukemia
4111 - Uncovering Ethnic Genomic Disparities Associated with Inferior Outcome in African Americans Diagnosed with Acute Myelogenous Leukemia

Bittenbring, J.

4758 - Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Bittenbring, J. T.

1309 - Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Bittenbring, J.

4185 - Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Bittencourt, H.

572 - Ruxolitinib in Pediatric Patients with Treatment-Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study

Bittencourt, R.

1897 - A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the Mmybrave Multi-Center Study

Bitto, N.

3783 - Liver Health in Patients with Hemophilia: Residual Risk Factors of Liver-Related Complications after HCV Clearance

Bittolo, T.

1785 - The CXCR4^dim/CD5^bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations

Bittolo, T.

1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment

Bittrich, M.

1839 - Impaired Death Receptor Signaling Mediates Cross-Resistance to Immunotherapy in MM
1841 - Multiomic Analysis of CD38 Expression Levels in 209 Untreated and Daratumumab-Resistant Patients

Bivins, C. A.

3440 - Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial

Biyani, N.

2156 - Development of a Potent DNA Damaging Agent LP-284 for Treatment of Mantle Cell Lymphoma

Bjeije, H.

3851 - The PRC2 Co-Factor JARID2 Regulates Hematopoiesis through Non-Canonical Mechanisms

Bjerrum, O. W.

743 - Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Bjordahl, R.

1986 - Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy
1992 - FT555: Off-the-Shelf CAR-NK Cell Therapy Co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Björkholm, M.

548 - Serum Proteome Profiling Reveals Inflammatory, Molecular and Prognostic Information Beyond the Ctdna in Aggressive B-Cell Lymphomas

Björkholm, M.

3049 - Patterns of Childbirth in Women with Myeloproliferative Neoplasms

Björklund, A. C.

3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations

Bjørn, M. E.

3029 - Combination Therapy with Ruxolitinib and Interferon in Newly Diagnosed Patients with Polycythemia Vera

Blaauwendraad, S. M.

3508 - Defining Anaemia across the Lifecycle in Healthy Reference Populations: An Analysis for Guideline Development

Blachly, J. S.

276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
536 - Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
963 - Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL
1326 - The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
2778 - Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
2891 - Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia
2903 - Retrospective Analysis of Residual Hairy Cell Leukemia Measured By IHC or Flow Cytometry and Frontline Treatment with Pentostatin on Time to Next Treatment
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
3950 - Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics
4094 - Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial
4215 - Incidence, Description, and Timing of Serious or Opportunistic Infections in Patients with Hairy Cell Leukemia Treated with Purine Nucleoside Analogues

Black, S. J.

2495 - Correlation between the 4T Score, Enzyme-Linked Immunosorbent Assay and Serotonin Release Assay for Diagnosis of Heparin Induced Thrombocytopenia

Black, S.

4003 - Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant

Blackledge, T.

1095 - Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality

Blackley, K.

4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Blackmon, A.

3400 - Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide
4766 - Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Blackwood, R.

4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Bladé Creixenti, J.

99 - Multiomics Profiling of Measurable Residual Disease (MRD) for Understanding the Biology of Ultra-Drug Resistance in Multiple Myeloma (MM)
865 - Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow
866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
969 - Immunoparesis Recovery in Transplant-Ineligible Newly Diagnosis Multiple Myeloma Patients: An Independent Prognosis Factor That Could Complement Prognostic Value of Minimal Residual Disease
1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
1892 - Evolving Pattern Improves the IMWG 2/20/20 Classification for Patients with Smoldering Multiple Myeloma
4561 - Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study
4619 - Bicistronic CAR T Cell Against CD229 and BCMA Effectively Controls Multiple Myeloma

Blade, J. S.

1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Bladé, J.

118 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)
3241 - Belantamab Mafodotin in Combination with Vrd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-Vrd Trial

Bladergroen, R.

1377 - A Novel Germline PAX5 Single Exon Deletion in a Paediatric Patient with B-Cell Leukaemia

Blaedel, J.

3580 - Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Blædel, J.

2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides

Blaeschke, F.

3296 - Highly Parallel Discovery of Synthetic Knockin Sequences for Enhanced Cancer Immunotherapies

Blagov, S.

872 - Tcrαβ+/CD19+-Depletion in Hematopoietic Stem Cells Transplantation from Matched Unrelated and Haploidentical Donors in Pediatric Acute Lymphoblastic Leukemia Patients in Complete Remission

Blahovcova, P.

1639 - How Relevant Are the Control Cohorts of Clinical Trials in Patients with Newly Diagnosed DLBCL in a Daily Practice?

Blahovcová, P.

1665 - Survival of Patients with Primary Mediastinal B-Cell Lymphoma Treated By Immunochemotherapy with or without Radiotherapy

Blair, B.

1983 - Development of Next-Generation NK Cell Optimized Chimeric Antigen Receptors (CARs) for iPSC-Derived NK Cell Therapies Targeting Both Solid and Liquid Tumors

Blair, D.

1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
1619 - First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Blair, H. J.

4137 - Dual Targeting of MDM2 and BCL2/Bclxl Demonstrates Potent Synergistic Activity in High-Risk Adult Acute Lymphoblastic Leukemia

Blair, T.

3763 - A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Blais, F.

2254 - Cognitive Screening in Adults with Sickle Cell Disease: Prospective Validation of the Rowland Universal Dementia Assessment Scale

Blaise, D.

439 - YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
985 - Dose of IV Busulfan in Reduced Toxicity Conditioning Regimen for Older and/or Frail Patients with AML or MDS
2067 - Treatment Duration, Symptom Resolution, and Survival in Defibrotide-Treated Patients with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation: Pooled Analysis of Defifrance and EBMT PASS Registries
2124 - Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT
2126 - Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
3434 - Autologous Stem Cell Transplant in 2^nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience
3441 - Impact of Allele-Level HLA-Matching on Outcomes after Double Unrelated Cord Blood Transplantation in Adults with Malignant Diseases
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study
3445 - Allogeneic Transplant As a Curative Option for Relapsed/Refractory Large B-Cell Lymphoma in the Era of CAR T-Cell Therapy: A Monocentric Retrospective Study
3450 - Graft-Versus-Leukemia Effect Is Independent from Graft-Versus-Host Disease Following Ptcy-Based HLA-Haploidentical Transplantation
4757 - Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
4758 - Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Blaize, J. P.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Blake, D. A.

4601 - Engineering Novel Multi-Cytokine Backpacks for Manufacturing Functionally Improved CAR T Cell Products

Blaker, Y. N.

2853 - Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

Blakey, A. O.

3526 - Disease Management Decision-Making Amongst Caregivers of Children with Sickle Cell Anemia

Blanc, L.

1260 - Developmental Stage-Specific Hematopoietic Failure In Vivo in a Novel Model of Diamond Blackfan Anemia
3640 - BMI1 Regulates Proliferation of Human Late-Stage Erythroid Progenitors
3660 - Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis

Blanchard, D.

3294 - Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blanchard, M. J.

866 - Clinical Impact of Next Generation Flow in Bone Marrow Vs Qip-Mass Spectrometry in Peripheral Blood to Assess Minimal Residual Disease in Newly Diagnosed Multiple Myeloma Patients Receiving Maintenance As Part of the GEM2014MAIN Trial
867 - Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Is an Independent Prognostic Factor for Multiple Myeloma and Could Complement Prognosis Value of Minimal Residual Disease
1707 - Analysis of Immunological and Clinical Response to Vaccination Against Sars-COV-2 in Patients with Chronic Myeloid Leukemia
1881 - Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Blanchard-Alvarez, A.

4486 - The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Blanchet Zumofen, M. H.

1588 - An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

Blanchet-Deverly, A.

3718 - Cervical Artery Lesions in Adults with Sickle Cell Disease : Are They Disease-Related ?

Blanchette, V.

2465 - Unravelling the Effect of Blood Type on FVIII:C Levels and Response to DDAVP in 20 Males with a Single Genotype (Twillingate Variant) Causing Mild Hemophilia Α
3790 - A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors

Blanchfield, L.

3763 - A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias

Blanco, A.

3096 - IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Blanco, G.

632 - CLECL1⁺ CLL Cells: A Key Subset That Drives CLL Survival and Proliferation and Shapes a Th2-Biased Tumor Microenvironment
4429 - Identification of Three Unique Clusters of Serum Proteins with Distinctive Functionalities in IGHV-Mutated MBL

Blanco, L.

863 - RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination
1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Blanco-Sánchez, A.

3831 - Hip Replacement Surgery and Anticoagulation; A Mortality, Transfusion Need and Venous Thromboembolism Rate Analysis with Trinetx
4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates

Bland, E.

3630 - Real-World Use of Ruxolitinib in Patients with Myelofibrosis Who Had Anemia or Thrombocytopenia at US Community Practices

Blaney, P.

100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
638 - Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma

Blangero, J.

1188 - The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas

Blank, B.

4472 - CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma

Blankstein, A. R.

2714 - Evaluation of Infection in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Systematic Review

Blanquer Blanquer, M.

1156 - Pilot, Multicenter and Cross-Sectional Study of Joint Health in Patients with Non-Severe Hemophilia
1177 - Thrombomodulin Resistance May be Involved in the Prothrombotic State of COVID-19
3793 - Esplorhem: Evaluation of Spanish Experience of Using Florio^® Haemo Digital Medical Device for Treatment Monitoring in Hemophilia Patients. a Preliminary Report

Blasczyk, R.

4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study

Blaser, B. W.

1341 - Acquired Resistance to PRMT5 Inhibition in Mantle Cell Lymphoma Is Associated with Compensatory Activation of Multiple Signaling Pathways
3876 - Epigenetic Regulation of Protein Kinase C Expression in the Hematopoietic Niche
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Blaslov, J.

1940 - A Phase 2 Trial of Colesevelam for Lenalidomide-Associated Diarrhea
2213 - A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - the Nutrition Prevention (NUTRIVENTION-3) Study
2219 - A Pilot Plant Based Dietary Intervention in MGUS and SMM Patients with Elevated BMI Is Feasible and Associated with Improvements in Metabolic and Microbiome Biomarkers of Progression

Blau, C. A.

496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Blau, I. W.

371 - Gvhd Prophylaxis Incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the Cmwp of the EBMT
539 - Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation
2075 - Risk Factors Influencing Humoral Response to COVID 19 Vaccination after Allogeneic Stem Cell Transplantation
2095 - Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT
4690 - Amsa/ARA-C Followed By TBI 4 Gy or High Dose Chemotherapy Conditioning Regimens in Primary Refractory AML – Significantly Worse Outcomes in Younger Patients Conditioned with 4 Gy TBI
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)
4758 - Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Blau, O.

2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Blaylock, H.

451 - Type 2 but Not Type 1 Calreticulin Mutants Exhibit Loss of Chaperone Function Due to C-Terminal Structural Interference, and Bind to Wild Type Calreticulin in a Dominant Negative Manner

Blayney, D. W.

1094 - Prevention of Docetaxel (Doc)-Induced Neutropenia (DIN) with Single Agent Plinabulin (Plin) Versus (vs) Control (No-Treatment or Placebo) in Non-Small Cell Lung Cancer (NSCLC) in Two Randomized Trials

Blayney, J.

3006 - UBASH3B knockout Downregulates STAT1 Mediated Interferon Signalling and Megakaryocyte Related Genes in a JAK2 V617F Positive MPN Model

Blazar, B. R.

109 - Single-Cell RNA-Seq Reveals an Interferon-Driven Inflammatory CD4 Naïve T Cell Subpopulation at Day 100 in Hematopoietic Stem Cell Transplant Patients That Ultimately Develop Chronic Gvhd
111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
359 - A Novel Human OX40L-CAR-Treg Specifically Targets Activated Antigen-Presenting Cells and Effectively Controls T Cell Alloreactivity and Xeno-GvHD
1942 - ACC1 Inhibition Enhances Treg Gvhd Treatment Efficacy through Reciprocal Fatty-Acid Synthesis and Oxidative Phosphorylation Regulation
4113 - Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy
4609 - Modulating Donor T Cell Graft-Versus-Host and Graft-Versus-Tumor Reactivity By Stat6
- The Long and Winding Road to Clinically Effective Graft-versus-Host Disease (GVHD) Therapeutics

Bleakley, M.

4586 - Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation

Bleam, M.

771 - Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Bledsoe, J. R.

2414 - The Morphologic Spectrum of Myelokathexis in WHIM Syndrome and Germline CXCR4 Variants: New Insights into Cellular Changes in the Bone Marrow and Peripheral Blood

Bleesing, J.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector

Blein, S.

353 - ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Blevins, F.

2187 - Fe-Armacist Run Iron Deficiency Management Clinic to Optimize Intravenous Iron Infusions in an Ambulatory Oncology Clinic

Blevins, W.

3741 - A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation

Blijlevens, N. M.

1692 - Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Blin, N.

3299 - Biological Differences between Axi-Cel and Tisa-Cel Products and Impacts on Outcomes in Lymphoma Patients

Blobel, G. A.

799 - Let-7 Inhibits HIC2 to Control BCL11A Transcription and Hemoglobin Switching
802 - Examining the Role of Individual Baf Chromatin Remodeling Complex Components in Globin Gene Regulation
1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)
2361 - Mechanisms of Polycomb Group Protein-Mediated Fetal Hemoglobin Silencing

Bloch, E.

2259 - Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis
3576 - Longitudinal Outcomes of Chronically Transfused Adults with Sickle Cell Anemia and a History of Childhood Stroke

Block, A.

3621 - Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study
3627 - Streamline – Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Blombery, P.

75 - Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
85 - Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies
412 - Biallelic Deleterious Germline SH2B3 Variants Cause a Novel Clinical Syndrome of Myeloproliferation and Multi-Organ Autoimmunity
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
1779 - Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)
3901 - Detection of Novel Occult Germline Multi-Exon Deletions in Patients with DDX41 Familial Predisposition to Myeloid Malignancy
4816 - Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Blonquist, T. M.

1435 - Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Bloom, M.

1212 - ETV6 Represses TNF during Stress Hematopoiesis and Regulates HSC Self Renewal
- Mouse Model of Pathogenic ETV6 Germline Variant Reveals Loss of HSC Self Renewal and Increased Production of TNF
- Q&A

Bloom, P. C.

1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Bloom-Saldana, E.

4787 - Targeting Leukemic Stem Cells in Acute Myeloid Leukemia Using a CpG-Linked Anti-Mir-126 Oligonucleotide

Bloor, A.

91 - MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
94 - Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study
871 - Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
2029 - Improvement in Lymphoma CAR-T Outcomes over Time in the UK – CAR-T Learning Curve or Better Bridging?
2034 - Severe Cytopenia after CD19 CAR T-Cell Therapy: A Retrospective Study from the EBMT Transplant Complications Working Party
3318 - Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies
4672 - Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Bloudek, B.

4846 - 10-Year Impact on Productivity Costs Associated with Mortality in Stage III or IV Classical Hodgkin Lymphoma Based on the Overall Survival Update of the ECHELON-1 Trial: Application of an Oncology Simulation Model in the United States

Blouet, A.

3212 - Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study
3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Bloye, G.

420 - IRX3 Oncogene Activation in T-ALL through Enhancer Hijacking Caused By fto Intron 8 Deletions
715 - The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Blue, B. J.

252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells
2118 - Similar Benefits of High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Elderly Myeloma Population Compared to the Younger Group: Single Center Experience
2268 - Comparing Outcomes of Outpatient Vs. Inpatient High-Dose Melphalan Based Conditioning Regimens Followed By Autologous Hematopoietic Cell Transplantation in Myeloma
3251 - Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study
3355 - Patterns of Relapse and Clinical Outcomes in Multiple Myeloma Patients after Anti-BCMA CAR T-Cell Therapy: Implications for Patient’s Monitoring after CAR T-Cell Therapy
4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Bluemn, T.

3913 - JMJD1C Interacts with the Ncor Corepressor Complex and Is Required for Human MLL-AF9 Leukemogenesis

Blum, H.

4018 - Acute Myeloid Leukemia with Isolated Trisomy 4 Is Characterized By Frequent Mutations of TET2 and a Distinct DNA Methylation Signature

Blum, J.

2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial

Blum, J.

2538 - Transcription Factor Profiling Reveals That CEBPA Promotes Ribosomal RNA Synthesis in Myeloid Progenitors

Blum, K. A.

4219 - Bendamustine, Obinutuzumab and Venetoclax Results in High Complete Response Rates in Untreated Mantle Cell Lymphoma

Blum, W. G.

386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
536 - Characterization of Survival Outcomes and Clinical and Molecular Modulators in Adult Patients with Core-Binding Factor Acute Myeloid Leukemia (CBF-AML) Treated with Hidac Consolidation: An Alliance Legacy Study
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
2778 - Molecular and Clinical Features of FLT3 Juxtamembrane Domain Point Mutations (muts) in Acute Myeloid Leukemia (AML)
2810 - Outcome Prediction By the New 2022 European Leukemia Net (ELN) Genetic-Risk Classification for Adult Patients (Pts) with Acute Myeloid Leukemia (AML): An Alliance Study
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
4130 - Genomic Integration of Adult and Pediatric Acute Myeloid Leukemia Reveals Age Dependent Risk Association

Blumenberg, V.

998 - Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
1987 - Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
3304 - Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL
3348 - Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
4618 - Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy
4669 - Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Blumenstock, G.

1490 - Overexpression of Oncogenic Inhibitory-ASPP (inhibitor of apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML

Blystadt, A. K.

LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Blyth, E.

3419 - Bone Mineral Densitometry Diagnostic Yield Remains High Beyond 10 Years Post Allogeneic Stem Cell Transplant

Bo-Subait, S.

4879 - Comparable Incidence Rates of Hematologic and Non-Hematologic Malignancies, Thrombotic Events, and Autoimmune Disorders in Unrelated Adult Donors Undergoing Bone Marrow Collection Versus Peripheral Blood Stem Cell Mobilization with Recombinant Human Granulocyte Colony-Stimulating Factor (rHuG-CSF): Results of the Donor Long-Term Follow-up Study By the National Marrow Donor Program (NMDP)

Boada, M.

1782 - Myelodysplastic Syndromes in Latin-America - Results from a Novel International Registry: Re-Glam

Boagni, D.

1970 - Cord Derived 8F4CAR-iNKT Cells to Prevent Acute Myeloid Leukemia Relapse and Graft Vs. Host Disease after Allogeneic Stem Cell Transplantation

Board, S.

904 - Severe Adverse Events Associated with Concentrations of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia Patients

Boardman, A. P.

2036 - Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy

Boardman, K.

4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Boateng, K.

3633 - Delirium and Healthcare Utilization in Patients Undergoing Hematopoietic Stem Cell Transplantation
4937 - Perception of Prognosis, Quality of Life, and Distress in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Boateng-Kuffour, A.

Boban, A.

3782 - Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Bobenchik, A.

3378 - Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Bobes-Fernández, A.

4818 - The Augmented Hematologist: Human-AI Feedback Loops to Assist Differential Cell Count during the Analysis of Bone Marrow Aspirates

Bobillo, S.

1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma
2038 - A 3-Year Follow-up Comparison of Clinical Outcomes from Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)
4205 - Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)
4211 - Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Bobin, A.

1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit
1939 - Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. Iskpd - IFM2018-03

Bobrowicz, M.

4615 - CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Bobrowska, H.

1159 - Real Pandemic World Results of Personalized Prophylaxis of Bleeds in Polish Children and Adolescents with Severe Hemophilia a

Bobruff, Y.

2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Boccadoro, M.

644 - Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients – Meta-Analysis of 5,808 Trial Patients
751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
1922 - Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years
1926 - Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years
2023 - DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)
3213 - Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
3236 - Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study
3242 - MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
4575 - Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion

Boccadoro, M.

2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Bocchia, M.

710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
2749 - Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
2824 - Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome
3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Bocci, G.

1649 - Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

Boccia, G.

3668 - Alterations of Neuromuscular Environment Are Associated with Chronic Tissue Hypoxia in β-Thalassemia Patients

Boccia, R. V.

1598 - Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)
2185 - Retrospective Assessment of Total Cost of Care in Non-Dialysis Dependent Chronic Kidney Disease Patients Receiving Parenteral Iron Therapy for Iron Deficiency Anemia
4271 - Phase 2 Trial to Evaluate Safety of Subcutaneous Epcoritamab Monotherapy in the Outpatient Setting Among Patients with Relapsed or Refractory Diffuse Grade 1–3a Large B-Cell and Follicular Lymphoma (EPCORE NHL-6)

Boccieri, E.

775 - Updated Analysis on the Outcomes of Children with Acute Leukemia (AL) Receiving an Alpha/Beta T and B-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (TBdepl-haploHSCT)
4721 - Mucosal-Associated Invariant T (MAIT) Cells Are Functionally Impaired in Pediatric Patients Following HCT and Their Recovery Is Associated with the Onset of GvHD

Boccomini, C.

1566 - Prognostic Role of Revised International Prognostic Score for Waldenstrom Macroglobulinemia (rIPSSWM) in Newly Diagnosed Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Report from the NF10 International, Prospective, Observational Study of the Fondazione Italiana Linfomi
4220 - Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial

Boch, T.

1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML
4132 - Exploring Genetic and Non-Genetic Changes Driving Tumor Evolution in CK-AML at Single-Cell Resolution

Bochenek, V.

586 - Aggregation of Enveloped Viruses By Platelet Factor 4 (PF4) and Neutrophil Extracellular Traps (NETs): Implications for the Anti-Viral Properties of NETs
2411 - Quantification of Neutrophil Extracellular Traps (NETs) in Pediatric Patients with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) through Plasma and Peripheral Smear Analysis
2434 - Neutrophil Extracellular Traps (NETs) Thrombogenicity and Endothelial Cell Toxicity Are Ameliorated By Platelet Factor 4 (PF4): Implications to the Treatment of Sepsis

Bochicchio, M. T.

710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation

Bociek, G. R.

2220 - Understanding the Treatment Preferences of Adults with Cancer

Bock, A. M.

1664 - Outcomes with Immunochemotherapy Plus Radiation Versus Immunochemotherapy Alone in Stage I Diffuse Large B-Cell Lymphoma: A Retrospective Study
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
4156 - Molecular Landscape of Primary Refractory DLBCL

Bodaar, K.

939 - Choline Kinase a Is Required for Alkylating Agent Resistance in T-Cell Acute Lymphoblastic Leukemia

Boddey, J.

3658 - Tmprss6 Depletion-Mediated Iron Deficiency Attenuates the Clinical Course of Plasmodium Berghei Infection in Mice

Bode, A.

3675 - Extracellular Vesicles from Sickle Red Blood Cells Activate Endothelial Cells and Trigger Von Willebrand Factor-Mediated Sickle Red Cell Adhesion
3687 - Membrane Bending Enhances Sulfatide Mediated Sickle Mature Erythrocyte Adhesion

Bodine, D. M.

391 - AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model
3686 - Specific Alterations in Membrane Lipid Levels Correlate with the Degree of Sickling in a Humanized Mouse Model

Bodmer, N.

49 - Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Bodmer, N.

1279 - Wnt and Notch Pathways Regulate Stemness of Myeloid Leukemia Cells Via IL33/ST2 Signaling

Bodo, J.

3917 - Molecular and Clinical PHF6 Mutant Myeloid Neoplasia Provides Clues As to Their Pathogenesis and Therapeutic Targeting

Bodo, W.

4701 - Interventional Antibiotic Treatment Replacing Antibiotic Prophylaxis during Allogeneic Hematopoietic Stem Cell Transplantation Is Safe and Feasible: A Single-Center Analysis

Bödör, C.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
3895 - Multiplex CRISPR/Cas9 Gene Editing in Human Stem Cells to Model Clonal Competition in GATA2 Deficiency

Bodova, I.

776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study

Boegeholz, J.

72 - Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Boehm, A.

488 - A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Boehner, C. J.

1837 - In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma
1854 - Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability

Boehner, C. J.

102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
1875 - High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
4457 - Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma

Boehner, C. J.

244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation

Boehnke, A.

4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer ⁸⁹Zr-Crefmirlimab Berdoxam

Boehringer, S.

1535 - Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Boelens, J. J.

786 - Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo, CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction
2094 - Bodyweight and Absolute Lymphocyte Count Based Dosing of Rabbit Anti-Thymocyte Globulin Results in Early CD4+ Immune Reconstitution in Patients with Inborn Errors of Metabolism Undergoing Umbilical Cord Blood Transplantation

Boellaard, R.

319 - External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL
4153 - Tumor Microenvironment Composition Correlates with Quantitative 18F-FDG PET-CT Features and Serum TARC in Patients with Relapsed or Refractory Hodgkin Lymphoma

Boelle, P. Y.

312 - EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients

Boeltz, S.

1993 - CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Boer, F. D.

1800 - Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/Sll; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Boer, J. M.

215 - Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders
1513 - The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia

Boerner, J.

2930 - Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients

Boerries, M.

1466 - Genetic and Epigenetic Changes at Secondary Resistance after Continued Treatment in the Randomized Phase II Study of All-Trans Retinoic Acid (ATRA) and/or Valproic Acid (VPA) Added to Decitabine (DAC) in Newly Diagnosed Elderly AML Patients (DECIDER Trial)

Boersma, R.

851 - A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

Boettcher, S.

199 - C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53-Independent Cell Death in Acute Myeloid Leukemia and Lymphomas
651 - Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations
2638 - Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage

Boey, D.

1294 - Single-Cell Multi-Omics Analysis Reveals Hematopoiesis of Aberrant Mast Cells in Systemic Mastocytosis

Boffa, J. J.

3212 - Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Bogaert, L.

2632 - CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release

Bogard, K.

3255 - In-Class Transition (iCT) from Parenteral Bortezomib to Oral Ixazomib Therapy in Newly Diagnosed Multiple Myeloma (NDMM) Patients from the Community-Based US MM-6 Study: Subgroup Analyses of the Fully Accrued Dataset in Patients Aged <75 and ≥75 Years

Bogard, P.

4171 - Detection of Early Molecular Response (EMR) and Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using a Validated Next Generation Sequencing (NGS) Assay for the Detection of Tumor Variants in Circulating Tumor (ct)DNA

Bogati, U.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Bogdanovic, A.

1248 - Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria

Boggio, L. N.

2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
2490 - Long-Term Follow-up of Patients with Congenital Thrombotic Thrombocytopenia Purpura Receiving Plasma-Derived Factor VIII Containing (Koate^®)

Boggio Merlo, M. E.

534 - The Role of Quiescence in Acute Myeloid Leukemia Growth

Bøgh Jørgensen, J.

2984 - Outcome after 3^rd Line Treatment for Diffuse Large B-Cell Lymphoma: A Danish Population-Based Study

Bohl, S.

2770 - The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax

Bohlander, S. K.

3080 - In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial
4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

Bohler, S.

3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

Bohlin, A.

2797 - Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing
2802 - Data-Driven Molecular Hallmarks of Acute Myeloid Leukemia: Biological, Prognostic and Therapeutic Implications

Böhme, M.

4077 - Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Böhmer, L. H.

152 - Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen
950 - Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial
1535 - Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival
4188 - Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

Bohnuud, T.

1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease

Bohorquez, A.

1049 - Pediatric Sickle Cell Disease: A Potential Role for the Complement System
1121 - The Complement System Mediates COVID-19 Endothelial Cell Injury, Modifying Cell Permeability

Bohorquez, O.

437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
1292 - Mechanisms of Cistromic Repositioning of the Transcription Factor PU.1

Boiarsky, J.

1462 - Measurable Residual Disease Conversion Rate with Consolidation Chemotherapy in Acute Myeloid Leukemia

Boiarsky, R.

1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Boiarsky, R.

102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology

Boileau, M.

2590 - The Role of Histone H3-K27M Mutation in Preleukemic HSC Expansion

Boisclair, S.

4066 - Outcomes with Venetoclax Dose De-Escalation and Variable Cycle Intervals: A Real-World AML Survival Analysis

Boise, L. H.

98 - Tumor-Immune Architecture and the Regulation of Antigen-Specific T-Cell Infiltration in Multiple Myeloma and Premalignant Plasma Cell Disorders
2627 - Gene Editing and Multi-Omics Reveal Novel Metabolic Vulnerabilities in t(4;14)-Associated Multiple Myeloma

Boisjoly, J. A.

2887 - Prognostic Significance of Interim PET/CT in Follicular Lymphoma Treated with Frontline Chemoimmunotherapy

Boismenu, R.

2140 - Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)

Boissard, F.

2958 - Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study

Boissel, N.

50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
211 - Blinatumomab during Consolidation in High-Risk Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL) Adult Patients: A Two-Cohort Comparison within the Graall-2014/B Study
439 - YTB323 (Rapcabtagene Autoleucel) Demonstrates Durable Efficacy and a Manageable Safety Profile in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Phase I Study Update
727 - Should Adolescents and Young Adults with Hodgkin Lymphoma be Treated As Children or Adults?
1368 - Updated Outcomes from the Historical Control Study SCHOLAR-3 Contextualizing ZUMA-3 Results of Brexucabtagene Autoleucel (KTE-X19) in Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
2619 - Metabolic Plasticity Reveals a Targetable Vulnerability in Leukemia
2724 - Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)
- New Developments in ALL in AYA

Boisson, C.

8 - Effects of Pyruvate Kinase Activators on Red Blood Cell Rheology, Sickling and Senescence in Sickle Cell Disease

Boiten, H. J.

4425 - High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Boivin, I.

2809 - Identification of Novel Cell Surface Therapeutic Targets for KMT2A-Rearranged Acute Myeloid Leukemia
4790 - Disruption of Intracellular Metal Homeostasis As a Vulnerability in SF3B1 Mutated AML

Bojanini, L.

3543 - Understanding Patient Perspective, Challenges, Behavioral Patterns, and Preferences Towards Participation in Multiple Myeloma Clinical Trials: A Prospective Study

Bojilova, V.

4583 - Immune Escape after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia

Bojko, P.

116 - Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Bokel, J.

3814 - Evaluation of Anti-PF4 Positivity and Platelet Activation after COVID-19 Vaccination with Ad26.COV2.S in Brazil

Bokemeyer, C.

759 - Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Boknäs, N.

689 - The Self-Organizing Thrombus: Spatiotemporal Coordination of Platelets Facilitates Structural Differentiation and Stability In Vivo

Bolaños, E.

3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)

Bolanos, L. C.

2585 - UBE2N Is a Druggable Target and an Essential Ubiquitin-Conjugating Enzyme in Myeloid Malignancies

Bolanos, N.

2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Bolanos-Meade, J.

3384 - Alternative Reduced Intensity Conditioning for Allogeneic Blood and Marrow Transplantation Using Pentostatin, Cyclophosphamide, and Total-Body Irradiation with Post-Transplant Cyclophosphamide
LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Bolaños-Meade, J.

2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Boldini, M.

3038 - Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination

Boldorini, R.

4158 - Molecular Clustering on Ctdna May Improve Prognostic Stratification of DLBCL Patients

Boldrini, V.

342 - Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis

Boldt, V.

539 - Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients

Bole-Feysot, C.

722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Bolen, C. R.

2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Bolen, E. E.

2511 - Venous Thromboembolism Prophylaxis in High-Risk Pediatric Oncology Patients

Boles, A. E.

4154 - Therapeutic Potential and Role of CD38 in Cutaneous T-Cell Lymphoma Pathogenesis

Boles, D.

4397 - Impact of the Updated IPSS-Molecular Prognostic Scoring System for Myelodysplastic Syndrome in 10,283 Real World Samples

Boletta, A.

1029 - Intracellular Iron Overload Induces Metabolic Switching in Active Hematopoietic Stem Cells in Beta-Thalassemia
3144 - Targeting the Mitochondrial Protease Clpp Unveils Mitochondrial Vulnerabilities in Multiple Myeloma

Bolger, S.

3519 - Inferior Vena Cava Filter Use at a Large Community Hospital: A Cross-Sectional Analysis

Böll, B.

51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Bollag, W.

3427 - Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Bollard, C. M.

2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
3339 - Phase I Study Evaluating Outcomes of Autologous HIV-Specific T Cells Targeting Non-Escaped Epitopes (HST-NEET) Therapy in HIV+ Individuals on ART (NCT03485963)
3388 - Percent Patient NK and T Cells at Day 28 Predict Graft Outcome after Haploidentical Hematopoietic Cell Transplant for Sickle Cell Disease
4598 - Phase I Study to Improve Anti-Viral Immunity after Cord Blood Transplantation Using Cord-Blood-Derived Multi-Virus-Specific T-Cells

Bolli, N.

862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures

Bolli, N.

464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Bollino, D. R.

3964 - Targeting Serine Biosynthesis in Combination with the Modulation of Glutamine Metabolism Enhances Cellular Cytotoxicity in Acute Myeloid Leukemia
3968 - Comprehensive Plasma Amino Acid Analysis Following Administration of Short- and Long-Acting Erwinia Asparaginase (Crisantaspase) Demonstrated Significant Increase in Plasma Serine and Glycine Levels
4075 - Phase 1 Dose Escalation Trial of Pegcrisantaspase in Combination with Venetoclax in Adults with Relapsed or Refractory Acute Myeloid Leukemia

Bologna, S.

1726 - Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study

Bolognini, S.

1114 - Role of Hemostatic Biomarkers for the Identification of Patients with LONG-COVID19 Syndrome: Results from the ‘Accordi’ Study
1118 - Inflammatory and Coagulation Biomarkers in Patients with Sars-COV2 Infection Receiving COVID-19 Convalescent Plasma: The Bergamo Registry

Bolomsky, A.

3152 - CTPS1 Is a Novel Therapeutic Target in Multiple Myeloma That Synergizes with Inhibition of ATR, CHEK1 or WEE1

Bolon, Y. T.

2073 - An Exploration of Unrelated Donor Existence for Patients Who Received Haploidentical Hematopoietic Cell Transplants
3081 - Prognostic Impact and Landscape of Mitochondrial DNA Variants in Myelodysplastic Syndromes Undergoing Allogenic Hematopoietic Cell Transplantation

Bolton, K. L.

862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
2550 - Arcch: Improving the Performance of Clonal Hematopoiesis Variant Calling and Interpretation Using a Consensus Based Approach

Boluda, B.

1492 - Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Interim Analysis of the PCR-LMA Protocol of the Pethema Group
2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4099 - Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)

Bolwell, B. J.

120 - Chip–Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

Bolyard, A. A.

588 - Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study
2414 - The Morphologic Spectrum of Myelokathexis in WHIM Syndrome and Germline CXCR4 Variants: New Insights into Cellular Changes in the Bone Marrow and Peripheral Blood
3729 - Novel TCIRG1 Mutations Causing Congenital Neutropenia

Bom, H. S.

4306 - Prognostic Significance of ¹⁸f-FDG PET/CT in the Treatment of Primary Central Nervous System Lymphoma

Bombaci, F.

3012 - ASC4FIRST: A Phase III Study of Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitor in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Bombaci, G.

2531 - Ribonuclease Inhibitor 1 (RNH1) Regulates Myeloid Lineage Choice through Cyclin-Dependent Kinase 1

Bombaci, G.

1268 - RNA Deadenylation Subunit CNOT3 Promotes Myeloid Leukemia By Driving Translation of Oncogenic Targets

Bomben, R.

1785 - The CXCR4^dim/CD5^bright Proliferative Fraction Reappears in Relapsed CLL Under Ibrutinib, Enriched in BTK Mutations
1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment
4422 - Clonal Evolution of Chronic Lymphocytic Leukemia with Bimodal CD49d Expression Reveals CD49d Plasticity

Bommer, E.

1360 - RG6333 (CD19-CD28), a CD19-Targeted Affinity-Optimized CD28 Bispecific Antibody, Enhances and Prolongs the Anti-Tumor Activity of Glofitamab (CD20-TCB) in Preclinical Models

Bommiasamy, H.

1943 - Absence of ILC2 Recovery Post-Transplant Is Mediated By Epigenetic Conversion of ILC2 to Pro-Inflammatory ILC1-like Cells
4582 - Amphiregulin Derived from Multiple Sources Is Important for Barrier Function of the Intestine Following Hematopoietic Stem Cell Transplantation
4594 - Cytotoxic Therapy Impairs the Stromal Niche Supporting ILC Development in the Bone Marrow

Bommier, C.

1557 - Time to Complete Response within 24 Months As a Good Surrogate Marker of 8 Year-Progression Free Survival in Extranodal Marginal Zone Lymphoma

Bomsztyk, J.

972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Bona, K. O.

1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

Bonadies, N.

2531 - Ribonuclease Inhibitor 1 (RNH1) Regulates Myeloid Lineage Choice through Cyclin-Dependent Kinase 1

Bonal, D. M.

1052 - Alterations in the Humoral Immunophenotype of Children with Sickle Cell Disease on Hydroxyurea
1280 - Proximity Proteomics Identifies Network of Lipid Metabolism Regulators in JAK2 V617F Interactome
3924 - Complement Factor I (CFI) Deficiency Is Linked to Alterations in Humoral Immunity and Accelerated Development of JAK2V617F-Dependent Phenotype

Bonanomi, S.

3728 - Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

Bonanomi, S.

1096 - Empagliflozin Modifies Neutrophils’ Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils
1266 - Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)

Bonato, A.

635 - Rapid Generation of Murine CLL/Richter Syndrome Models By Multiplexed CRISPR/Cas9 Editing of Common CLL Driver Genes

Boncan, J.

1349 - New Mechanistic and Therapeutic Insights into Purified Phospholipase A₂ from Pseudechis Australis Snake Venom - a Novel Anticancer Agent for the Treatment of Precursor B-Cell Acute Lymphoblastic Leukaemia

Boncek, M.

1244 - Autophagy Plays a Role in the Maintenance of Acute Myeloid Leukemia Stem Cells in the Hypoxic Bone Marrow Microenvironment

Bond, C.

571 - A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following Allogeneic Hematopoietic Cell Transplantation

Bond, D. A.

73 - Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma
323 - Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study
965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
1669 - High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
2897 - Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
2963 - Impact of Circulating Lymphoma at Diagnosis on Outcomes in Patients with Diffuse Large B-Cell Lymphoma
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Bond, J.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Bonder, M. J.

3928 - Multi-Omics Profiling of JMML HSPCs Reveals Onco-Fetal Reprogramming and Identifies Novel Prognostic Biomarkers and Therapeutic Targets in High-Risk JMML

Bondesson, E.

1753 - Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271⁺ Mesenchymal Stromal Cells

Bondu, S.

88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Bone, R. N.

4923 - The Determination Trial Impact on Upfront (vs Delayed) Autologous Stem Cell Transplantation for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Bonello, F.

751 - Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Bonfim, C.

986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)
1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)

Bongarzoni, V.

3179 - Long Term Survival in Multiple Myeloma Patients: A Multicenter Italian Experience

Bongcaron, V.

687 - Endothelial-Targeted CD39 Ameliorates Pulmonary Hypertension in a Murine Model of Endothelial Toxin Administration

Bongiovanni, L.

2886 - Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Bonham, L.

2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Bonham, V. L.

809 - Examining Sickle Cell Trait Associated Clinical Outcomes in the All of Us research Program
810 - Association of Sickle Cell Trait and Venous Thromboembolism in the 23andMe Cohort
3509 - Democratizing Knowledge for Sickle Cell Disease Gene Therapy: A Community Based Model for Creating Patient Education Materials

Boni, C.

587 - Deletion of eif6 Partially Rescues Survival, but Not Neutropenia, of Zebrafish Model of Shwachman-Diamond Syndrome: The Roles of Sbds and Eif6 in Perturbing Lipid Metabolism

Boni, J.

4192 - CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
4297 - CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Boni, R.

4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer ⁸⁹Zr-Crefmirlimab Berdoxam

Bonifacio, M.

623 - Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study
744 - Ropeginterferon Alfa-2b Versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. Final Results of Low-PV Randomized Phase II Trial
1700 - Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A “Campus CML” Study
1706 - Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A “Campus CML” Study
2726 - Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
4048 - BCL-2 and BCL-X_L Antagonists for the Treatment of Relapsed and Refractory Adult Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. a Campus ALL Real-Life Study
4346 - BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study
4355 - Dosing Pattern of Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) in Italy: Results from a Prospective Observational Study (ROMEI)
4371 - Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: The “RAMP” Multicenter Prospective Study

Bonifay, V.

971 - Minimal Residual Disease Monitoring By Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma

Bonifazi, F.

3403 - Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT
4717 - Impact of Fourth Methotrexate Dose in ATG-Cyclosporine GvHD Prophylaxis in HLA-Matched Unrelated HSCT: A GITMO Study
4765 - Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis

Bonifer, C.

2593 - Functional and Molecular Characterisation of Prospectively Isolated Subclones in Individual AML Patients Reveals Distinct Gene Regulatory Networks Linked to Targetable Metabolic Vulnerabilities

Bonig, H.

3864 - Frequent Whole Blood Donations Select for DNMT3A variants Mediating Enhanced Response to Erythropoietin
4670 - CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany

Bonmati, C.

50 - In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival – Results from the Graall-2014 Trial
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Bonneil, E.

2809 - Identification of Novel Cell Surface Therapeutic Targets for KMT2A-Rearranged Acute Myeloid Leukemia

Bonner, A.

2031 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Bonner, E.

89 - Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition

Bonnet, C.

956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”

Bonnet, D.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
2560 - Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell
3864 - Frequent Whole Blood Donations Select for DNMT3A variants Mediating Enhanced Response to Erythropoietin

Bonnet, D.

- Cell Competition in the Hematopoietic Niches

Bonnet, S.

222 - Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Bonneville, F.

3714 - Parasympathetic System Impairment Is Associated with Cerebral Microangiopathy in Adults with Sickle Cell Disease

Bonney, D.

997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
1418 - Reduced Intensity Reinduction Followed By Blinatumomab Achieves Excellent MRD Clearance with Reduced Toxicity and Facilitates Timely Transplant in Children and Young People with Relapsed B-Precursor Acute Lymphoblastic Leukemia
4052 - Blinatumomab As Toxicity Sparing First Line Treatment of Children and Young Persons with B-Precursor Acute Lymphoblastic Leukaemia (B-ALL)
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL
4656 - Donor-Derived, In Vivo T-Cell Expansion Using Granulocyte Transfusions after Cord Blood Transplant Induces Remission in Children with Relapsed, Refractory Acute Myeloid Leukemia and Is Associated with a Cytokine Release Syndrome

Bonney, D.

1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010

Bonnin, A.

4718 - Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Bonnotte, B.

23 - Platelet Count Threshold Associated with Bleeding in Adult Patients with Immune Thrombocytopenia Treated with Antiplatelet Drugs. Results from the Carmen-France Registry

Bonnotte, B.

2449 - Multirefractory Primary Immune Thrombocytopenia in Adults: Prevalence and Burden. Results from the Carmen-France Registry

Bono, R.

3088 - Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Bonofiglio, F.

2880 - Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL

Bonolo De Campos, C.

1799 - Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma

Bonometti, A.

1741 - Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Bonometti, D.

3055 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: Role of Disease Status and Chimerism on Long-Term Outcomes

Bonomini, L.

2886 - Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial

Bonsu, K. O.

2510 - Comparative Analysis of 4 Risk Stratification Models to Identify Patients with Acute Pulmonary Embolism at Risk of Short Term Mortality in a Canadian Health Region
2514 - Trends in Drug Treatment of Outpatients with Acute Pulmonary Embolism - a 5-Year Retrospective Cohort Study in One Canadian Health Region
3822 - Predictors of 90-Day Mortality in Patients with Acute Pulmonary Embolism– a 5-Year Retrospective Cohort Study of Patients in One Canadian Health Region

Bont, L. J.

2730 - Variable Immune Response Following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Patients with Hematological Malignancies Under Treatment

Bontkes, H. J.

808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Bonvini, E.

3961 - Modeling Flotetuzumab-Associated CRS in AML Using in Vitro and in Vivo Preclinical Models

Bonzheim, I.

1309 - Hyper N-Glycosylated SEL1L3 As B-Cell Receptor Autoantigen of Primary Vitreoretinal Lymphoma

Boo, Y. L.

2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore
3386 - Sequential Use of Flamsa, FLAG, CLAG or TEC-Based Conditioning Regimen Followed By Allogeneic Hematopoietic Transplantation Results in Favorable Outcome for High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasia Patients: 15 Year Follow-up of the Multicenter Study in Singapore
4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore

Boocock, D.

3294 - Putative Predictors of Response to WU-NK-101, an Allogeneic, Enhanced Memory (ML) Natural Killer (NK) Cell Therapy Product, for Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Boominathan, R.

97 - Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC‑1

Boonstra, P. S.

4279 - A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Boonyabaramee, P.

3721 - Good Prognosis of Adult Hemophagocytic Lymphohistiocytosis (HLH) Associated with the HAVCR2 germline Mutation

Boos, J.

49 - Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Boot, J.

1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Booth, C.

2211 - Time to Event Surrogate Endpoints in Multiple Myeloma Randomized Trials from 2005-2019: A Surrogacy Analysis
4866 - Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website

Booth, C. A.

827 - Clonal Hematopoiesis Evolves into Dendritic Cell Neoplasm through the Acquisition of UV Mutations in the Skin
828 - BPDCN MYB Fusions Bind Cell Cycle Gene Promoters, Reactivate Self-Renewal in Progenitor Cells and Induce Myeloid/Dendritic Leukemia

Booth, C.

782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector
4775 - Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials

Booth, C.

3460 - Interim Results from an Ongoing Phase 1/2 Study of Lentiviral-mediated Ex-vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Booth III, J. N.

1178 - Use of Plasmic Scores to Aid Diagnosis of aHUS: A Real-World Analysis of Hospitalized Patients from the Premier Healthcare Database

Booth, K.

LBA-5 - Low-Molecular-Weight Heparin Versus Standard Pregnancy Care for Women with Recurrent Miscarriage and Inherited Thrombophilia (ALIFE2): An Open-Label, Phase III Randomized Controlled Trial

Booth, N.

4604 - ICOS and OX40 Signaling Optimization Improves CAR-T Cell Persistence in Preclinical Models

Booth, S.

732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Booth, S.

1644 - Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group

Booth-Jones, M.

2043 - Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Bootz, A.

2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd

Boque, C.

1701 - Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line
1708 - Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Boquimpani, C.

3008 - Dynamics of Response and Response Factors in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 Ascembl Study
4334 - ASC4OPT: A Phase 3b Open-Label Optimization Study of Oral Asciminib in Chronic Myelogenous Leukemia in Chronic Phase Previously Treated with 2 or More Tyrosine Kinase Inhibitors

Borate, U.

236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
1425 - A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Conventional Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia
1458 - Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial
1770 - Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndrome (MDS)
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial
4085 - A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)
- New Investigational Combinations For Higher-Risk MDS
- Innovative Participant-Centered Trial Design

Borcherding, N.

310 - Clonal Evolution of Cutaneous T Cell Lymphoma Revealed at Single Cell Resolution

Borchert, N.

2782 - Prognostic Impact of Clonal Hierarchy of Myelodysplasia-Related Gene Mutations in AML Patients

Borchmann, P.

316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment
317 - Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma: Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial
736 - High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients – a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
2002 - Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects
2910 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma
3533 - Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
3539 - Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) – a Retrospective Health Claims Data Analysis
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Borchmann, S.

1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing
- Management of Nodular Lymphocyte Predominant HL

Bordeleau, M. E.

2809 - Identification of Novel Cell Surface Therapeutic Targets for KMT2A-Rearranged Acute Myeloid Leukemia

Bordon, V.

4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Bordoni, R.

1598 - Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Borel, C.

112 - Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Borella, C.

2905 - How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia

Borella, G.

3878 - Mesenchymal Stromal Cell Secretome in Acute Myeloid Leukemia Bone Marrow Niche

Borella, M.

3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Borg, A.

4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme

Borgel, D.

2373 - High Incidence of Intra-Cardiac Supra-Centimetric Thrombosis and Embolic Complications in Sickle Cell Disease Patients with Dual Lumen Ports

Borges, P.

2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients

Borghero, C.

3413 - Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia

Borgstein, E.

4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Borgsten, F.

Bories, P.

1923 - Subcutaneous Isatuximab Administration By an on-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Bories, P.

553 - Late Failure of Aggressive B-Cell Lymphoma Following CAR T-Cell Therapy: A Lysa Study from the Descar-T Registry
767 - Causes and Risk Factors of Early and Late Non-Relapse Mortality after CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL): A Lysa Study from the Descar-T Registry
2035 - French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry
2210 - Improving Patient Selection for Phase I Trials in Hematology: An External Validation of the Gustave Roussy Scoring System at Toulouse University Cancer Institute, Oncopole (IUCT-O)

Borin, L.

464 - Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes
3079 - Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study

Borisenkova, E.

964 - Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Borji, M.

2098 - Expansion of a CD8+ Temra Population and Activating T-Cell Interactions Characterize the Graft Versus Leukemia Response in Relapsed AML

Borkhardt, A.

150 - Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia
1343 - Targeting Hyperactivated Lck in PAX5 Rearranged Pediatric B-Cell Precursors Acute Lymphoblastic Leukemia
1506 - A Human iPSC Model Reveals Specific Upregulation of Linker Histone H1‑0 in ETV6::RUNX1⁺ Preleukemia and B Cell Precursor Acute Lymphoblastic Leukemia
2833 - Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia
3939 - The Role of Adult Cancer Predisposition Genes in Hematological Malignancies of Childhood
4007 - Familial Predisposition to B-Cell Precursor Acute Lymphoblastic Leukemia Mediated By PAX5 Germline Variants
4148 - Deciphering the Somatic and Germline Structural Variation Landscape in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia By Whole Genome Optical Mapping

Borkhoff, C. M.

3508 - Defining Anaemia across the Lifecycle in Healthy Reference Populations: An Analysis for Guideline Development

Borlenghi, E.

710 - Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
1266 - Prospective and Retrospective Observational Study in Adult and Pediatric Patients with GATA2 Variants (GATA2 Deficiency)
2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
2824 - Dissecting Ph-like ALL: The Role of Genomic Lesion and Minimal Residual Disease in Refining Outcome
4079 - Evolutionary Portrait of Adult Core-Binding Factor Leukemia Patients Treated with a Continuation Therapy with Midostaurin: Preliminary Results

Borleri, G. M.

1996 - Final Results of Phase I/II Study of Donor-Derived CAR T Cells Engineered with Sleeping Beauty in Pediatric and Adult Patients with B-Cell Acute Lymphoblastic Leukemia Relapsed Post-HSCT
4638 - Immune Reconstitution Following Infusion of Autologous Blinatumomab Expanded T-Cells (BET) in CD20+ Indolent Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia Receiving Front-Line Treatment with Fludarabine-Cyclophosphamide-Rituximab or Bendamustine-Rituximab
4644 - Carcik-CD19 Cells Expand In Vivo Toward a CD8⁺ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response

Bormann, M.

622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group
729 - Nivolumab and AVD in Early-Stage Unfavorable Hodgkin Lymphoma: Follow-up Analysis of the Randomized GHSG Phase II Nivahl Trial

Bornhaeuser, M.

217 - Single Versus Double Induction with “7+3” Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
1438 - Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial
1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
2786 - Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Bornhauser, B.

435 - The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action
1504 - IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Bornhäuser, M.

4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
1499 - Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia
1500 - Proteomic Characterization of Acute Myeloid Leukemia
1753 - Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271⁺ Mesenchymal Stromal Cells
3443 - Artificial Intelligence Methods to Estimate Overall Mortality and Non-Relapse Mortality Following Allogeneic Hematopoietic Cell Transplantation in the Modern Era: An EBMT Transplant Complications Working Party Study

Borobia, A.

1997 - A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)

Borodo, A. M.

2395 - Rationale and Design of a Randomized Controlled Double-Blind Internal Pilot Trial for Prevention of Recurrent Ischemic Priapism in Men with Sickle Cell Disease (PIN Trial)

Borogovac, A.

1543 - Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Borowitz, M. J.

2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
2734 - Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

Borrego Borrego, A.

3451 - Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study

Borrello, I. M.

2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
4113 - Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Borri, F. C.

1720 - Impact of Higher Calreticulin Gene Mutation Variant Allele Frequency in Patients with Myelofibrosis

Börries, M.

1788 - Establishment and Characterization of Mouse Models with Primary and Acquired BTK Inhibitor Resistance
2880 - Effective and Safe Immune Checkpoint Blockade Induces Complete Responses in Murine PTCL Model of ALCL

Borrill, R.

4656 - Donor-Derived, In Vivo T-Cell Expansion Using Granulocyte Transfusions after Cord Blood Transplant Induces Remission in Children with Relapsed, Refractory Acute Myeloid Leukemia and Is Associated with a Cytokine Release Syndrome

Borrow, P.

653 - Graft Versus Leukaemia (GvL): Identification & Characterisation of Alloreactive Antigens and Cognate T Cell Responses in Acute Myeloid Leukemia

Borsani, O.

451 - Type 2 but Not Type 1 Calreticulin Mutants Exhibit Loss of Chaperone Function Due to C-Terminal Structural Interference, and Bind to Wild Type Calreticulin in a Dominant Negative Manner
3033 - Protection Against Breakthrough Delta/Omicron Variants in Vaccinated Patients with Myeloproliferative Neoplasms (MPN)
3038 - Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination
3042 - Long Term Follow-up of an Investigator-Initiated Phase 2 Study of Ruxolitinib in MPN-Associated Splancnic Vein Thrombosis (SVT-RUXO)

Borsi, E.

645 - A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies

Börsum, J.

2291 - Light-Chain Amyloidosis in Sweden (2011-2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients

Borthakur, G.

Borthakur, G.

4411 - A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Bortolotti, M.

1012 - Autoimmune Hemolytic Anemia during Pregnancy or Post-Partum: An International Multi-Center Experience
1747 - Evaluation of Red Blood Cell Metabolism in Patients with Low-Risk Myelodysplastic Syndrome (LR-MDS): A Proof-of-Concept Study
3883 - Deciphering Treatment Patterns in Non-Severe Aplastic Anemia: An International Observational Study

Bortoluzzi, S.

2843 - A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

Bortone, D.

1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Bortz, H.

4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Bos, J.

9 - Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat
3680 - An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease

Bos, R. S.

3944 - Establishment and Characterization of a Model of Acquired Resistance to DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic Leukemia Cells

Boscarol, G.

3728 - Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry

Bosch, D.

2401 - A New Genetic Immunodeficiency Syndrome Caused By Autosomal Dominant Mutations in LCP1 Identified By Mosaic Tetraploidy and Severe Neutropenia in Unrelated Pedigrees

Bosch, F.

712 - Iadademstat Combination with Azacitidine Is a Safe and Effective Treatment in First Line Acute Myeloid Leukemia. Final Results of the Alice Trial
737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
1103 - Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic
1643 - PET Radiomic Features Are Predictive of Outcomes after Chimeric Antigen Receptor T-Cell Therapy in Patients with Large B-Cell Lymphoma
2014 - Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data
3089 - TP53 Allelic State in Myelodysplastic Syndromes with 5q Deletion
3096 - IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice
4205 - Rituximab Maintenance (RM) after First-Line (1L) Treatment Is Associated with a Lower Risk of Early-POD in Patients with Mantle Cell Lymphoma (MCL)
4211 - Impact of Coronavirus (COVID-19) Pandemic on Maintenance Therapy for Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
4631 - Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry

Bosch i Crespo, M.

976 - Genetic Disruption of Blimp-1 Drastically Augments the Persistence and Anti-Tumour Efficacy of BCMA-Targeting CAR-T Cells

Bosch, M. V. D.

2769 - Targeting the WT1^mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia

Bosch Schips, M.

1103 - Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic
3096 - IPSS-M Applicability and Clinical Impact in Decision-Making Process in Real-Life Clinical Practice

Bose, P.

95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
96 - Venetoclax Consolidation Achieves Durable Off-Treatment Remissions in Patients with High Risk CLL Who Have Been on Ibrutinib More Than a Year
619 - Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia
626 - Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM)
628 - Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis
630 - Clinical Benefit Associated with Biomarker Changes Indicative of Disease Modification in Patients with Myelofibrosis Treated with the BET Inhibitor Pelabresib As Monotherapy or in Combination with Ruxolitinib
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
1710 - An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety
3041 - Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
3044 - Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
4038 - The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms
4059 - A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up
4344 - Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
4353 - Long Term Results of Phase 2 Study of Pegylated Interferon in Patients with Essential Thrombocythemia and Polycythemia Vera: Median Follow-up of 15 Years

Bose, R.

2313 - Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Bose, S.

3272 - Sustained Engraftment in Fanconi Anemia (FA) Mice Using in Utero Hematopoietic Cell Transplantation (IUHCT)

Boselli, D.

2313 - Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
4939 - Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Bosgra, S.

3254 - Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody^®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Bosi, A.

3079 - Efficacy and Safety of Danazol in Patients with Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms: A Multicenter Observational Study
3438 - Allogeneic Hematopoietic Cell Transplantation in Advanced Phase Mycosis Fungoides and Sézary Syndrome: A Retrospective Analysis of 57 Consecutive Patients

Bosilkovska Weisskopf, M.

3669 - Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial
3671 - Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β‑Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis

Bosio, K.

3055 - Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: Role of Disease Status and Chimerism on Long-Term Outcomes

Boska, I.

2188 - Developing a Cancer-Associated Thrombosis Clinic: Two-Year Experience

Bosler, D. S.

120 - Chip–Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders

Bosma, G.

2751 - Overall Survival and Its Interplay with Allogeneic Stem Cell Transplant and Age in Newly Diagnosed AML Patients Treated with Ven/Aza
2753 - Response to Intensive Induction Chemotherapy after Failure of Frontline Azacitidine+Venetoclax in Acute Myeloid Leukemia
4129 - Clinical and Molecular Features of Highly Durable Response to Azacitidine+Venetoclax in Acute Myeloid Leukemia

Boss, I. W.

162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
2779 - Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
3135 - Synergistic Antitumor Activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T Cell Engager (TCE), and Celmod Agents in Multiple Myeloma (MM) Preclinical Models
3143 - Suppression of Myeloid Cell–Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)
3162 - Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing
4017 - Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Boss, I. W.

3166 - Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Bossard, C.

722 - Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Bossi, A.

4505 - Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Bossuyt, P. M.

851 - A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

Boston, R.

4794 - Mouse Model of Combination Targeted Therapy in PTPN11 Driven Leukemia

Boswell, H. S.

1473 - Molecular Landscaping of Exosomal Protein and miRNA Cargo in Acute Myeloid Leukemia

Bosworth, A.

119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report

Botchwey, E.

175 - Neuroinflammation Underlies the Development of Social Stress Induced Cognitive Deficit in Sickle Cell Disease

Botella, C.

2707 - Prognostic Impact of NPM1 and FLT3-ITD Mutations in Patients Treated with Non-Intensive Regimens: A Pethema Registry Study
4021 - Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study

Botta, C.

1827 - Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)
2972 - Ibrutinib Alone or in Combination with R-CHOP Chemoimmunotherapy in Relapsed or Refractory Primary Central Nervous System Lymphoma (rrPCNSL): A «Real-Life» Study
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
4465 - High TIM-3 Expression May Contribute to the Functional Impairment of Bone Marrow and Circulating Gamma Delta T Lymphocytes during the Progression of Multiple Myeloma

Böttcher, S.

343 - Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

Botteman, M.

4872 - Understanding What Matters to Myelodysplastic Syndrome Patients – a Study of Preferences for Treatments with Hypomethylating Agents

Botten, G. A.

419 - Structural Variation Cooperates with Permissive Chromatin to Control Enhancer Hijacking-Mediated Oncogenic Transcription
3915 - Targeting Cell Adhesion Molecules in IDH Mutant Myeloid Malignances

Bottino, D.

1879 - Mathematical Models for Early Detection of Relapse in Multiple Myeloma Patients Treated with Bortezomib/Lenalidomide/Dexamethasone
3024 - Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is <1% and Decreasing

Botto, L. D.

516 - Congenital Erythrocytosis Due to Novel CMTR1^K769L Mutation Has Augmented Hypoxia Signaling and Features of Both Primary and Secondary Erythrocytosis

Bottomly, D.

427 - Defining Clinical and Molecular Biomarkers for Venetoclax-Based Drug Combinations to Augment AML Therapy
1324 - The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist
3953 - Characterize Biomarkers and Mechanisms of Resistance for MDM2 Inhibitors in AML

Bottos, A.

1544 - Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Bottrel, N.

2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial

Botwinick, M.

3455 - Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Bou, M.

1997 - A Phase II Randomized Multi-Center Study to Evaluate the Safety and Efficacy of Infusion of Memory T Cells As Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia (RELEASE NCT04578210)

Bouabdallah, K.

956 - Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. “the TOTAL Trial”
1596 - The ALK-OBS Trial: Results of a Multicenter Prospective Study Assessing the Prognostic Value of New Markers in Adults with ALK-Positive ALCL Treated By CHOEP: A Lysa Study
2026 - CAR T-Cell Therapy Remain Effective in Patients with Relapse/Refractory B-Cell Non-Hodgkin Lymphoma after Bispecific Antibodies Exposure: Results of a Lysa Study Based on the Descar-T Registry
2882 - Pooled Safety Analysis from Phase I–III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib
2948 - Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Final Results of 18 Patients Treated at RP2D of Selinexor in the Selinda Phase Ib Lysa Study
4262 - A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Bouabdallah, R.

3434 - Autologous Stem Cell Transplant in 2^nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Bouabdallah,, K. K.

233 - Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

Bouafia, F.

2282 - Evaluation of Participation and Recruitment Bias in a Prospective Real-Life Multicentric Cohort « Real World Data in Lymphoma and Survival in Adults » (REALYSA study) for Newly Diagnosed Lymphoma Patients over One Year in a Hematology Department of Teaching Hospital

Bouchacourt, B.

3434 - Autologous Stem Cell Transplant in 2^nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Boucher, A. A.

- Pediatric Clinical Hematology

Boucher, G.

3976 - Targeting PLZF Enhances Glucocorticoid Sensitivity in Acute Myeloid Leukemia

Boucher, J. C.

486 - A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia
4616 - Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Boucher, K.

4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival

Boucher, R. H.

91 - MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Bouchla, A.

2780 - Differential Gene Expression Profile in DNA Damage Signaling Pathways, in De Novo Acute Myeloid Leukemia Patients before Induction Chemotherapy

Boudot, A. J.

3325 - Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Bougeret, C.

3473 - DIACC2010, Sole-in-Class Selective Inhibitor of Kinesin KIF20A, Has Potent Preclinical Efficacy in Acute Myeloid Leukemia

Boughan, K. M.

3320 - Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Bouguenina, H.

243 - Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway

Bouhali, I.

3034 - Polycythemia Vera Patients with >20% Reduction in Whole Blood JAK2^V617F Allele Frequency Have Improved Myelofibrosis-Free Survival but Not Overall Survival

Bouhassira, E. E.

3639 - Cytokine Independent Production of Enucleated Red Blood Cells from Induced Pluripotent Stem Cells

Bouhlal, J.

46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
3734 - Single-Cell Functional Genomics of Natural Killer Cell Interaction with Blood Cancers

Bouhris, J. H.

2126 - Conditioning Regimen Intensity and Donor Choice Do Not Impact Outcomes of Patients (pts) with Acute Myeloid Leukemia (AML) after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in First Complete Remission (CR1): An EBMT Analysis

Bouhuijs, J. H.

808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Boulet, D.

845 - CARD11 and BCL2A1 Join Forces to Promote Resistance to Ibrutinib/Venetoclax Combination in Lymphoma Patients

Boulianne, L.

48 - High Fatality CBFA2T3-GLIS2 Pediatric Acute Megakaryoblastic Leukemia Is Sensitive to BCL-X_L Inhibition

Bouligny, I. M.

2314 - Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML
2817 - IDH1/2^mut for the Win: Comprehensive Molecular Stratification of Venetoclax in Combination with Hypomethylating Agents in AML

Boultwood, J.

3071 - Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes
4398 - Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Boumendil, A.

957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
3403 - Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT
4758 - Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT

Boumendil, A.

2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Bourcier, J.

480 - Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39
750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Bourgeois-Petit, E.

1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort

Bourgeois-Petit, E.

1667 - Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype
1927 - Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). IFM2020-05/Benefit

Bourges, D.

4486 - The Novel Trifunctional Anti-BCMA NK Cell Engager SAR’514 Has Potent in-Vitro and in-Vivo Anti-Myeloma Effect through Dual NK Cell Engagement

Bourhis, J. H.

2124 - Risk Factors Influencing Transplant Outcomes of Adults with Acute Lymphoblastic Leukemia in First Complete Remission: A Retrospective Analysis from the ALWP of the EBMT

Bourhis, J. H.

988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation
2136 - Improved Post-Transplant Outcomes in Recent Years for AML Patients with Intermediate Karyotype, FLT3-ITD and Wild Type NPM1: A Report from the EBMT Acute Leukemia Working Party
2918 - Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin’s Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party

Bourlon, C.

4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme

Bourlon De Los Rios, C.

1001 - Why Are Patients Not Getting a Graft? an Intent-to-Transplant Analysis in the Times of Universal Coverage and Haploidentical Donors
2272 - Hematopoietic Stem Cell Transplantation Activity for Lymphoma: A Multicentric Study By the Transplantation and Cellular Therapy Mexican Working Group
3742 - The Decisive Role of Pronounced Hyperferritinemia for Diagnosis and Prognosis in the Spectrum of Hematological Disorders

Bourquin, J. P.

435 - The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action
1409 - ALL-REZ BFM 2002 Is Associated with Improved Outcome as Compared to ALL-R3 Strategy in Children with Standard Risk Isolated CNS Relapse of Acute Lymphoblastic Leukemia, while Maintaining Comparable Efficacy in Patients with Bone Marrow Relapse. Results of the Multi-National, Multi-Center Trial IntReALL SR 2010
1504 - IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Bouscary, D.

88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation
222 - Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Bousiou, Z.

2091 - Risk Factors, Prevalence, and Outcomes of Invasive Fungal Disease Post Cellular Therapies: A Real-World Analysis

Bouska, A. C.

843 - Co-Occurrence of TP53/PTEN and CCR4 genetic Alteration Deregulates T_H-Cell Differentiation and Drives T_H2-like Lymphomagenesis and T-Cell Signaling
1565 - Integrative Analysis of Genetic and Tumor Microenvironment Topology to Delineate Prognostic Subtypes in Mantle Cell Lymphoma
2628 - PRDM1 Deletion and STAT3 Mutations Cooperatively Promote CD8⁺ T-Cell and NK-Cell Growth in Vitro

Bouskill, V.

2465 - Unravelling the Effect of Blood Type on FVIII:C Levels and Response to DDAVP in 20 Males with a Single Genotype (Twillingate Variant) Causing Mild Hemophilia Α
3790 - A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors

Boussaid, I.

88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Boussi, L. S.

4931 - Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Boussiotis, V. A.

585 - SHP-2 Regulates Myeloid Cell Differentiation, Anti-Tumor Responses and Innate Immune Memory
1107 - Loss of the Nuclear Receptor Pparγ Primes T Effector (T_EFF) Differentiation of Antigen-Specific CD8⁺ T Cells

Bousso, E. S.

4270 - Clinical Research in Western Africa: Efficacy and Safety of a Phase II Study of R-CHOP in First-Line DLBCL in Senegal
4278 - Clinical Research in Africa: Collaborative Project between Senegal and France to Improve the Diagnosis and Therapeutic Management of Adult Lymphoma Patients

Boutboul, D.

1554 - Characteristics of Circulating KSHV-Infected Cells during Active KSHV+ Multicentric Castleman Disease
3206 - Higher Rate of Relapse of KSHV/HHV-8 Associated Multicentric Castleman Disease after Rituximab Therapy in HIV- Patients Than in HIV+ Patients

Bouteloup, J.

3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Boutilier, A. J.

4193 - Gli3 Is Required for M2 Macrophage Polarization and M2-Mediated Waldenström Macroglobulinemia Growth and Survival

Boutin, E.

3719 - Impact of Transfusion Program during Pregnancy on the Obstetrical Outcomes in Sickle Cell Disease Women

Boutsis, D.

4299 - Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: Incidence and Risk Factors in the Rituximab Era

Bouvard, B.

4407 - Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias

Bouvier, A.

4407 - Prevalence of Osteoporosis in Myelodysplastic Syndrome Patients and Association with Cytopenias

Bouvier, C.

1705 - Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.
4343 - Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Bouvier, R.

165 - Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site
440 - A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

Bouvy, C.

1126 - DP-Filter, a Rapid and Ergonomic Device to Remove Direct Thrombin Inhibitor Argatroban from Plasma for Routine Hemostasis Tests

Bouyssou, J. M.

827 - Clonal Hematopoiesis Evolves into Dendritic Cell Neoplasm through the Acquisition of UV Mutations in the Skin
828 - BPDCN MYB Fusions Bind Cell Cycle Gene Promoters, Reactivate Self-Renewal in Progenitor Cells and Induce Myeloid/Dendritic Leukemia

Bouzidi, A.

312 - EBV Dictates Lower Tumor Neoepitopes Scores and Intra-Tumoral Repertoire Diversity in NHL from Immuno-Compromized Patients

Bouzy, S.

4404 - Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening
4413 - Molecular Response Analysis By High Throughput Sequencing in Higher Risk Myelodysplastic Syndrome (HR-MDS) Treated Intensively with CPX-351

Bove, V.

3199 - Multiple Myeloma Patients Aged 40 Years and Younger Have the Same Prognosis As Older Patients in an Analysis of Real-World Evidence from Latin America: A Study of 1,316 Patients from the Gelamm Latin American Multiple Myeloma Studygroup

Bovée, J.

68 - Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments
1535 - Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Bover, L.

4081 - Humanized T Cell Receptor-like Antibody Hu8F4 Reduces Leukemia By Fc-Mediated Mechanism

Boveri, E.

1741 - Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes

Bowden, R.

1026 - Iron Supplementation May Selectively Reprofile the Gut Microbiome in Iron-Deficient Bangladeshi Infants

Bowen, A.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Bowen, D.

4405 - Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Bowen, J.

721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features

Bowen, J.

4839 - Cardiovascular Disease Prevention in Persons with Hemophilia

Bower, L.

2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Bowers, A.

3455 - Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL

Bowers, C.

1259 - Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model

Bowhay-Carnes, E.

2943 - Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Bowie, K.

1448 - Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Bowlby, R.

2629 - DNMT3A Limits Myeloid Signaling Responses in Committed T Cells during Normal and Leukemic Development

Bowles, K. M.

351 - Malignant Plasma Cell Derived Mitochondrial Damps Activate Macrophages Via Sting Signalling to Promote Myeloma Development
2548 - LC3-Associated Phagocytosis Is Impaired in Bone Marrow Macrophages during Ageing Leading to Defective Processing of Apoptotic Cells and Suppression of Sting Activation
3852 - Mitochondrial Membrane Potential Defines the HSC Population with Serial Repopulating Potential in Young but Not Aged Animals
4096 - Sting Agonists Activate Bone Marrow Macrophages and Synergise with Anti-CD47 Blockade Improving Survival in Animal Models of Acute Myeloid Leukemia

Bowles, K. M.

758 - Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine Trial

Bowling, M.

3134 - High Prevalence of Beta-Human Papilloma Virus in Patients with Concurrent Chronic Lymphocytic Leukemia and Non-Melanoma Skin Cancer

Bowman, A.

583 - A Noncoding Germline Variant Creates a Gain-of-Function De Novo Enhancer That up-Regulates IL5 Transcription to Cause Familial Hypereosinophilia, Revealing a Previously Undescribed Mechanism for Human Disease

Bowman, A. S.

2862 - Validation of a Cell-Free DNA NGS Assay for Hematological Malignancies

Bowman, K.

3293 - Enhancing α-CD19 CAR T Antitumor Efficacy Using the BH3 Mimetic, Venetoclax
3989 - Enhanced Anti-Tumor Activity with Exposure to BCL-2 and BRD4 Inhibitors in Mantle Cell Lymphoma

Bowman, M.

136 - Hemostatic Biomarkers Predict Risk of Thromboembolism (TE), Severe COVID-19 and Mortality: A Report from the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS)

Bowman, R. L.

330 - Jak2^V617F Reversible Activation Shows an Essential Requirement for Jak2^V617F in Myeloproliferative Neoplasms (MPNs)
947 - Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia
3908 - Cohesin Dependency in Npm1^c/+ and Flt3-ITD Mutant Hematopoietic Stem and Progenitor Cells

Bowman, T. V.

821 - A Link between Blood Flow and the Inflammatory Networks That Govern Hematopoietic Stem Cell Specification

Bowman, W. P.

411 - Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children

Boxaspen, T.

4800 - Affibody-Based BCMA x CD16 Dual Engagers for Activation of NK Cells Towards Multiple Myeloma

Boyapati, A.

4551 - Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma
4555 - Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Boyce, P.

2297 - Patients’ and Caregivers’ Perspectives from Social Media Towards Disease Burden and Innovative Treatment Options in Multiple Myeloma

Boyd, K.

754 - Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

Boye-Doe, A.

- Remote Assessments of Transition-Readiness in Adolescents and Young Adults with Sickle Cell Disease

Boyer, O.

484 - Impact of Epichaperome Inhibitor PU-H71 on Anti-Tumor T Cell Responses and Its Implications for Immune and Cellular Therapy
1971 - Low-Dose Radiation Improves Anti-CD19 CAR T-Cells Efficacy in Diffuse Large B-Cell Lymphoma through Fas/FasL Pathway

Boyer perrard, F.

235 - Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)
1726 - Prospective Follow-up of Patients with Myelofibrosis (MF) and Treated with Ruxolitinib in France: The Rumycup Study
3045 - Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim
3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis
4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Boyer, T.

1398 - Standard Risk-Assessment of AML Doesn’t Predict the Outcome in Older AML Patients Undergoing Non-Intensive Chemotherapy
3886 - Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Boyiadzis, M. M.

834 - A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up
2736 - Trial-in-Progress: A Phase 2 Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Acute Myeloid Leukemia That Persisted after the 1^st Induction Regimen
2759 - Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Boykin, D. W.

1292 - Mechanisms of Cistromic Repositioning of the Transcription Factor PU.1

Boyle, E.

470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
638 - Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma

Boyle, E. M.

100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
3170 - The Mutagenic Impact of Radiotherapy in Multiple Myeloma

Boyle, L. D.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)
4921 - Current Status of Demographics and Survival Outcomes of Cutaneous T-Cell Lymphoma - Not Otherwise Specified in United States: A Contemporary Population Based Study with Focus on Hispanics

Boyle, M.

546 - Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
555 - Risk of Central Nervous System Involvement in High-Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements: Analysis of a Population-Based Cohort with Routine Fluorescence in Situ Hybridization Testing in British Columbia

Boyle, M.

1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
2858 - Clinical Impact of Cell-of-Origin and Double-Hit Signature of DLBCL in Japan
4160 - Genome-Wide Methylation and Haplotype-Resolved Aberrant Somatic Hypermutation Patterns in B-Cell Lymphomas
4166 - Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement?

Boyle, S.

2029 - Improvement in Lymphoma CAR-T Outcomes over Time in the UK – CAR-T Learning Curve or Better Bridging?
3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Boyne, D.

3581 - External Validation of the FLIPI Risk Score Measured at Initial Diagnosis and POD24 Among Previously Treated Individuals with Progressed Follicular Lymphoma in Alberta, Canada

Boysen, J. C.

3862 - Differential Susceptibility to Senescence in CART Cells Based on Co-Stimulatory Signaling

Boytsov, N.

1891 - Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study
4549 - Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Bozic, B.

4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Bozza, P. T.

3814 - Evaluation of Anti-PF4 Positivity and Platelet Activation after COVID-19 Vaccination with Ad26.COV2.S in Brazil

Braat, S.

907 - Randomised Controlled Trial of Intravenous Iron (ferric carboxymaltose) for Second Trimester Anaemia in Malawian Pregnant Women (REVAMP)
1026 - Iron Supplementation May Selectively Reprofile the Gut Microbiome in Iron-Deficient Bangladeshi Infants
3508 - Defining Anaemia across the Lifecycle in Healthy Reference Populations: An Analysis for Guideline Development

Brabrand, M.

743 - Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Bracken, A. P.

1313 - EZH1-PRC2 Identifies a Potential Reservoir for Disease Relapse in Quiescent Cancer Cells Refractory to EZH2 Enzymatic Inhibition

Bracken, S.

479 - The DNA-Sensor AIM2 Promotes BCR-Activated B Cells in Chronic Graft-Versus-Host-Disease

Brackett, J.

3584 - COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies

Brackman, D.

1625 - A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies

Bradbury, C.

1128 - Retrospective, Observational, Multicenter Study Assessing the Thrombopoietin Receptor Agonist (TPO-RA) Romiplostim and Other Treatments for Patients with Newly Diagnosed or Persistent Primary Immune Thrombocytopenia (ITP) in Routine Clinical Practice in the United Kingdom (UK)

Bradbury, H.

3328 - A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Bradeen, X.

958 - Results from a Phase I Trial Using Nivolumab in Combination with Dose Adjusted EPOCH in Newly Diagnosed Peripheral T-Cell Lymphomas

Bradford, M.

382 - Race, Ethnicity and Experienced Racism Are Associated with Adverse Physical and Mental Health Outcomes Among Cancer Survivors

Bradley, J.

2303 - Experiences and Views of Leukemia Patients: A Global Survey
3615 - From Survey to Resource Hub: Chronic Lymphocytic Leukemia (CLL) Global Support Provision

Bradley, J.

4802 - A Rapid Genotyping Assay for CSF Accelerates Diagnosis and Treatment Initiation for CNS Malignancies

Bradley, S.

4564 - Peri-Transplant and Maintenance Daratumumab for Minimal Residual Disease (MRD) Eradication in Transplant-Eligible Multiple Myeloma (MM) Patients

Bradley, T.

1434 - Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
1713 - MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
2771 - CDK 8/19 Kinase Inhibitor RVU120 in Patients with AML or Higher-Risk MDS: Safety and Efficacy Results from New Dose Escalation Cohorts
3051 - Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Bradshaw, D.

2049 - Strategies to Optimize the Utilization of Stored Autologous Peripheral Blood Stem Cells for Second Transplantation in Multiple Myeloma
2699 - Clinical Outcomes of Patients with TP53-Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
2721 - Impact of Qualified Dedicated APL Leukemia Specialist and Simplified Treatment Algorithm on Early Deaths in APL, a Monocenter Experience
2795 - Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD^highbut Not FLT3-ITD^low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
4025 - Time to Abandon the Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy
4035 - Musculoskeletal Pain Syndrome in a Subset of APL Patients during Induction Therapy

Bradt, J.

680 - Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

Bradvica, V.

4905 - Evolution of Treatment Patterns and Prognostic Biomarkers in Latin American Patients with Chronic Lymphocytic Leukemia: A Study By the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)

Brady, L. K.

3254 - Preliminary Dose-Escalation Results from a Phase 1/2 Study of GEN3014 (HexaBody^®-CD38) in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM)

Brady, S. W.

2659 - Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL

Braekeleer, E. D.

825 - Genome-Wide CRISPR Screen Reveals Dependency of PPM1D-mutant Cells on DNA Repair

Braekkan, S.

5 - C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis

Braess, J.

280 - Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Braga, A. C. F.

2243 - Risk Factors Associated with in-Hospital COVID-19 Mortality in a Public Hospital in Brazil

Braggio, E.

637 - Vκ*MYC Mouse Model Recapitulates Key Genomic Defining Events in Multiple Myeloma
1799 - Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion
3172 - LP-118, a Novel BCL2 Inhibitor, Shows Potent in Vitro Anti-Myeloma Activity
3195 - A Single Next Generation Sequencing Assay for Detection of Driver Mutations, Translocations and Copy Number Alterations in Patients with Multiple Myeloma
4165 - Genomic Pathways Differentiating IgM-MGUS from Waldenstrom Macroglobulinemia: The Integrated microRNA and Gene Expression Landscape

Braida, A.

1789 - An Unsupervised Machine Learning Method Stratifies Chronic Lymphocytic Leukemia Patients in Novel Categories with Different Risk of Early Treatment

Brain, I.

937 - KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Brake, M. A.

2438 - Pregnancy Induces a Thrombogenic Platelet Transcriptome in Mice

Brakeman, P.

1176 - MAC Plus Study: A Retrospective Study Correlating DNA Variants, Clinical Course and Outcomes from 187 Patients Who Underwent Testing Using an Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathy Genetic Sequencing Panel

Bramanti, S.

4261 - Patients Outcome after Chimeric Antigen Receptor (CAR) T-Cells Failure in Aggressive B-Cell Lymphomas: Role of Immunotherapy and Prognostic Factors

Brambilla, D.

2389 - Plasma Free Hemoglobin Is Associated with LDH, AST, Total Bilirubin, and the Hemolytic Component in Patients with Sickle Cell Anemia

Brambilla, V.

1999 - Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Brame, C.

4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)

Brammeier, K. L.

782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA

Brammer, J. E.

615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas
777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
3993 - ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
4154 - Therapeutic Potential and Role of CD38 in Cutaneous T-Cell Lymphoma Pathogenesis
4225 - Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Bran, J.

2003 - Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial

Branagan, A. R.

231 - Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinem

Author Index: B